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Cell reprogramming methods have been studied extensively in recent years as a strategy to 
replace the neuronal cells lost in injury or disease. Much progress has been made regarding the 
direct conversion of murine astrocytes and fibroblasts into neurons, however, there are still 
many limitations that need to be overcome before these strategies can be relevant for clinical 
applications. One of the major reprogramming hurdles recently identified is the metabolic 
switch from glycolysis to oxidative phosphorylation (oxphos) that occurs as astrocytes adopt a 
neuronal identity. The forced cellular transition requires remodeling of the metabolic 
machinery, leading to increased stress and cell death. In order to overcome this impediment to 
efficient reprogramming, my PhD projects focused on further understanding the changes in 
mitochondrial metabolism during reprogramming, and alleviating the stress associated with 
this change. One of my projects investigated the conversion of murine astrocytes into neurons 
and delved into the mitochondrial proteome of astrocytes and neurons. Unique pathways for 
each cell type were discovered, and by upregulating neuron-enriched proteins in murine 
astrocytes undergoing reprogramming, a significant improvement in the efficiency of the 
conversion process was obtained. My second project analyzed the role of the mitochondria 
during neuronal reprogramming in human astrocytes and fibroblasts. Functional oxphos 
metabolism was shown to be necessary for human neuronal conversion as well, as cells with a 
mitochondrial deficiency were significantly hindered in their reprogramming ability. The 
unfolded protein response (UPR) pathway of the endoplasmic reticulum was shown to have a 
novel role in direct neuronal reprogramming, and inhibition of this pathway could increase 
reprogramming efficiency even in cells with a mitochondrial deficiency in Complex I of the 
electron transport chain. Therefore, the aim of my thesis was to improve the current strategies 
for neuronal replacement by untangling the mechanisms related to the metabolic shift and 






The Central Nervous System (CNS) is composed of the brain and the spinal cord, and it is 
responsible for integrating information and directing activity across the body. Although the 
CNS is a very impressive and well-orchestrated system, the complexity and careful balancing 
of its many components provides ample opportunity for things to go awry. The failure of the 
system can be clearly seen in neurodegenerative diseases, which are increasing in prevalence 
worldwide and result in a tremendous strain on society through the disease-related health costs 
(Chen et al., 2016; Gan et al., 2018). Therefore, further understanding the mechanisms 
underlying these diseases and swiftly discovering viable treatments is imperative. Although 
some of the same elements are found in both acute traumatic brain injury and chronic injury 
(disease), for the purpose of this thesis the focus will be on chronic disorders.  
The loss of functional neurons is one of the hallmarks of neurodegenerative diseases, resulting 
largely from the reduction of oxygen and metabolic substrates (Gan et al., 2018). Neurons are 
especially susceptible to sub-optimal environments due to their high energy requirements 
(Harris et al., 2012). A steady flow of glucose and oxygen is required for proper brain function, 
and although accounting for only 2% of all body mass, the high metabolic demand of the brain 
cellular environment causes it to consume 20% of the metabolic energy (Dienel, 2019). In order 
to help meet these high energy demands, glial cells such as oligodendrocytes and astrocytes 
play crucial roles due to their metabolic resilience and plasticity (Amaral et al., 2013; 
Magistretti & Allaman, 2015; Morita et al., 2019). Indeed, the majority of astrocytes have 
endfeet that cover brain vessels, and thus are able to exert control of the nutrients and substrates 
that flow from the periphery across the blood-brain-barrier (BBB) (Mathiisen et al., 2010). 
Astrocytes are a prominent glia cell in the mammalian brain, comprising 20-40% of all glia 
cells and being responsible for a myriad of functions (Liddelow & Barres, 2017; Verkhratsky 
& Nedergaard, 2018). These tasks range from the regulation of cerebral metabolism and blood 
flow (Attwell et al., 2010; Iadecola & Nedergaard, 2007) to neurotransmission and 
neurodevelopment (Chung et al., 2015).  
The complicated interaction between neurons and astrocytes adds further complexity to the 
therapeutic strategies for neurodegenerative diseases. One of the most promising options to 
replace the loss of functional neurons is to directly reprogram other somatic cell types into 
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neurons (Gascón et al., 2017; Lu & Yoo, 2018; Masserdotti et al., 2015). Indeed, the direct 
neuronal reprogramming of both murine and human fibroblasts (Pang et al., 2011; Vierbuchen 
et al., 2010) and glial cells (Berninger et al., 2007; Heinrich et al., 2010) has been achieved. 
However, as will be discussed in more detail later, there are still many obstacles that hamper 
complete maturation of the induced neurons, as well as prevent a high reprogramming 
efficiency. In particular, the metabolic barriers to reprogramming are not well understood 
(Gascón et al., 2017). A greater understanding of mitochondrial metabolism is not only relevant 
for neuronal conversion, but is also imperative for directly treating disease pathology, as 
disruptions to energy generation and increased oxidative damage are common characteristics 
of disease (Watts et al., 2018). 
I will first introduce the very different metabolic profile of neurons and astrocytes, and then 
examine the molecular and functional reasons underlying their differences.  I will discuss that 
in spite of these differences, the roles of neurons and astrocytes in the CNS are extremely 
interconnected and they cooperate synergistically. I shall then consider the effect of 
mitochondrial dysfunction on neuron and astrocyte function, and its role in neurodegenerative 
diseases. Next, I will discuss the therapeutic strategy of direct neuronal reprogramming, and 
the hurdle of the metabolic switch during forced cell fate conversion. I will conclude by 
considering patients suffering from a mitochondrial disorder and examine what can be learned 
from these patients to further understand and alleviate the metabolic disruptions that occur in 
numerous diseases.  
1.1 Metabolism in the CNS: focus on astrocytes and neurons 
One of the predominant sources of energy for cells in the brain is glucose (Mergenthaler et al., 
2013). Glucose is used for the generation of building blocks for biosynthesis and reducing 
equivalents for powering redox reactions. Many metabolic intermediates of glucose, such as 
lactate, pyruvate, acetate, and glutamate, can be further processed to generate energy (Zielke 
et al., 2009). As will become clear below, the different cell types in the brain preferentially 
send glucose down different pathways as they balance their bioenergetic demands with their 
antioxidant needs. The synergistic interactions of different cell types, especially neurons and 
glia, allow them to maintain their delicate metabolic homeostasis.  
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The two major pathways used by cells to generate energy through glucose metabolization are 
oxidative phosphorylation (oxphos) and glycolysis. Both pathways utilize glucose to form 
adenosine-5′-triphosphate (ATP), which is a main energy currency in the brain. However, one 
molecule of glucose processed through the glycolytic pathway only generates 2 ATP 
molecules, whereas oxphos yields 36 molecules of ATP (Camandola & Mattson, 2017). 
Astrocytes are able to flexibly use both pathways for energy generation, whereas neurons rely 
more on the oxphos pathway to meet their high energy demands (Bélanger et al., 2011; 
Kasischke et al., 2004). Despite the strikingly lower metabolic efficiency demonstrated by 
glycolysis, the pathway compensates by providing reducing equivalents such as reduced 
nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH2), 
which are essential for oxphos function and many other metabolic reactions (Camandola & 
Mattson, 2017). Notwithstanding their differences, neurons and astrocytes actually have 
complementary metabolic profiles, as will be discussed in more detail below. The main glucose 
metabolic pathways and their different roles in neurons and astrocytes will be introduced in 
more detail first, before synergistic activity is described.  
1.1.1 Glucose metabolic pathways 
Before glucose can be metabolized, it enters neurons, glia, and endothelial cells through their 
respective glucose transporters (GLUTs) (Thorens & Mueckler, 2010). The enzyme 
hexokinase (HK) then proceeds to phosphorylate glucose and produce glucose-6-phosphate 
(G6P), which can be utilized by different metabolic pathways (Mergenthaler et al., 2013). As 
can be seen in Figure 1, the main routes for G6P to traverse include (1) glycogenesis, (2) the 
pentose phosphate pathway (PPP), and (3) glycolysis with the downstream choices of either 
(a) mitochondrial metabolism in the form of oxphos, or (b) lactate production. Both neurons
and astrocytes can utilize PPP and glycolysis, however, only astrocytes can take advantage of
the first pathway, glycogenesis, and store glucose energy in the form of glycogen (Camandola
& Mattson, 2017).
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Figure 1. Schematic overview of the different glucose metabolic pathways, highlighting the differences 
between neurons and astrocytes. (Camandola & Mattson, 2017; License Number: 5076090684520) 
Throughout the body, glycogen is mainly localized to the skeletal muscle and liver where it 
appears at much higher concentrations than in the brain (Nelson et al., 1968). However, despite 
its relatively low concentrations, brain glycogen has been shown to be instrumental in aiding 
astrocyte support to neurons (Brown, 2004; Swanson & Choi, 1993). Glycogen phosphorylase 
(GP) is present mainly in astrocytes, which contain both the skeletal muscle and brain isoforms 
of the enzyme (Pfeiffer-Guglielmi et al., 2003). The presence of two isozymes in astrocytes 
indicates the cells’ ability to manipulate glycogen in response to extracellular as well as 
intracellular signals. In contrast, neurons contain GP to a much lower percent, and then only 
the brain isoform (Pfeiffer-Guglielmi et al., 2003). Furthermore, although neurons contain 
muscle glycogen synthase (MGS), and thus have the ability to synthesize glycogen, the MGS 
enzyme has reduced activity in these cells due to proteasomal degradation and the prevalence 
of its phosphorylated state (Vilchez et al., 2007). Astrocytes are therefore able to store glycogen 
as a future energy source, which is instrumental during periods of heightened activity, 
considering that astrocytes can break glycogen down into lactate and provide it to neighboring 
neurons (Pellerin & Magistretti, 1994; Rich et al., 2019). Indeed, a distinct functional role for 
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the energy produced through glycogenesis has been shown in vitro (Sickmann et al., 2009), as 
well as in vivo (Gibbs et al., 2006; Suzuki et al., 2011).  
The PPP branch is distinct from the other pathways because it does not generate ATP but 
instead uses G6P to furnish the cell with ribose 5-phosphate (R5P) and reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) (Bélanger et al., 2011). The redox energy from 
NADPH is essential for the synthesis of non-essential amino acids and fatty acids, while R5P 
is used as a main component for nucleotide biosynthesis (Bélanger et al., 2011). In addition, 
NADPH is used to regenerate the antioxidant glutathione, thus providing protection for the cell 
against oxidative stress (Bolaños et al., 2010). Therefore, glucose is sent down different 
pathways depending on the specific needs of the different cell types, as both the ATP energy 
demands, and the antioxidant needs of the cell need to be met. The cell-specific metabolic 
profiles of astrocytes and neurons will continue to be examined as the other glucose metabolism 
pathways are introduced.  
The third option, glycolysis, turns G6P into pyruvate through multiple reactions catalyzed by 
10 different enzymes. The glycolytic reactions also generate two molecules of ATP, as 
mentioned previously, and essential cofactors such as NADH, FADH2, and coenzyme A 
(CoA). The ability of astrocytes to flexibly use glycolysis is supported by their high expression 
of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) (Herrero-Mendez et al., 
2009). The glycolytic pathway is stimulated by PFKFB3 because it generates a main driver of 
the pathway, fructose-2,6-bisphosphate (fructose-2,6-BP). Conversely, neurons are limited in 
their use of glycolysis, because PFKFB3 is constantly undergoing proteasome degradation and, 
as a result, is only present at low levels (Herrero-Mendez et al., 2009). The pyruvate generated 
through glycolysis can then be used in two different ways depending on the metabolic 
requirements of the cell and the presence of oxygen.  
In aerobic conditions where oxygen is present, pyruvate is transported to the mitochondria and 
converted into acetyl coenzyme A (acetyl-CoA). Pyruvate follows this pathway preferentially 
in neurons, because the enzyme pyruvate dehydrogenase (PD) that converts pyruvate into 
acetyl-CoA is present in neurons to a greater degree in its active form (Itoh et al., 2003; Zhang 
et al., 2014). In contrast, astrocytes highly express pyruvate dehydrogenase kinase isoform 4 
(PDK4), which phosphorylates and consequently inhibits the activity of PD. Therefore, the 
fraction of inactive PD is higher in astrocytes, leading to a reduced production of acetyl-CoA 
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from pyruvate (Itoh et al., 2003; Zhang et al., 2014). Regardless, once acetyl-CoA is produced, 
the tricarboxylic acid (TCA) cycle within the mitochondria uses it to generate even more of the 
energetic cofactors mentioned above, NADH and FADH2. The TCA cycle also provides many 
amino acids and lipids to the cell (Akram, 2014). The reduced cofactors NADH and FADH2 
are then used along with oxygen to power the metabolic machinery of oxphos, known as the 
electron transport chain (ETC), composed of five complexes present at the inner mitochondrial 
membrane (IMM) (Wilson, 2017). Electrons are passed from NADH and FADH2 through the 
different ETC complexes, and this in turn powers the transfer of protons (H+) across the IMM. 
The resulting electrochemical gradient is then able to propel the synthesis of ATP by Complex 
V, ATP synthase (Wilson, 2017). The ETC will be discussed later in more detail.  
In anaerobic conditions, pyruvate is diverted from the TCA cycle and is instead used for lactate 
production. In astrocytes, instead of sending pyruvate through to the mitochondria the cells 
prefer to convert pyruvate into lactate using the lactate dehydrogenase 5 (LDH5) enzyme 
(Magistretti & Allaman, 2018). Not only do astrocytes have a lower activity of PD and 
subsequent reduced generation of acetyl-CoA as mentioned above, but astrocytes also express 
much higher levels of LDH5 than neurons (Bittar et al., 1996). The LDH5 form of LDH favors 
converting pyruvate into lactate, whereas the LDH1 enzyme found more often in neurons 
prefers to convert lactate into pyruvate (Bittar et al., 1996). The pyruvate produced through 
glycolysis can thus either be directly channeled to the oxphos pathway for energy generation 
or converted into lactate. Interestingly, astrocytes can provide lactate to neighboring neurons 
during times of high activity as a method of metabolic support (Pellerin & Magistretti, 1994).  
As has become apparent, energy generation varies greatly between astrocytes and neurons. 
Astrocytes have more flexibility to meet their metabolic needs, whereas neurons funnel glucose 
preferentially through the PPP branch and supplement their oxphos machinery with lactate 
from neighboring astrocytes. Indeed, when oxphos was inhibited in primary cultures of rat 
cells, astrocytes were able to recover their ATP levels through the glycolytic pathway, whereas 
neurons failed to recover (Almeida et al., 2001). Even in vivo, when astrocytes were unable to 
use oxphos as a form of energy production, there was no evidence of their survival being 
affected (Supplie et al., 2017). To understand the mechanisms underlying these results, it has 
been shown that when oxidative respiration is inhibited, astrocytes can compensate by 
upregulating glycolysis activator 6-phosphofructo-1-kinase (PFK1), whereas neurons are 
unable to compensate in a similar fashion (Almeida et al., 2004). However, the failure of 
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neurons to utilize glycolysis to the same extent as astrocytes is not a failure of the system. In 
contrast, when glycolysis in neurons was enhanced through transfection with the glycolytic 
driver PFKFB3, it actually led to increased oxidative stress and ultimately neuronal cell death 
through apoptosis (Herrero-Mendez et al., 2009). The bioenergetic differences between 
astrocytes and neurons can even be distinguished in terms of their ETC subunit assembly, as 
the Complex I supercomplexes more often found in neurons were correlated with their reduced 
reactive oxygen species (ROS) production compared to astrocytes (Lopez-Fabuel et al., 2016). 
Therefore, the preferred energy generation pathways are carefully chosen based on the 
neuroprotective abilities of the cell. 
1.1.2 Alternative metabolic pathways 
Although the metabolism of glucose is a main source of energy, the complexity and high energy 
demand of the mammalian brain necessitate alternative routes of energy production. Fatty acid 
oxidation is one such track, which accounts for up to 20% of brain energy requirements (Panov 
et al., 2014). It is postulated that fatty acid oxidation occurs primarily in astrocytes as an extra 
source of ATP generation that allows them to further metabolically support neurons. As was 
mentioned previously, astrocytes are able to produce lactate from pyruvate and provide the 
lactate to neurons, rather than allowing pyruvate to be converted into acetyl-CoA, enter the 
TCA cycle and subsequently generate ATP through oxphos. In order to still obtain enough ATP 
to maintain their cellular functions, astrocytes need another option to power their oxphos 
pathway. Indeed, in astrocytes, fatty acids are the favored substrate for producing acetyl-CoA, 
which they accomplish by undergoing β-oxidation (Panov et al., 2014). One of the reasons β-
oxidation of fatty acids is not as prominent in neuronal cells is because this pathway has 
multiple sites of ROS generation, and thus challenges the low oxidative stress threshold of 
neurons (Perevoshchikova et al., 2013; Schönfeld & Reiser, 2013). 
Another additional metabolic substrate for ATP generation is glutamate, which can also be 
processed and fed into the TCA cycle (McKenna, 2007; Schousboe, 2019). Traditionally, 
glutamate is viewed as a main excitatory neurotransmitter in the brain that is essential for cell 
signaling. During neurotransmission, glutamate released into the synapse stimulates activity on 
the post-synaptic neurons and is then cleared from the extracellular space by astrocytes. 
Glutamate is subsequently converted into glutamine by astrocytes and transferred to 
neighboring neurons, where it can be deamidated back to glutamate and used for further 
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neurotransmission. Alternatively, glutamate can be transformed to α‐ketoglutarate and enter 
the TCA cycle (McKenna, 2013; McKenna et al., 2016). Astrocytes can utilize glutamate as a 
substrate for the TCA cycle (Nissen et al., 2015), but neurons have also been shown to employ 
this metabolic option, which can be crucial for preventing glutamate accumulation and the 
resultant excitotoxicity (Divakaruni et al., 2017).  
Therefore, although similar metabolic energy pathways are present in both astrocytes and 
neurons, their cell-specific functions cause them to preferentially utilize select avenues, which 
is enforced by the expression of specific enzymes and transporters in each cell type. Neurons 
favor the PPP pathway over the glycolytic pathway and are unable to utilize the third option of 
storing glucose as glycogen. The end compound of pyruvate obtained directly through 
glycolysis, or indirectly in the form of lactate provided by astrocytes, is then funneled into the 
oxphos energy pathway in the mitochondria. In contrast, the metabolic profile of astrocytes 
shows greater flexibility, as they are able to use glucose for glycogen synthesis and subsequent 
energy storage, and when oxphos is blocked they are better able to compensate with the 
glycolytic pathway for energy generation.  
1.2 Astrocyte and neuron interaction 
It was shown more than 30 years ago (Rosenberg & Aizenman, 1989), and has been 
demonstrated consistently in the years following (Mederos et al., 2018; Wade et al., 2011), that 
astrocytes provide essential support to neurons through a variety of crosstalk mechanisms. 
Astrocytes protect neurons against excitotoxicity (Rothstein et al., 1996) and oxidative stress 
(Drukarch et al., 1998), as well as provide transmitophagy (Davis et al., 2014; Morales et al., 
2020). A more novel method of support was recently proposed, whereby astrocytes provide 
functional mitochondria to neurons in a mouse model of ischaemic stroke (Hayakawa et al., 
2016) or following traumatic brain injury (Ren et al., 2021); although this is still debated 
(Berridge et al., 2016).     
This neuroglia interplay is especially essential for buffering the relatively low toxicity 
threshold of neurons. For example, fatty acids generated by neurons during periods of high 
activity can be transferred to astrocytes, where they are subsequently broken down and, as a 
result, do not become toxic to the neuronal cells (Ioannou et al., 2019). Besides removing toxic 
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elements, astrocytes can also directly boost the antioxidant defense of neurons (Jimenez-Blasco 
et al., 2015). For instance, neurons tend to oxidize glucose through PPP to regenerate 
glutathione and accordingly protect themselves against oxidative damage. However, in times 
of high activity, astrocytes themselves will provide glutathione precursors to neurons, thereby 
providing them an alternative way to counter ROS (Jimenez-Blasco et al., 2015).  
A form of neurometabolic coupling has also been proposed, known as the astrocyte-neuron 
lactate shuttle (ANLS) hypothesis (Magistretti & Allaman, 2015; Pellerin et al., 1998). This 
model suggests that upon feedback from neurons, such as through neurotransmitter release, 
astrocytes release lactate into the extracellular space, whereby neurons can uptake the lactate 
to meet their energy needs, especially during periods of heightened activity. Neurons can 
convert lactate back into pyruvate and then channel pyruvate directly into their oxphos 
pathway, which is more energy conserving than producing pyruvate through the multiple steps 
of glycolysis. As was mentioned previously, astrocytes can provide the lactate either by 
breaking down their stored glycogen (Dringen et al., 1993; Rich et al., 2019) or by having their 
aerobic glycolysis stimulated (Pellerin & Magistretti, 1994).  
It is clear that astrocytes have a prominent role in the neurometabolic coupling throughout the 
human brain. These tight connections mean that astrocytes not only provide support to 
neighboring neurons but can also cause negative effects when the astrocytes themselves are 
dysfunctional. For example, when the mitochondria of glial cells were inhibited using 
fluorocitrate, the adjoining neurons had increased vulnerability to excitotoxicity (Voloboueva 
et al., 2007). Thus, the investigation of disease pathophysiology should not only be focused on 
neurons, but also consider other cell types to properly address the glitches in these 
interconnected networks. One common attribute of disorders that is becoming increasingly 
evident and affects cell populations throughout the brain is mitochondrial dysfunction.   
1.3 Mitochondrial dysfunction and its role in neurodegeneration 
Mitochondria have been linked to aging and neurodegeneration, and thus are viewed as one of 
the early hallmarks of age-related disorders (Koopman et al., 2012). Mitochondrial dysfunction 
has indeed been identified in various pathological conditions as an early occurrence 
contributing to the disease progression, including diabetes (Kim et al., 2008), cancer (Porporato 
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et al., 2018), and multiple sclerosis (de Barcelos et al., 2019). Furthermore, impaired 
mitochondria function has also been implicated in many neurodegenerative diseases (Mishra 
& Chan, 2014; Srivastava, 2017; Stanga et al., 2020), such as at the early stages of Alzheimer’s 
disease (AD) pathogenesis (Yao et al., 2009). The pathological effects of the APOE4 risk gene 
for AD have been shown to include mitochondria dynamics, as the mitochondria of astrocytes 
in APOE4 transgenic mice demonstrated reduced mitophagy and mitochondrial fission 
(Schmukler et al., 2020). Impaired mitochondrial dynamics were also demonstrated in a tau 
mouse model of AD (Kandimalla et al., 2018). In multiple sclerosis (MS), it was established 
that mitochondrial dysfunction specifically in astrocytes is a key cause of the neurological 
dysfunction found in that disease (Sadeghian et al., 2016). In particular, the relationship of the 
mitochondria with inflammation signaling, such as through the generation of ROS, has been 
tied to various pathologies (Missiroli et al., 2020). 
One of the other main connections between neurodegenerative diseases and mitochondria is 
oxidative stress. Impaired mitochondrial function can lead to increased levels of oxidative 
stress, which is a common characteristic of neurodegenerative diseases (Lin & Beal, 2006; Xie 
et al., 2013). Mitochondrial dysfunction has certainly been implicated in various diseases, but 
even in healthy aging it has been shown that both neuronal and glial mitochondrial metabolism 
is reduced and altered (Boumezbeur et al., 2010). The metabolic networks connecting 
astrocytes across brain regions partially explain the spread of damage that occurs in most 
disorders, as was shown in a glaucoma mouse model (Cooper et al., 2020). Furthermore, the 
neurometabolic coupling between astrocytes and neurons that was previously described has 
been shown to be instrumental in disease pathology. For example, in a mouse model of 
Huntington’s disease (HD), region-specific metabolite analysis revealed that a reduced amount 
of glucose, as well as its amino acid precursors, were present in the mouse striatum compared 
to the cerebellum (Polyzos et al., 2019).  The astrocytes in the HD striatum subsequently 
compensated for the reduced glucose levels by relying more on fatty acid oxidation to obtain 
energy. The resulting increase of ROS levels then oxidatively damaged the nearby neurons and 
might have partially accounted for the neuronal death observed in the disease (Polyzos et al., 
2019). Metabolic reprogramming might thus be a viable therapeutic option to counteract the 
mitochondrial deficiencies observed in various diseases.  
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1.4 Direct neuronal reprogramming 
It was accepted as a universal doctrine that once cells had obtained a fully differentiated cell 
fate their developmental potency was lost. However, it was then discovered that somatic cells 
could regain their pluripotent potential under the influence of four transcription factors (Oct4, 
Sox2, Klf4, and c-Myc) (Okita et al., 2007; Takahashi & Yamanaka, 2006). The pluripotent 
reprogramming was initially successfully achieved in mouse cells (Wernig et al., 2007), and 
then subsequently in human cells (Takahashi et al., 2007). Many doors were opened as the 
reprogramming potential was thereafter investigated in many different types of somatic cells 
(Vierbuchen & Wernig, 2011). Induced pluripotent stem cells (iPSCs) are an invaluable 
method for disease modelling (Sharma et al., 2020; Singh et al., 2015) and their ability to 
generate specific human cell types in vitro can also be used in transplantation therapies (Kondo 
et al., 2014; Nagoshi & Okano, 2018; Windrem et al., 2017). Another advantageous 
reprogramming tool is the ability to directly change the identity of a fully differentiated cell 
type into another, thus bypassing the pluripotent state. In particular, direct neuronal 
reprogramming is of special interest as a therapeutic tool for the many neurodegenerative 
diseases.  
Understanding the role of transcription factors in endogenous neurogenesis paved the way for 
unlocking their use in direct neuronal reprogramming. The initiation of neuronal lineage 
development is controlled by a few proneural genes that belong to the basic helix-loop-helix 
(bHLH) family of transcription factors, and these factors specifically bind DNA sequences that 
have an E-box motif (Bertrand et al., 2002). Achaete-scute homolog 1 (Ascl1) and 
Neurogenin2 (Neurog2) are two well-known and extensively studied examples of proneural 
bHLH transcription factors. For example, overexpression of Ascl1 in the developing chick 
neural tube (Nakada et al., 2004) and murine cerebral cortex (Cai et al., 2000) led to the 
generation of neurons. Conversely, mice expressing a null allele of Ascl1 had a reduction of 
olfactory neuroepithelium (Guillemot et al., 1993) and neural progenitors in the ventral 
telencephalon (Casarosa et al., 1999). Neurog2, on the other hand, has been shown to be 
essential for the generation of sensory cranial ganglia neural progenitors (Fode et al., 1998). 
The importance of the Neurog family of transcription factors in maintaining dorsal-ventral 
neural specification was demonstrated in Neurog mutant embryos (Fode et al., 2000). Without 
the usual presence of Neurog in the dorsal domain, Ascl1 expression would extend out from 
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its ventral region and infiltrate the dorsal territory (Fode et al., 2000). Therefore, Neurog2 and 
Ascl1 have important and distinct roles in the initiation of neuronal specification and 
regionalization in the developing brain.  
 
The direct switch to a neuronal cell fate was first accomplished using postnatal mouse astroglial 
cells in vitro (Heins et al., 2002). The transcription factor Pax6 was used initially, and then 
neuronal subtype specificity was explored by using Neurog2, Ascl1, and Dlx2 (Heinrich et al., 
2010, 2011). Human and murine fibroblasts have also been successfully converted into neurons 
using a variety of different transcription factors (Colasante et al., 2015; Pang et al., 2011; 
Vierbuchen et al., 2010; Wapinski et al., 2017). Not just transcription factors, but also small 
molecule cocktails have been utilized for direct neuronal reprogramming (Gao et al., 2017; Li 
et al., 2015; Yang et al., 2019; Yin et al., 2019; Zhang et al., 2015). For therapeutic applications, 
direct neuronal reprogramming is often aimed at endogenous cells in the brain, such as glia 
cells (Berninger et al., 2007; Blum et al., 2011; Hu et al., 2019; Masserdotti et al., 2015; Rivetti 
Di Val Cervo et al., 2017) and pericytes (Karow et al., 2012, 2018; Liang et al., 2018). The 
subtype specificity of the reprogrammed neurons has been further explored in order to replace 
the relevant populations of cells that are lost in various neurodegenerative diseases. For 
example, with the aim of potentially transplanting healthy dopaminergic neurons into the brain 
of a Parkinson’s disease (PD) patient, murine and human fibroblasts have been successfully 
converted into dopaminergic neurons (Caiazzo et al., 2011; Liu et al., 2012; Pfisterer et al., 
2011). The investigation of disease pathology has also been possible through direct 
reprogramming strategies, and this form of disease modeling has been utilized for both PD 
(Lee et al., 2019) and AD (Hu et al., 2015), among others (Drouin-Ouellet et al., 2017). 
Neuronal reprogramming was successfully achieved not only in vitro, but also in vivo, 
specifically in the mouse brain (Buffo et al., 2005; Gascón et al., 2016; Heinrich et al., 2014; 
Liu et al., 2021; Mattugini et al., 2019).  
 
The field of direct neuronal reprogramming has expanded its knowledge base over time, with 
more work focusing on the potential hurdles to reprogramming and understanding the 
underlying cascades involved in the process. It was determined that Ascl1 and Neurog2 activate 
very distinct neurogenic cascades when transduced in murine astrocytes (Masserdotti et al., 
2015). Furthermore, the efficacy of the transcription factors has been shown to be context 
dependent and strongly affected by the starting cell population. For example, Neurog2 exhibits 
poor neuronal reprogramming efficiency when applied to murine embryonic fibroblasts 
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(Chanda et al., 2014), but in contrast is very effective in reprogramming murine postnatal 
astrocytes (Masserdotti et al., 2015). The reprogramming of somatic cells into neurons is 
influenced by the accessibility of target genes, as was shown with Ascl1 and its ability to access 
closed chromatin targets in fibroblasts (Wapinski et al., 2013).  Not only epigenetic hurdles, 
but also metabolic differences between cells can greatly influence the viability and efficiency 
of reprogramming (Gascón et al., 2016; Russo et al., 2021).  
As was mentioned previously, certain metabolic states are required for each cell type in order 
to support the cell-specific functions that are performed. The localization of different cell types 
on the spectrum of glycolysis to oxphos based on their metabolic preferences is demonstrated 
in Figure 2. Therefore, when cell fate conversion occurs, such as in direct neuronal 
reprogramming, a parallel switch in metabolic identity must also take place. Indeed, even 
during the differentiation of neurons from iPSCs a shifted metabolic profile to favor oxphos 
for energy generation was detected (Fang et al., 2016; Zheng et al., 2016). This metabolic 
switch was also shown to be essential for direct neuronal reprogramming, for when oxphos 
was blocked by treating the cells with Oligomycin A, the resultant glycolytic-dependent 
astrocytes were no longer able to transform into neurons (Gascón et al., 2016). During 
successful neuronal reprogramming, increased oxidative stress was observed as the cells 
changed their metabolic components to favor oxphos and thus more ROS was generated by the 
ETC. Interestingly, it was shown that by treating cells with anti-oxidative compounds the 
success of reprogramming increased dramatically both in vitro and in vivo (Gascón et al., 
2016). These results imply that by alleviating the stress occurring during the metabolic switch 




Figure 2. Schematic of the metabolic profiles of different cell types, and the subsequent changes in 
metabolism that must occur during cell fate transition. (Gascón et al., 2017; License Number: 
5076091092613) 
 
1.5 Complex I deficiency: NDUFS4-mutation  
 
In order to improve the therapeutic potential of direct neuronal reprogramming, it is imperative 
to further increase the reprogramming efficiency and the viability of reprogrammed neurons. 
Successful metabolic conversion is a main hurdle to reprogramming that is still not well 
understood. One option to further understand and thus improve the switch from glycolytic to 
oxphos metabolism is to study patients who have mitochondrial deficiencies. However, before 
discussing mitochondrial disorders, the oxphos machinery will first be described in more detail. 
As mentioned previously, the oxphos metabolic pathway in the mitochondria is comprised of 
five multi-subunit complexes embedded in the IMM (Letts & Sazanov, 2017). The reduced 
electron carriers NADH and FADH2 transfer electrons to Complex I (CI) and Complex II (CII), 
respectively. The electrons are then passed down the other complexes in the electron transport 
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chain, enabling said complexes to pump protons from the matrix to the intermembrane space. 
The resulting electrochemical proton gradient across the membrane causes protons to naturally 
flow back into the matrix through the Complex V (ATP synthase) pore and thereby generate 
ATP (Letts & Sazanov, 2017). The electrochemical gradient is not only important for the 
production of cellular energy in the form of ATP but is also critical for other mitochondrial 
functions such as calcium homeostasis and apoptosis (Koopman et al., 2013). Therefore, when 
there are issues with the performance of the ETC, it has deleterious consequences for the 
various essential functions of the mitochondria within the cell. Indeed, oxphos deficiencies are 
often associated with severe phenotypes in the patients, including neurodegeneration 
(Koopman et al., 2013).   
 
Mitochondrial diseases are associated with deficiencies in key mitochondrial functions, such 
as oxphos, although they are very heterogenous, both in their clinical presentation and genetic 
basis (Gusic & Prokisch, 2021; Tan et al., 2020). Indeed, since mitochondrial proteins are 
encoded by both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA), mutations can 
occur in both genomes (Schlieben & Prokisch, 2020). The wide range of mitochondrial disorder 
phenotypes makes diagnosis difficult, although some specific syndromes have been defined, 
such as Leber’s hereditary optic neuropathy (LHON), Leigh’s syndrome (LS), and 
mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) (Baertling et 
al., 2014; Rahman et al., 1996; Schlieben & Prokisch, 2020). As was mentioned previously, 
mitochondrial defects are also involved in the pathogenesis of various diseases, including AD 
and PD, as well as amyotrophic lateral sclerosis (Filosto et al., 2011; Lin & Beal, 2006; Stanga 
et al., 2020). Mitochondria dysfunction can even be an early hallmark of neurodegenerative 
diseases, as increased oxidative damage was detected in patients with mild dementia (Keller et 
al., 2005). The most common defects of mitochondrial metabolism are mutations in CI of the 
ETC (Distelmaier et al., 2009a; Smeitink et al., 2001a; Smeitink et al., 2001b). Human 
NADH:ubiquinone oxidoreductase, also known as CI, is the largest multi-subunit complex of 
the ETC and is encoded by both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) 
(Smeitink et al., 2001a). CI is located on the inner mitochondrial membrane and is responsible 
for oxidizing NADH to NAD+ and passing the resulting electrons onto CIII (Friedrich & 
Böttcher, 2004). Four protons are also translocated from the mitochondrial matrix to the 
intermembrane space, thus supporting the proton motive force across the membrane (Friedrich 
& Böttcher, 2004). Structural analysis revealed that CI is composed of a hydrophobic 
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membrane arm that inhabits the IMM and a peripheral arm that extends into the mitochondrial 
matrix, forming an L shape (Clason et al., 2010; Wirth et al., 2016).  
One common mutation in the mammalian CI occurs in the 18kDa nuclear-encoded subunit 
NDUFS4 (NADH dehydrogenase [ubiquinone] iron‐sulfur protein 4), an accessory subunit of 
the peripheral arm of CI (Breuer et al., 2013; Van Den Heuvel et al., 1998). The NDUFS4 gene 
is important for the assembly of a functional complex, as evidenced by the lack of complete CI 
detected in patients with NDUFS4 mutations (Petruzzella et al., 2001; Scacco et al., 2003). 
Indeed, compared to the fully assembled CI at ~980kDa, the much smaller ~800kDa 
subcomplex detected in an NDUFS4-mutant patient indicates that multiple subunits are unable 
to bind and complete the assembly (Lazarou et al., 2007). Therefore, NDUFS4 most likely 
plays an essential role in the final assembly stages of CI (Vogel et al., 2007). A regulatory role 
for NDUFS4 is also possible, as it has been shown that cAMP‐dependent protein kinase (PKA) 
phosphorylates NDUFS4 and this process is the manner by which CI is activated by cAMP 
(Papa et al., 2012). 
NDUFS4-mutant patients have a variety of symptoms, which occur shortly after birth, and 
many patients die within the first few years of life (Fiedorczuk & Sazanov, 2018). The patients’ 
phenotype is characterized by infantile-onset Leigh syndrome (LS), lactic acidosis and 
encephalomyopathy (Fiedorczuk & Sazanov, 2018). Tissues with high energy demand are 
particularly affected by mitochondrial dysfunction, and as a result cardiac, muscular, and neural 
pathologies are common clinical features. Indeed, the patients exhibit abnormal ocular 
movements, muscular hypotonia, cardiomyopathy, and respiratory failure (Budde et al., 2003; 
Ortigoza-Escobar et al., 2016). In accordance with these symptoms, the patients present with 
lesions in the basal ganglia and brainstem (Ortigoza-Escobar et al., 2016).  
Skin fibroblasts from NDUFS4-mutant patients analyzed by blue native polyacrylamide gel 
electrophoresis (BN-PAGE) demonstrated partially assembled 830kDa subcomplexes but an 
absence of fully assembled CI (Assouline et al., 2012). Concomitant with the lack of complete 
CI, spectrophotometric analysis revealed reduced CI enzyme activity in patient skin fibroblasts 
and muscle tissue (Assouline et al., 2012). The low level of CI activity, that can still be detected 
in patient tissues despite being only partially assembled, can be explained by the formation of 
supercomplexes between CI and CIII (Calvaruso et al., 2012). The stabilization that CIII gives 
to CI is especially relevant for allowing the NADH dehydrogenase module to properly 
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associate with the complex (Calvaruso et al., 2012). When the mitochondrial ROS production 
in human fibroblasts was measured using a mitochondria-targeted superoxide detector 
(MitoSOX Red), NDUFS4-deficient fibroblasts displayed increased ROS levels compared to 
controls (Melcher et al., 2017). Considering that increased ROS can have detrimental effects 
on cell function, reducing ROS levels was investigated as a possible therapeutic strategy. Co-
culturing with mesenchymal stem cells (MSCs) reduced the ROS levels of patient cells back 
to control cell levels. Interestingly, even with normalized ROS levels there was no detectable 
recovery of CI assembly or activity in the patient cells (Melcher et al., 2017). The separation 
of ROS from the bioenergetic effects of deficient CI activity was further demonstrated when 
investigating NDUFS4-mutations in heart tissue. Mice with a heart-specific NDUFS4-mutation 
had severe cardiomyopathy and CI activity was reduced by ~50% (Chouchani et al., 2014). 
However, there was no increase in hydrogen peroxide levels in the heart or markers of oxidative 
damage, indicating that the cardiac dysfunction was primarily due to the reduced CI activity 
and not ROS influences (Chouchani et al., 2014).  
In order to further understand the disease progression and to develop therapeutic strategies, a 
Ndufs4 knockout (KO) mouse model was developed (Kruse et al., 2008). The KO mice are 
similar to wild type (WT) mice for the first four weeks, but after postnatal day(P)35 the mice 
start to exhibit motor dysfunction and they die by ~P50. Reduced CI activity and the presence 
of fewer fully assembled CI was confirmed in the KO mice. Overall, the mice seemed to 
resemble the human CI deficiencies (Kruse et al., 2008). Although the full body KO mouse 
model partially represents the human mitochondrial encephalomyopathy, other mouse models 
have also been developed that target specific cell populations. For example, Ndufs4 was 
selectively knocked out in neurons and glia, referred to as the NesKO mouse model (Quintana 
et al., 2010). Interestingly, this restricted KO led to a very similar phenotype as the full KO 
mouse model, indicating the important role of the CNS in disease progression (Quintana et al., 
2010). In order to further understand the role CI dysfunction has in the basal ganglia and 
striatum, a mouse line was generated that targeted the Ndufs4 knockout to medium spiny 
neurons (MSN KO mice) (Chen et al., 2017). Although the mice exhibited a progressive motor 
impairment, no reactive gliosis or neuronal cell death was detected. The inflammation observed 
in the other KO models could thus be due to the axons projecting to the striatum, since the 
MSNs by themselves do not seem to elicit such a reaction (Chen et al., 2017). Another 
conditional deletion of Ndusf4, this time in dopaminergic neurons (Ndufs4 cKO), also did not 
cause neuronal cell death (Choi et al., 2017). In this case, there were no motor impairments but 
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there was impaired cognitive function and a reduced amount of dopamine in the brain (Choi et 
al., 2017). To sum up, mouse models of CI-deficiency can be instrumental in further untangling 
the cell-specific contributions to mitochondrial disease. However, mouse models still do not 
properly recapitulate the human disease pathogenesis (Lorenz et al., 2017; Tzoulis et al., 2014), 
and thus the influence of mitochondrial mutations on different human cell types still needs to 
be further investigated.  
Models for studying mitochondrial disease in humans have been revolutionized with the 
discovery of iPSC reprogramming. Patient-specific phenotypes can now be more accurately 
represented, and their disease mechanisms investigated, which not only allows for a greater 
understanding of the disease pathogenesis but also provides the opportunity for drug screening 
(Inak et al., 2017). These iPSC disease-modeling strategies allow for, in particular, the study 
of cells from tissues that are not easily accessible, such as the human brain (Mertens et al., 
2016). Indeed, iPSC-derived neural progenitor cells (NPCs) have been used successfully as a 
cellular model system for mitochondrial disease that not only portrays the mutant phenotypes 
but can also be rescued upon drug treatment (Liang et al., 2020; Lorenz et al., 2017). The 
pathogenic phenotype of neuronal cells, specifically in LS, was successfully investigated using 
patient iPSC reprogramming (Galera-Monge et al., 2020). Altered bioenergetics could be 
detected in iPSC-derived neural cells from a LS patient, as well as compromised mitochondrial 
calcium regulation (Galera-Monge et al., 2020). The course of neuronal development has also 
recently been studied in patients with a mitochondrial mutation, specifically in the protein 
SURF1, which is involved in the assembly of CIV (Inak et al., 2021). Interestingly, aberrant 
neuronal maturation could be detected in SURF1-mutant patient cells in both 2D, as well as 
3D organoid, culture models. Diminished neurite outgrowth was additionally observed in 
NPCs from patients with mutations in NDUFS4, which as discussed previously, is another 
common LS-associated mutation. Therefore, impaired neuronal morphogenesis is potentially a 
consistent pathogenic feature across LS (Inak et al., 2021). The underlying cause for the 
defective neuronal differentiation could be explained by the negative impact of these 
mitochondrial mutations on the oxphos metabolic pathway. Indeed, NPCs from patients with 
other mutations related to LS demonstrated altered bioenergetics, and more specifically, an 
enhanced dependence on glycolysis (Ma et al., 2015). Cells from patients with a SURF1 
mutation also exhibited defects already at the NPC stage, including the inability to shift their 
metabolism from a glycolytic progenitor state into the oxphos metabolism preferred by mature 
neuronal cells (Inak et al., 2021). These results further corroborate the importance of being able 
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to utilize the oxphos metabolic machinery in order to successfully obtain a neuronal fate. 
Therefore, iPSC technology is instrumental for studying human mitochondrial disease, 
especially the CNS pathogenesis. 
In conclusion, investigating patients with mitochondrial disorders can reveal new therapeutic 
strategies not only for treating the mitochondrial dysfunction that is an early hallmark of many 
diseases, but can also be used for analyzing the metabolic switch that occurs during direct 
neuronal reprogramming.  
1.6 Aim of the thesis 
The overall aim of my PhD studies was to investigate the underlying mechanisms, and in 
particular the metabolic switch, that influence the ability of a cell to directly convert into a 
neuronal fate. Although direct neuronal reprogramming is a promising tool for replacing the 
functional neurons lost in neurodegenerative disease, further optimization is required to make 
it a viable treatment in human patients. Thus, the identification and mitigation of 
reprogramming barriers not only in murine reprogramming, but also in human cell 
reprogramming, is imperative.  
The first aim of my PhD research was to study the influence of the mitochondria during 
neuronal reprogramming, especially in regard to the known metabolic shift. To this end, the 
mitochondrial proteome of murine astrocytes and neurons was explored, and their respective 
mitochondria structure was analyzed. The distinct mitochondrial composition of the two cell 
types was then used to determine the extent of metabolic programming that occurs during 
forced neuronal fate acquisition. Additionally, the manipulation of neuron-enriched 
mitochondrial proteins and their effect on the reprogramming efficiency were investigated.   
For the focus of my second aim, I examined the role of mitochondrial metabolism in human 
cells during neuronal reprogramming, as well as the influence of mitochondrial mutations on 
different cell types. The ability of NDUFS4-mutant iPSCs to be differentiated into astrocytes 
in vitro was first investigated, and their phenotype compared to cells from control donors. Then 
the relative proficiency of the glial cells from both donors to reprogram into neurons, and the 
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contribution of the mitochondrial deficiency on reprogramming, was determined. Finally, 
various treatments were tested to alleviate cell stress during reprogramming, as well as to 
address the mitochondrial dysfunction, leading to the discovery of a novel limiting pathway in 






2.1 Aim of the Study I 
The aim of the first study was to investigate and compare the mitochondrial metabolism 
between astrocytes and neurons and determine how manipulation of cell-type-specific-
enriched mitochondrial proteins can influence direct neuronal reprogramming.  
CRISPR-Mediated Induction of Neuron-Enriched Mitochondrial Proteins 
Boosts Direct Glia-to-Neuron Conversion 
Gianluca L Russo, Giovanna Sonsalla, Poornemaa Natarajan, Christopher T Breunig, 
Giorgia Bulli, Juliane Merl-Pham, Sabine Schmitt, Jessica Giehrl-Schwab, Florian Giesert, 
Martin Jastroch, Hans Zischka, Wolfgang Wurst, Stefan H Stricker, Stefanie M Hauck, 
Giacomo Masserdotti and Magdalena Götz 
For this paper I conducted the time course analysis of the changes in specific mitochondrial 
proteins during astrocyte to neuron reprogramming. I was also involved in the review and 
editing of the manuscript.  
The paper is published in Cell Stem Cell, 4 March 2021, pages 524–534.e7. 
https://doi.org/10.1016/j.stem.2020.10.015 
This is an open access paper and being an author of this article, I have the right to include it 
in a thesis or dissertation, provided it is not published commercially. 
Note that due to elevated number of pages Supplementary Table 1 and Supplementary Table 2 are not 
included in the PDF version of this thesis but are available as separate excel files.  
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https://doi.org/10.1016/j.stem.2020.10.015SUMMARYAstrocyte-to-neuron conversion is a promising avenue for neuronal replacement therapy. Neurons are partic-
ularly dependent on mitochondrial function, but how well mitochondria adapt to the new fate is unknown.
Here, we determined the comprehensive mitochondrial proteome of cortical astrocytes and neurons,
identifying about 150 significantly enriched mitochondrial proteins for each cell type, including transporters,
metabolic enzymes, and cell-type-specific antioxidants. Monitoring their transition during reprogramming
revealed late and only partial adaptation to the neuronal identity. Early dCas9-mediated activation of genes
encoding mitochondrial proteins significantly improved conversion efficiency, particularly for neuron-
enriched but not astrocyte-enriched antioxidant proteins. For example, Sod1 not only improves the survival
of the converted neurons but also elicits a faster conversion pace, indicating that mitochondrial proteins act
as enablers and drivers in this process. Transcriptional engineering ofmitochondrial proteins with other func-
tions improved reprogramming as well, demonstrating a broader role of mitochondrial proteins during fate
conversion.INTRODUCTION
The ability to regenerate lost neurons after an injury or in neuro-
degenerative disease is still a key challenge in the field of regen-
erative medicine. Among different therapeutic approaches
(Barker et al., 2018; Grade and Götz, 2017), direct conversion
of local glia into neurons has become a viable option to replace
functional neurons (Vignoles et al., 2019). Because direct
neuronal conversion is dramatically hindered by increased gen-
eration of reactive oxygen species (ROS) during the process,524 Cell Stem Cell 28, 524–534, March 4, 2021 ª 2020 The Author(s)
This is an open access article under the CC BY-NC-ND license (http://Bcl2 or pharmacological application of antioxidants could dras-
tically improve neuronal generation in vitro and in vivo (Gascón
et al., 2016). At the same time, neurons rely on oxidative phos-
phorylation (OxPhos) (Harris et al., 2012; Herrero-Mendez
et al., 2009), so an increase in mitochondrial activity is required
during neuronal conversion. Mitochondria perform a plethora
of additional functions (Spinelli and Haigis, 2018), and specific
mitochondrial proteins may be required to implement the cell-
type-specificmetabolic needs (Calvo andMootha, 2010; Folmes
et al., 2012; Pagliarini et al., 2008). Because changes in. Published by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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neuronal reprogramming, we assessed the similarities and differ-
ences in mitochondrial composition for cultured neurons and as-
trocytes and aimed to improve mismatching during reprogram-
ming by regulating the respective genes by CRISPRa
(clustered regularly interspaced short palindromic repeat activa-
tion)-mediated transcriptional engineering.
RESULTS
Mitochondrial Morphology Changes during Cortical
Astrocyte-to-Neuron Reprogramming In Vitro
We first monitored morphological changes of mitochondria dur-
ing reprogramming. Astrocytes isolated from postnatal day 5
(P5) murine cerebral cortex (Heinrich et al., 2011) were
transduced with a retrovirus encoding mitochondrion-targeted
green fluorescent protein (mitoGFP) with or without the reprog-
ramming proneural factor Achaete-scute homolog 1 (Ascl1-
ires-mitoGFP, ires [intra ribosome entry site]), shown previously
to reprogram astrocytes into GABAergic neurons (Heinrich
et al., 2010; Masserdotti et al., 2015). MitoGFP co-localized
with Tomm20, a pan-mitochondrial marker protein, revealing
an elongated and ramified mitochondrial network in astrocytes
(Figure 1A, left panel). This was maintained in Ascl1-transduced
astrocytes failing to reprogram (positive for the astroglial protein
glia fibrillary acidic protein [Gfap], negative for neuron-specific
bIII-tubulin; Figure 1A, center panel), whereas successfully con-
verted neuronal cells (bIII-tubulin+, Gfap) had smaller mito-
chondria with shorter and rounder morphology (Figure 1A, right
panel). These data are in line with neurons in vivo possessing
smaller mitochondria and higher fission properties (Misgeld
and Schwarz, 2017), whereas astrocytes have more elongated
mitochondria and fusion events (Motori et al., 2013). To gain a
better understanding of mitochondrial restructuring during the
reprogramming process, we investigated the proteins that
mediate morphological and functional changes in mitochondria.
Astrocytes and Neurons Differ in Mitochondrial
Structure and Function In Vitro
To determine the comprehensive mitochondrial proteome of
neurons and astrocytes, we chose highly pure neuronal cultures
derived from embryonic day 14 (E14) cerebral cortex, cultured
for 7 days (Walcher et al., 2013); i.e., young neurons comparable
with reprogrammed neurons at 7 days post-transduction (DPT)
in reprogramming) and primary cultures of astrocytes as usedFigure 1. Astrocytes and Neurons Differ in Mitochondrial Structure an
(A) Micrograph of mitochondrial morphology in control (mitoGFP) astrocytes (left p
neurons (right panel, Ascl1-mitoGFP), 7 DPI. Scale bars, 20 mm and 6 mm (insets
(B) t-SNE plot of samples considering only mitochondrial proteins.
(C) Volcano plot of mitochondrial proteins with log2 ratio of abundance of neuro
(p value, y axis); 2-fold changes (vertical lines), significance cutoff p = 0.05 (horizo
and more abundant in neurons in red. Names highlight proteins covered in this s
(D) Unsupervised heatmap cluster analysis of all detected mitochondrial proteins.
Z score.
(E and F) GO terms of the top 10 biological processes (BPs; blue, left panels) and
neuron-enriched (F) mitochondrial proteins. The color bar represents the fold cha
considered if exact Fisher test < 0.01.
(G–J) Examples of 2 terms identified by gene set enrichment analysis (GSEA) (G
terms (in G or I).
526 Cell Stem Cell 28, 524–534, March 4, 2021in direct neuronal reprogramming. Functional bio-energetic dif-
ferences of neurons and astrocytes from these cultures were
confirmed by Seahorse analysis (Figures S1A–S1C). A cell frac-
tionation-based method (Schmitt et al., 2013) enriched mito-
chondria, as assessed by western blot (Figure S1D) and electron
microscopy (EM) (Figure S1E), and functional assays confirmed
the isolation of intact mitochondria from both cell types (Figures
S1F and S1G). EM confirmed the cell-type-specific differences in
mitochondrial morphology (Figures 1A and 1E) and also revealed
some other organelles in the neuronal samples, probably
because small mitochondria are tightly linked to the cytoskeleton
in the thin neuronal processes and the endoplasmic reticulum
(ER) (Fecher et al., 2019).
Astrocytes and Neurons Exhibit Profound Differences in
Their Mitochondrial Proteome
We then used liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) to identify proteins in neuronal and astrocytic
mitochondria. A t-distributed stochastic neighbor embedding
(t-SNE) plot for all identified proteins normalized for abundance
(Figures S1J; normalization in Figure S1H) or mitochondrion-
specific proteins (Figure 1B; normalization in Figure S1K), as
classified by MitoCarta 2.0 (Table S1; Calvo et al., 2016),
revealed clear separation of neurons and astrocytes. Unsuper-
vised cluster analysis confirmed the cell type dependent similar-
ity, considering whole proteins (Figure S1I) or only mitochondrial
proteins (Figure S1L). Overall, we detected 757 (±1) mitochon-
drial proteins in astrocytes and 738 (±1) in neurons (Figures
S1M and S1N) of which 164 (22%) were more abundant in astro-
cytes and 141 (19%) more abundant in neurons (p < 0.05 and
2-fold enrichment; Figure 1C; Table S1), with high reproducibility
across samples (Figure 1D). Thus, about a fifth of the mitochon-
drial proteome differs significantly between these cell types.
Western blotting of whole-cell lysates from independent cultures
confirmed enrichment of Sfxn5 and Cpox in astrocytes (Fig-
ure S1O, left and center panel) and glutaminase (Gls) in neurons
(Figure S1O, right panel).
Gene Ontology (GO) term analysis of mitochondrial proteins
significantly enriched in astrocytes (Figure 1E, left panel; top
10 enriched biological processes [BPs]; Fisher’s exact test <
0.01; see Table S2A for a complete list) revealed terms such as
fatty acid catabolic process, fatty acid b-oxidation, and lipid
catabolic process, also relevant pathways for astrocytes in vivo
(van Deijk et al., 2017). This was supported by the analysis of mo-
lecular function (MF) GO terms (Figure 1E, right panel; Tabled Proteome
anel), Ascl1-non-reprogrammed astrocytes (center panel), and Ascl1-induced
).
ns/astrocytes (x axis) and the –log10 of the corresponding significance value
ntal line). Proteins significantly more abundant in astrocytes are shown in blue
tudy.
Astrocytes, blue; neurons, red. n = 3 for each group. The color scale indicates
molecular functions (MFs; green, right panels) for astrocyte-enriched (E) and
nge compared with the expected number of genes for each term. Terms were
and I) and barplots (H and J) of the main genes associated with the respective
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ing, in line with a recent study of mitochondria of Bergmann glia
from adult mice (Fecher et al., 2019). Likewise, gene set enrich-
ment analysis (GSEA) identified fatty acid b-oxidation-related
proteins in astrocytes (Figure 1G; Table S2E), comprising key
regulators such as Acads, Cpt1a, and Cpt2 (Figure 1H; Tables
S1 and S2E).
To explore the functional relevance of the fatty acid b-oxida-
tion pathway in direct reprogramming, we blocked this pathway
using etomoxir, an inhibitor of Cpt1a (Jernberg et al., 2017), early
during the conversion process (Figure S2A). Medium to high
doses of etomoxir (25 mM and 100 mM, respectively) improved
reprogramming compared to the control (no etomoxir) upon
Ascl1 (Figures S2B and S2C) or Neurogenin2 (Neurog2) expres-
sion (Figures S2D and S2E). Interestingly, co-treatment with
a-tocotrienol, an analog of the ROS scavenger vitamin E,
reduced Ascl1-mediated reprogramming efficiency, suggesting
that the positive effect of etomoxir might be partly due to an in-
crease in ROS, as shown previously (O’Connor et al., 2018).
Thus, b-oxidation is a general hurdle in glia-to-neuron
reprogramming.
GO terms significant for neuron-enriched mitochondrial pro-
teins were associated with RNA metabolism and function (BP
in Figure 1F, left panel, and Table S2C; MF in Figure 1F, right
panel, and Table S2D) and further supported by GSEA (Figures
1I and 1J, tRNA metabolic process; full list in Table S2E). This
highlights the notion that tRNAbiogenesis is an important activity
in neuronal mitochondria and its dysfunction is associated with
neurodevelopmental disease (Schaffer et al., 2019). Among
neuron-enriched mitochondrial proteins, we also detected Gls,
the enzyme regulating glutamine metabolism and glutamate
neurotransmitter levels (Márquez et al., 2009), and ATP citrate
lysate (Acly), involved in production of cytosolic acetyl-CoA
(Lin et al., 2013; Table S1).
Enrichment of the mitochondrial fusion protein Mitofusin 1
(Mfn1) in astrocytes is in line with the presence of more elon-
gated mitochondria in such cells (Figure 1A), whereas the fission
master regulator Dynamin-related protein (Dnm1l, also known as
Drp1) is more prevalent in the neuronal mitochondrial proteome
(Table S1). Interestingly, the antioxidant proteins Gpx1, Gpx4,
Prdx6, and Mgst1 were more enriched in astrocytes (Table S1),
whereas Mgst3, Prdx2, and Sod1 were more abundant in neu-
rons (Table S1), suggesting that different members of antioxidant
protein families (e.g., peroxiredoxins and microsomal gluta-
thione S-transferases) are enriched in specific cell types. This
raised the intriguing question of whether these proteins (Prdx2
and Prdx6 or Mgst1 and Mgst3) are functionally similar and
only expressed in a cell-type-specific manner or whether the
neuron-enriched antioxidant proteins may be specifically
required in neurons and, hence, during the direct conversion
process.
We also compared our data with mitochondrial proteins iso-
lated from adult murine cerebellum (Purkinje cells, granule cells,
and astrocytes; Fecher et al., 2019). Despite the very different
experimental conditions (in vivo versus in vitro, adult versus post-
natal, cerebellum versus cortex, immunoprecipitation [IP]-based
versus fractionation-based-method), we found 117 proteins
enriched in both astrocyte-derived samples; i.e., 60% of all mito-
chondrial proteins identified by Fecher et al. (2019) were alsopresent in our astrocyte-enriched mitochondrial proteome (Fig-
ure S1P). Likewise, 46% of neuron-enriched mitochondria
identified by Fecher et al. (2019) were common to our neuronal
dataset (Figure S1Q).
Thus, themitochondrial proteome already differs profoundly in
astrocytes and neurons in vivo and in vitro, comprising broad
categories of protein functions frommetabolism to tRNA synthe-
sis and mitochondrial translation.
Mitochondrial Protein Changes during Astrocyte-to-
Neuron Reprogramming
To determine whether and when astrocytes downregulate their
characteristic mitochondrial proteins and express neuron-
enriched ones during reprogramming, we chose differentially
enriched functionally relevant candidates detectable by immu-
nostaining (Table S1). The immunofluorescence intensity of the
candidates was quantified and normalized to the signal intensity
of the pan-mitochondrial protein Tomm20, preventing any bias
of the total mitochondrial mass on quantification.
Sfxn5, a mitochondrial transporter of citrate (Miyake et al.,
2002), an essential intermediate of the tricarboxylic acid cycle
(TCA), was enriched in astrocyte-derived mitochondria (Table
S1). Accordingly, its level was much higher in astrocytes or
DsRed-transduced controls than in reprogrammed neurons (Fig-
ures 2A, 2B, and 2D). During Ascl1-mediated reprogramming,
Sfnx5 was similar to control astrocytes at early stages (Figures
2A and 2D), whereas bIII-tubulin+ reprogrammed neurons had
significantly lower levels (Figures 2B and 2D). Notably, Sfxn5
and Tomm20 showed a greater colocalization in Ascl1-trans-
duced cells at 1 than 7 DPT (Figure 2C), supporting the notion
that Sfxn5 is mitochondrially localized in astrocytes and disap-
pears in induced neurons (iNeurons). Likewise, the astrocyte-en-
riched mitochondrial protein Cpox (Mori et al., 2013), highly ex-
pressed in astrocytes (Figures S3A, S3B, and S3D) was
downregulated significantly in Ascl1-transduced cells (Figures
S3B and S3D, center panel), but to a lower degree in Ascl1-
transduced astrocytes than in Ascl1-iNeurons (Figures S3C
and S3D). These data show a relatively late (5–7 DPT) regulation
of Sfnx5 and Cpox. The lack of downregulation in reprogram-
ming-resistant astrocytes prompts the suggestion that this
may contribute to failure of reprogramming.
Among neuron-enrichedmitochondrial proteins, we examined
Prdx2, which catalyzes the reduction of peroxides and, hence,
protects against oxidative stress (Boulos et al., 2007). Prdx2
was not detected in astrocytes (Figures 2E, 2F, and 2H), while
Ascl1-transduced cells had some Prdx2 signal at 3 DPT, with
the strongest increase at 5–7 DPT in Ascl1-iNeurons (Figures
2F and 2H). At 7 DPT, Prdx2 reached a level similar to that
observed in primary neurons (Figure 2H) and co-localized with
Tomm20 (Figure 2G). Similarly, Gls, fundamental for glutamate
production and glutamate and GABA transmitter levels as well
as neuronal differentiation (Velletri et al., 2013), showed the
strongest expression in iNeurons (5–7 DPT; Figures S3F and
S3H), where it colocalized with Tomm20 (Figure S3G). Notably,
its upregulation started earlier, at 1 DPT (Figure S3H), but did
not reach the levels of primary cortical neurons (Figure S3H, right
panel).
Mitochondrial proteins enriched in astrocytes (Sfxn5 and
Cpox) or neurons (Prdx2 and Gls) change relatively late duringCell Stem Cell 28, 524–534, March 4, 2021 527
Figure 2. Mitochondrial Protein Changes during Astrocyte-to-Neuron Reprogramming
(A, B, E, and F) Micrographs showing immunostaining in astrocytes transduced with DsRed or Ascl1-ires-DsRed as indicated. Scale bars, 20 mm.
(C andG) Examples of scatterplots of the pixel intensity correlation between Tomm20 and Sfxn5 (C) or Prdx2 (G) in Ascl1-transduced cells on day 1 (left panel) and
in reprogrammed cells on day 7 (right panel). Pearson’s coefficient as average of 3 cells/biological replicate; n = 3 biological replicates.
(D and H) Violin plots of the log2 ratio of the intensity of the expression of Sfxn5 (D) or Prdx2 (H) normalized to Tomm20 intensity over time. Each dot represents 1
cell. 10 cells analyzed/biological replicate/condition/day. n = 3 biological replicates; ***p % 0.001.
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with the degree of conversion, prompting the hypothesis that
they may be functionally relevant.
CRISPRa-Mediated Induction of Neuron-Enriched
Mitochondrial Proteins Improves theEfficiency of Direct
Neuronal Reprogramming
To test the above prediction, we chose 8 candidates enriched in
neuronal mitochondria (Figures S4A and S4B; Table S1; Fecher
et al., 2019): Sod1 and Prdx2 for their antioxidant activity in neu-
rons (Liu et al., 2020; Rosen, 1993), acyl-CoA thioesterase 7
(Acot7), arginase 2 (Arg2), Gls, microsomal Gst3 (Mgst3), mito-
chondrial serine/threonine protein phosphatase (Pgam5), and
solute carrier 25 member 22 (Slc25a22) (Figure 3A). Among
astrocyte-enriched antioxidant mitochondrial proteins, we
selected Prdx6 (Fisher, 2011) and the microsomal glutathione
S-transferase Mgst1, a member of the membrane-associated
proteins in eicosaonid and glutathione metabolism (MAPEG)
family, as Mgst3 (Bresell et al., 2005). Dynamin 3 (Dnm3) was
included as a protein with mitochondrion-unrelated functions
(Gu et al., 2010; Figure 3A).
Quantitative RT-PCR from cells isolated by fluorescence-acti-
vated cell sorting (FACS) 48 h after transfection of the dCas9-
VPR coding plasmid (Breunig et al., 2018b) and non-targeting
control gRNAs or gRNAs designed to target the promoter region
of the above candidates showed different levels of induction
(Figure 3C; Arg2, 94-fold; Acot7, Prdx2, Sod1, Slc25a22,
Dnm3, Mgst1, and Prdx6,  5-fold; Gls, Mgst3, and Pgam5,
2-fold). Multiple gRNAs targeting different genes (e.g., Arg2+-
Gls) did not alter the induction levels of their specific targets,
and no significant induction was detectable for six putative off
targets of each gRNA (Figure S4C).
gRNAs for the selected candidates were cloned in a plasmid
with a GFP reporter module whose activation depends on the
presence of the self-transcribed gRNAs (e.g., for Sod1) and
dCas9-CAM (Figure 3B). Then, primary cultures of astrocytes,
obtained by crossing a transgenic mouse line in which the
dCas9 gene is fused to three transactivating domains (VP64,
p65, and RTA[R transactivator]) and SAM (synergistic activator
Mediator) components (dCAM) (Chavez et al., 2015; Konermann
et al., 2015; STARMethods) with the astrocyte-specific Aldh1l1:-
Cre mouse line (Tien et al., 2012; Figure 3B), were co-transfected
with the constructs forAscl1-ires-DsRed and the control STAgR-
GFP (gRNA-GFP) or gene-specific gRNA, and neuronal conver-
sion was examined 8 DPT. Strikingly, the induction of many, but
not all, genes coding for neuron-enriched mitochondrial proteinsFigure 3. CRISPRa-Mediated Activation of Neuron-Enriched Mitochon
(A and B) Schemes of the selected candidates in mitochondria and the dCas9-C
(C) Real-time quantitative PCR (qPCR) of the candidates in dCas9-CAMgene-spe
scramble control (mean ± SEM). n = 3 for each group.
(D) Micrographs showing reprogrammed cells (bIII-tubulin+-DsRed+-GFP+) upo
(green). Scale bar, 100 mm.
(E) Reprogramming efficiency as the percentage of bIII-tubulin+/DsRed+/GFP+ a
experimental condition.
(F) Examples of the morphology of reprogrammed neurons co-expressing Ascl1
(G) Morphological analysis of reprogrammed neurons upon induction of selected
n = 4 biological replicates.
(H) Sholl analysis of reprogrammed neurons co-expressing Ascl1 and the indicat
biological replicates.
530 Cell Stem Cell 28, 524–534, March 4, 2021improved the reprogramming efficiency (Figures 3D and 3E). In-
duction ofSod1 resulted in the highest reprogramming efficiency
alone or in combination with Prdx2 (Figure 3D and 3E; Fig-
ure S4D). In addition, induction of Arg2 and Mgst3 as well as
Pgam5 and Slc25a22, which do not have any reported antioxi-
dant activity, significantly improved the conversion efficiency
(Figures 3D and 3E). Remarkably, the induction of genes coding
for astrocyte-enriched mitochondrial proteins, even with antiox-
idant function (Mgst1 and Prdx6), was not beneficial for reprog-
ramming, likeDnm3 (Figures 3D and 3E). This highlights the need
for neuron-enriched antioxidants (e.g., Sod1 and Mgst3) and
shows that members of the same family (e.g., Mgst1 and
Mgst3) are clearly not functionally redundant. The expression
of neuron-enriched candidates also resulted in a more complex
morphology of iNeurons, with more neurite outgrowth in Ascl1-
Sod1+Prdx2-co-expressing neurons and more branches in
Ascl1-Slc25a22-co-expressing neurons (Figures 3F and 3G).
These data suggest that neuron-specific mitochondrial pro-
teins are particularly important during the conversion process
and that their earlier and/or higher expression improves
reprogramming.
CRISPRa-Mediated Induction of Prdx2 and Sod1
Improves Neuronal Reprogramming by Faster
Conversion into Neurons with a Longer Lifespan
To investigate the effect of the early activation of mitochondrial
proteins on neuronal conversion, we followed single cells by
live imaging as described before (Costa et al., 2011), from 28 h
after the transfection for 6 days with GFP/DsRed pictures taken
every 4 h (Figure 4A; Figure S2F; Video S1). Ascl1-Prdx2-Sod1-
co-transfected cells with neuron-like morphology (smaller cell
soma and processes longer than 33 the soma length; Gascón
et al., 2016) were already increased significantly at 75 h
compared with Ascl1-only cells (Figure 4B). Prdx2 and Sod1
co-activation significantly increased the lifespan of all tracked
cells (Figure 4C), mainly because of an increased lifespan of
the converted neurons (Figures 4E and 4F), but not of non-re-
programmed astrocytes (Figure 4D), consistent with the cell-
type-specific role of antioxidants. Measuring the conversion
speed (when cells first acquire a neuron-like morphology)
showed a bi-phasic distribution in Ascl1-transfected cells (Fig-
ure 4G). Cells turning into neurons fast (red dots) typically died
before the end of the experiment, whereas those that reprog-
rammed at a slower pace (blue dots) survived until the end of
the video session at 6 DPT (Figure 4G). This was remarkably
different in Ascl1-Prdx2-Sod1-expressing cells: many cellsdrial Proteins Improves Neuronal Reprogramming
AM-STAgR (string assembly gRNA) system employed here.
cific gRNA-expressing cells. Data are shown as log2 fold change over the gRNA
n co-transfection of Ascl1-ires-DsRed (red) and different STAgR constructs
t 7 DPT. Data are shown as mean ± SEM. *p < 0.05, ***p < 0.001. n = 5 per
and the indicated gRNAs.
candidates (x axis). Data are shown as mean ± SEM. Paired t test, *p % 0.05;
ed candidates. Data are shown as mean ± SEM. Paired t test, *p% 0.05; n = 4
Figure 4. Continuous Single-Cell Live Imaging Reveals Several Roles of Prdx2-Sod1 Activation in Neuronal Reprogramming
(A) Scheme of continuous live imaging and the analysis performed.
(B) Time course analysis of the percentage of cells acquiring neuronal morphology over double-transfected cells at the indicated time points. Data are shown as
mean ± SEM. *p % 0.05. n = 3 biological replicates for each group.
(C and D) Violin plot showing the lifespan of all cells analyzed irrespective of their final identity (C) and cells that died without converting (D), following expression of
Ascl1-gRNA-GFP or Ascl1-gRNA-Prdx2-Sod1. n = 5 biological replicates for each group. *p % 0.05
(E–G) Violin plots showing the lifespan (E and F) and speed of reprogramming (G) upon expression of Ascl1-gRNA-GFP or Ascl1-gRNA-Prdx2-Sod1. n = 5
biological replicates (color-coded) for each group. *p % 0.05, **p % 0.01, ***p % 0.001.
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(Figure 4G). Importantly, this is not due to improved survival of
the fast-converting cells that would die under the Ascl1-only
condition because a similar number of cells converting fast
and dying (blue dots and curve in Figure 4G) was observed
among Ascl1-Prdx2-Sod1 cells. Rather, many more cells were
recruited for reprogramming under theAscl1-Prdx2-Sod1 condi-
tion and in a fast manner (Figure 4G). We therefore conclude that
activation of these neuron-enriched mitochondrial proteins
speeds up the conversion process in addition to its role in pro-
tecting neurons from cell death.
DISCUSSION
Here we describe the comprehensive mitochondrial proteomes
of cortical astrocytes and neurons that show quantitative differ-
ences in a fifth of the identified proteins. The functional relevance
of these differences is shown by the fact that cells failing to up-
regulate neuron-enriched mitochondrial proteins often do not
reprogram; activating their expression improved the reprogram-
ming efficiency, and astrocyte-enriched mitochondrial proteins,
even with known antioxidant function, have no such effects.
Astrocyte Metabolism and Its Influence on Neuronal
Reprogramming
Astrocytes share similarities with neural stem cells (NSCs) (Götz
et al., 2015). For example, we and others (Fecher et al., 2019)
found the mitochondrial proteome of astrocytes to be enriched
for the GO terms lipid metabolism and fatty acid b-oxidation,
also highly represented in neural stem cells (NSCs) and downre-gulated during adult neurogenesis (Knobloch et al., 2017; Llo-
rens-Bobadilla et al., 2015). Despite the fast transcriptional
changes at early stages of reprogramming (Gascón et al.,
2016; Masserdotti et al., 2015), genes associated with lipid
metabolism (e.g., Cpt1a) are not yet downregulated after 48 h
(Gascón et al., 2016; Masserdotti et al., 2015), suggesting slow
metabolic conversion, a limiting factor in induced pluripotent
stem cell (iPSC) reprogramming (Wu et al., 2016). Accordingly,
etomoxir-mediated reduction of fatty acid b-oxidation improved
neuronal reprogramming (Figure S3), indicating that the manipu-
lation of specific metabolic pathways might substantially
contribute to remove hurdles during the conversion. The addition
of ROS scavenger reduced the reprogramming efficiency com-
bined with etomoxir, suggesting potential beneficial effects of
ROS under this condition. It will be interesting to determine the
level of ROS above which it shows deleterious effects.
Early Activation of Neuron-Enriched Mitochondrial
Proteins with a Wide Functional Spectrum Improves
Astrocyte-to-Neuron Conversion
The comprehensive mitochondrial proteome revealed cell-type-
specific enrichment of antioxidant proteins; e.g., Mgst1 and
Mgst3 were enriched in the mitochondrial proteome of astro-
cytes and neurons, respectively. Remarkably, early CRISPRa-
mediated induction of the latter, but not the former, improved
direct neuronal conversion, demonstrating the key functional
role of cell-type-specific but similar antioxidant proteins. Sod1
activation had the most potent effect, in line with its functional
relevance in neurodegeneration (Kaur et al., 2016). However,
other mitochondrial proteins with antioxidant functions, suchCell Stem Cell 28, 524–534, March 4, 2021 531
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tively) did not improve reprogramming, showing that only some
antioxidants perform highly cell-type-specific functions relevant
in direct neuronal reprogramming.
The early activation of neuron-enrichedmitochondrial proteins
without any reported antioxidant activity also significantly
increased direct reprogramming efficiency. Pgam5, a mitochon-
drial phosphatase that associates with the RIP1/RIP3/MLKL
(Mixed lineage kinase domain-like pseudokinase) complex,
doubled Ascl1-induced reprogramming efficiency, possibly by
inhibiting necroptosis (Gascón et al., 2016; Lu et al., 2016). In
addition, Pgam5 regulates mitochondrial homeostasis and dy-
namics by dephosphorylating Drp1, BCL-xL (B-cell lymphoma
extra large), and FUNDC1 (Ma et al., 2020), a key process for
neuronal function and survival (Lu et al., 2014). Likewise, the
mitochondrial glutamate transporter Slc25a22, which also
improved reprogramming by 2-fold, is important for brain func-
tion (Cohen et al., 2014; Molinari et al., 2005, 2009; Poduri
et al., 2013) by regulating glutamate levels (Goubert et al., 2017).
Conversely, the activation of Gls did not significantly improve
reprogramming, suggesting that glutamate biogenesis does not
have a major role in this process. Likewise, the activation of a
non-mitochondrial protein, Dnm3, expressed at similar levels in
astrocytes and neurons, had no effect. These results confirm
our cutoff criteria and highlight a potent role of only some
neuron-enriched mitochondrial proteins in direct conversion by
influencing several functional pathways.
Notably, astrocyte-enriched mitochondrial proteins, like Sfnx5
and Cpox, were only partially downregulated in reprogramming
andmaintained a higher expression in cells that failed to convert.
This indicates that these cells face a ‘‘confused’’ metabolic state
that may hinder reprogramming and highlights the importance to
further ease the metabolic transition for proper conversion.
Indeed, ‘‘on-memory’’ genes not shut off during reprogramming
from the original starter cell limit the conversion process (Hor-
manseder et al., 2017).
Neuron-EnrichedMitochondrial Protein Activation as an
Enabler and Driver in Reprogramming
Most improvement in reprogramming efficiencywas achieved by
early expression of the neuron-enriched mitochondrial proteins
Sod1 and Prdx2: they increased recruitment of more cells into
the conversion process and improved survival only of reprog-
rammed neurons and their differentiation. Thus, early activation
of these neuron-enriched mitochondrial antioxidants protects
neurons, but not astrocytes, against aberrant ROS levels
(Gascón et al., 2016).
Remarkably, Ascl1-expressing cells showed a significant dif-
ference in conversion speed between neurons that survive and
those that do not survive for 6 days, with the former converting
much slower. This is reminiscent of natural neurogenesis, where
the transition from progenitors to neurons often occurs more
gradually via intermediate progenitors (Khacho et al., 2016; Llo-
rens-Bobadilla et al., 2015), suggesting the need for a period of
adaptation to support the new identity. Surprisingly, the expres-
sion of Prdx2 and Sod1 speeds up the conversion process in
cells surviving until the end of the time lapse, similarly to co-
expression of Bcl2 (Gascón et al., 2016). Thus, different mito-
chondrion-dependent pathways may speed up the conversion532 Cell Stem Cell 28, 524–534, March 4, 2021rate by improving cell survival and/or protecting against ROS
damage. We therefore propose that failure or late activation of
neuron-enriched mitochondrial proteins may impair the conver-
sion process at several levels, ultimately causing cells to die.
Importantly, this occurs despite the expression of a multitude
of antioxidant and metabolic proteins present in astrocytes.
Thus, direct neuronal reprogramming sheds new light on the
function of cell-type-enriched mitochondrial proteins.
Limitations of Study
Clearly, it would be desirable to follow the mitochondrial prote-
ome in a comprehensive manner during the reprogramming pro-
cess, which will be made easier by newly developed mouse lines
with tagged mitochondrial proteins (Fecher et al., 2019), also in
the murine brain in vivo or human cells in vitro. Ideally, these
could be compared with fully differentiated neurons; here we
choose culture conditions and time points to match the reprog-
ramming protocol.
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Stoykova, A., Cvekl, A., Ninkovic, J., and Götz, M. (2013). Functional dissec-
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Lichtmannegger, J., Jennen, L., M€uller-Höcker, J., Roggel, F., Göttlicher, M.,
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Goat anti-ANT Santa Cruz Cat# sc.9299; RRID: AB_671086
Total Oxphos Rodent Ab cocktail Abcam Cat# ab110413; RRID: AB_2629281
Mouse anti-b-III-Tubulin Sigma-Aldrich Cat# T8660; RRID: AB_477590
Mouse anti-GFAP Dako Cat# Z0334; RRID: AB_100013482
Rabbit anti-GFAP Sigma-Aldrich Cat# G3893; RRID: AB_477010
Rat anti-RFP Chromotek Cat# 5F8; RRID: AB_2336064
Rabbit anti-RFP Rockland Cat# 600-401-379; RRID: AB_2209751
Chicken anti-GFP Aves Labs Cat# GFP-1020; RRID: AB_10000240
Rabbit anti-CPOX Abcam Cat# Ab169766
Rabbit anti-Prdx2 Abcam Cat# Ab109367; RRID: AB_10862524
Rabbit anti-Gls Proteintech Cat# 20170-1-AP; RRID: AB_10665373
Rabbit anti-Sfxn5 Abcam Cat# Ab172971
Anti-Aldh1l1 Merck Millipore Cat# MABN495; RRID: AB_2687399
Anti-Tomm20 Abnova CAt# H00009804-M01; RRID: AB_1507602
Anti-Mouse-HRP linked Invitrogen Cat#626520; RRID: AB_2533947
Anti-Mouse, HRP linked Cell Signaling Cat# 7076; RRID: AB_330924
Anti-Rabbit, HRP linked Cell Signaling Cat# 7074; RRID: AB_2099233
Anti-Rabbit, HRP, linked GE Healthcare Cat#NA934; RRID: AB_2722659
Anti-Goat, HRP linked Santa Cruz Cat# sc-2020; RRID: AB_631728
Anti-Mouse Alexa Fluor 488 Molecular Probes Cat# A-21202; RRID: AB_141607
Anti-Chicken Alexa Fluor 488 Thermo Fisher Cat# A-11039; RRID: AB_2534096
Anti-Rat Cy3 Dianova Cat# 112-165-167; RRID: AB_2338251
Anti-Mouse IgG2b 633 Innovative Research Cat# A21146; RRID: AB_1500899
Anti-Mouse IgG1 647 Molecular Probes Cat# A21240; RRID: AB_141658
Anti-Rabbit Alexa Fluor 488 Molecular Probes Cat# A21206; RRID: AB_141708
Anti-Mouse IgG1 Biotin Southernbiotech Cat# 1070-08; RRID: AB_2794413
Streptavidin Alex Fluor 405 Thermo Fisher Cat# S32351
Bacterial and Virus Strains
RV CAG-Neurog2-ires-DsRedExpress2 Gascón et al., 2016 N/A
RV CAG-Ascl1-ires-DsRed Gascón et al., 2016 N/A
RV CAG-DsRedExpress2 Gascón et al., 2016 N/A
RV CAG-mitoGFP This study N/A
RV CAG-Ascl1-ires-mitoGFP This study N/A
RV CAG-Ascl1-ires-mitoRFP This study N/A
Chemicals, Peptides, and Recombinant Proteins
EGF GIBCO Cat# PHG0311
bFGF GIBCO Cat# 13256029
Poly-D-Lysine Sigma-Aldrich Cat# P0899
B27 GIBCO Cat# 17504044
HBSS medium Thermo Fisher Cat# 24020117
HEPES Thermo Fisher Cat# 15630080
DMEM/F12 Thermo Fisher Cat# 10565018
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trypsin/EDTA 0,25% Thermo Fisher Cat# 25200056
Neurobasal Medium GIBCO Cat# 21103149
Glucose GIBCO Cat# A2494001
GluataMAX GIBCO Cat# 35050061
OptiMEM – GlutaMAX Thermo Fisher Cat# 51985-026
EGTA Sigma-Aldrich Cat# E3889
Lipofectamine 2000 Thermo Fisher Cat# 11668019
Rhodamine 123 Thermo Fisher Cat# R302
Oligomycin A Sigma-Aldrich Cat# 73351
FCCP Sigma-Aldrich Cat# C2920
Rotenone Sigma-Aldrich Cat# R8875
Antimycin A Sigma-Aldrich Cat# A8674
2-Deoxy-D-glucose Sigma-Aldrich Cat# D8375
Triton X-100 Sigma-Aldrich Cat# T9284
Etomoxir Sigma-Aldrich Cat# E1905
Bovine Serum Albumine (BSA) Sigma-Aldrich Cat# A9418
Critical Commercial Assays
Arcturus PicoPure RNA Isolation Kit Thermo Fisher Cat# 12204-01
Bradford Protein Assay Kit BioRad Cat# 5000201
First Strand cDNA Synthesis Kit Thermo Fisher Cat# K1621
PowerUp SYBR Green Master Mix Thermo Fisher Cat# A25742
Agencourt AMPure XP Beckman Coulter Cat# 10136224
RC DC Protein assay BioRad N/A
Deposited Data
mitoProteomic data, identifier: PXD014886 This study https://www.ebi.ac.uk/pride
Experimental Models: Organisms/Strains
C57BL/6 LMU animal Facility N/A
Aldh1l1-Cre LMU animal Facility N/A
Rosa26-LoxP-Stop-LoxP-dCAM HMGU N/A
Oligonucleotides







pCDNA-miniCMV-GFP This study N/A
STAgR_cntrl This study N/A
STAgR_Acot7 This study N/A
STAgR_Arg2 This study N/A
STAgR_Gls This study N/A
STAgR_Mgst3 This study N/A
STAgR_Pgam5 This study N/A
STAgR_Sod1 This study N/A
STAgR_Slc25a22 This study N/A
STAgR_Dnm3 This study N/A
STAgR_Mgst1 This study N/A
STAgR_Prdx6 This study N/A
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STAgR_Arg2-Gls (A-G) This study N/A
STAgR_Prdx2-Sod1 (P-S) This study N/A
STAgR_Arg2-Dnm3 (A-D) This study N/A
Software and Algorithms
ZEN software Zeiss https://www.zeiss.com/microscopy/en_us/products/microscope-
software/zen.html RRID:SCR_013672
ImageJ ImageJ https://imagej.net/Downloads RRID: SCR_003070
Morphometric analysis SNT Ferreira et al., 2014
Sholl Analysis ImageJ N/A
Co-localizatioin Coloc2 https://imagej.net/Coloc_2
Proteome discoverer 2.2 software Thermo Fisher https://www.thermofisher.com/order/catalog/product/
IQLAAEGABSFAKJMAUH RRID:SCR_014477
SwissProt Database Mouse NCBI Protein https://www.ncbi.nlm.nih.gov/protein RRID:SCR_003257
mitoCARTA 2.0 database Calvo et al., 2016) N/A
Perseus Software Perseus http://maxquant.net/perseus/ RRID:SCR_015753
GraphPad Prism 7.0 GraphPad Software https://www.graphpad.com:443/ RRID:SCR_002798
Adobe Illustrator Adobe Illustrator https://www.adobe.com/de/products/catalog.html
RRID:SCR_010279
Zeiss AxioVision 4.7 software Zeiss http://www.zeiss.com/microscopy/us/products/microscope-
software/zen-core.html?vaURL=www.zeiss.com/microscopy/
us/products/microscope-software/axiovision.html
Microsoft Excel Microsoft Excel https://www.microsoft.com/en-gb/ RRID:SCR_016137
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prof.
Magdalena Götz (magdalena.goetz@helmholtz-muenchen.de).
Materials Availability
d Plasmids generated in this study are available upon request.
d gRNA sequences used to activate gene-specific loci are listed in Methods S1.
d Aldh1-Cre transgenic mice are available at Jackson Lab (stock n.023748).
d There are restrictions to the availability of dCAM mice due to MTA request.Data and Code Availability
d Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE, partner repos-
itory, with dataset identifier PXD014886.Cell Stem Cell 28, 524–534.e1–e7, March 4, 2021 e3
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Wild-type mice (Primary Cell culture, Proteomics, IHC)
All experimental procedures in this study, done at the LMU M€unchen, were performed in accordance with German and European
Union guidelines and were approved by the government of Upper Bavaria. For most of the experiments, primary cultures of astro-
cytes were obtained frombrains of C57BL/6Jmice of 5-7 days of age; no specific gender was considered. Primary cultures of cortical
neurons were obtained from brains of C57BL/6J embryos at 14.5 days post conception (14.5 dpc or E14.5). Mice were fed ad libitum
and housed with 12/12 h light and dark cycle and kept under specific-pathogen-free (SPF) conditions.
Aldh1-Cre and Cre-inducible dCas9-VPR mice
The activation of specific mitochondria-coding genes was performed in primary cultures of astrocytes obtained from Aldh1l1-Cre
(Tien et al., 2012) crossedwith dCAMmice (Rosa26-loxP-Stop-LoxP-dCas9VPR-SAMmice (J.G.-S., unpublished data). Both strains
were used as heterozygotes. The background strain of the mice was C57BL/6.
Primary cultures of cortical astrocytes
Astrocytes were isolated and cultured as previously described, with small changes (Heins et al., 2002). After removal of themeninges,
gray matter tissue from cerebral cortex of C57BL/6J mice at postnatal day 5-7 (P5–P7) was dissected and dissociated mechanically.
Subsequently, cells were centrifuged for 5min at 1,300 rpm, re-suspended, and plated in a T25 flask inmedium consisting of DMEM/
F12 (1:1), 10% fetal bovine serum (FBS), penicillin /streptomycin, and 1x B27 serum-free-supplement, 10 ng/ml epidermal growth
factor (EGF), and 10 ng/ml basic fibroblast growth factor (bFGF) (astro-medium). Cells were passaged at 80%–90% confluency after
7-10 days using trypsin/EDTA and plated on poly-D-lysine coated glass coverslips at a density of 50,000-60,000 cells per coverslip (in
24-well plates) in fresh astro-medium. The vast majority of the cells (> 90%) in these cultures were positive for glial fibrillary acidic
protein (Gfap) as previously described. Primary cultures of astrocytes were maintained in an incubator for 6-8 days at 37C and
5% CO2.
Cells undergoing direct neuronal conversion
One day after transduction or transfection, astro-medium was replaced with fresh medium consisting of DMEM/F12 (1:1), penicillin/
streptomycin, supplemented with 1x B27 and Glutamax, but not FBS, EGF and FGF (differentiation medium). Small molecules were
added once, at the time of medium replacement (24h after transduction or transfection). Cultures were maintained in an incubator for
6-8 days at 37C and 9% CO2.
Primary cultures of cortical neurons
Cerebral cortices were dissected from embryonic day (E) 14 mice as described before (Hartfuss et al., 2001; Walcher et al., 2013).
Cortices were isolated, meninges removed and samples mechanically dissociated in 1x HBSSmedium containing 10mMHEPES, on
ice. Subsequently, cells were digested for 15 min in trypsin-EDTA (0.05%) and centrifuged for 5 min at 1,000 rpm. The pellet was
resuspended in medium containing 10% FBS to stop trypsin, then centrifuged again and resuspended in 1x Neurobasal Medium,
supplemented with 1x Glutamax, penicillin/streptomycin, and 1x B27. Cells were counted and plated at a density of 600,000 cells
per well in 6-well plates, pre-coated with poly-D-lysine. After one week in culture the cells had mostly differentiated into neurons,
with a high purity and little contamination by other cell types.
METHOD DETAILS
Transfection and Transduction
For transfection, DNA-liposome complexes were prepared in OptiMem medium using the retroviral plasmids described below
and Lipofectamine 2000. Astrocytic cultures, plated the day before in 24-well plates at a density of 60,000-80,000 cells per
well, were transfected with DNA-liposome complexes composed of 0.6 mg total DNA, mixed with 0,75ml of Lipofectamine2000
per well, in 400ml of OptiMem medium for 4 hours. Then, transfection medium was replaced by a solution composed to 1:1 ratio
of fresh astro-medium and astro-medium collected from the same cells before the transfection (and filtered). One day later, the
medium was replaced with differentiation medium and cells maintained in culture until 6-7 days post-transfection in 9% CO2 incu-
bator. For FACSorting, RNA extraction and RT-PCR, astrocytes were plated in 6-well plates pre-coated with PDL at a concentra-
tion of 350,000 cells per well. The following day, cells were transfected with DNA-liposome complexes containing 1mg total DNA
and 1,25ml Lipofectamine 2000 per 1ml of OptiMem medium for 4 hours and cultured in astro-medium for 48hours before sorting.
For STAgR experiments, primary cultures of astrocytes, obtained from double positive Aldh1l1-Cre dCAM mice (Rosa26-loxP-
Stop-LoxP-dCas9VPR-SAM mice (Giehrl-Schwab J. et al., in revision), were transfected with plasmids encoding the indicated
STAgR and Ascl1 with a molar ratio 1:1. For transduction, astrocytes were infected with 1ml of virus per well one day after plating.
The viruses used are listed in the key resource table and were produced as previously described (Gascón et al., 2016).e4 Cell Stem Cell 28, 524–534.e1–e7, March 4, 2021
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WT astrocytes were transfected with gRNAs-GFP and dCas9-VPR-DsRed plasmids. Cells were collected 48 hours after transfection
and sorted for RFP+/GFP+, using the FACSAria III (BD Bioscience) system at high purity mode and a flow rate lower than 600 cells per
second. Alternatively, astrocytes obtained from Aldh1l1-Cre x dCAM transgenic mice were transfected only with gRNA-expressing
plasmids and subjected to FACS analysis at 48 hours, collecting GFP+ cells. Cells were washed twice with 1x PBS, treated with
trypsin (0,05% in EDTA) for 5%, then astro-medium was added. Cells were harvested by centrifugation (1,000 rpm, 5min, 4C),
washed twice with 1x PBS and, then, resuspended in 400ml of DMEM/F12 (1:1), phenol-red-free. Single cell suspension was filtrated
using a 70-mm cell strainer. Cells were sorted using the FACS Aria III (BD). Gates were set by using un-transfected cells, as well cells
expressing GFP or DsRed as positive control. 15,000 cells were sorted directly in extraction buffer (Picopure RNA isolation kit) to
enhance RNA quality and efficiency, for subsequent extraction and qRT-PCR.
Mitochondria isolation
Mitochondria isolation from cultured astrocytes and neurons was performed as previously described (Schmitt et al., 2013) using the
pump-controlled cell (PCC) rupture method; a cell homogenizer (Isobiotec, Germany) combined with 1 mL Luer Lock Gas-Tight
Syringes (4.608 mm i.d., SGE Supelco, USA) and a high-precision pump (Pump 11, Harvard Apparatus, USA). The homogenizer
was pre-cooled on ice to ensure cooling of the samples during the isolation, the tungsten carbide ball (6um diameter) was inserted
and the homogenizer was equilibrated with isolation buffer (300 mM sucrose, 5 mM TES, and 200 mM ethyleneglycoltetraacetic acid
[EGTA], pH 7.2). The sample of dissociated astrocytes or neurons was added to 1mL of isolation buffer and passed three (neurons) to
six (astrocytes) times through the system at a constant rate (700 ml/min). To recover the homogenate, the system was rinsed once
with 1 mL of isolation buffer. The sample preparation and the tunable parameters of the PCC, such as the clearance and the number
of strokes, were optimized for each sample. Yield and functionality (mitochondrial transmembrane potential, Dcm) of the isolated
mitochondria were used to assess the optimal parameters. Around 1million astrocytes and neurons respectively were used to obtain
a sufficient amount of mitochondria for further processing. The pooled homogenate was cleared from cell debris and nuclei by centri-
fugation (8003 g, 5 min at 4C), and mitochondria were pelleted at 90003 g (10 min at 4C). After the isolation, syringes were rinsed
3-4 times with double distilled water (ddH2O). The tungsten carbide ball and the cell homogenizer were cleaned with isopropanol
followed by ddH2O to allow processing of the next sample without contamination.
Characterization of isolated mitochondria
The functional analysis of isolated mitochondria was performed by measuring Rhodamine 123 (Rh123) fluorescence quenching in
order to determineDcm, as well as measuring the absorbance change at 540nm (Synergy 2, BioTek, USA) to determinemitochondrial
swelling, as described previously (Schmitt et al., 2013). Protein concentrations were determined by the Bradford assay. For immu-
noblotting analysis, 10 mg of protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and
separated proteins were transferred onto PVDF membrane. Equal protein loading and proper transfer were controlled by Ponceau
red staining. The primary and secondary antibodies used for Western Blot analysis are listed in the Key Resource table.
Electron microscopy analysis of the isolated mitochondria was done as described previously (Zischka et al., 2008). ZE-FFE-
separated mitochondrial fractions were immediately pelleted, fixed in 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide,
dehydrated with ethanol and embedded in Epon. Ultrathin sections were negatively stained with uranyl acetate and lead citrate
and then analyzed on a Zeiss EM 10 CR electron microscope.
Seahorse experiments
Primary cortical astrocytes or neuronswere plated onto XF24 V3PET cell culturemicroplates fromSeahorse biosciences, pre-coated
with PDL, and analyzed the day after plating. Cells were seeded at 20,000, 30,000, 50,000 for neurons; and 15,000, 25,000 or 40,000
for astrocytes. The final cell number was assessed by counting DAPI+ nuclei and measuring DNA content to normalize the data to mg
DNA or 1000 cells. Before measuring cellular respiration, cells were washed twice with assay medium (XF DMEM + 25 mM glucose)
and then incubated in 750 mL of assaymedium for 10min in an air incubator without CO2 at 37
C. The XF24 plate was then transferred
to the XF24 Extracellular Fluxanalyzer (Seahorse Bioscience). Basal respiration was determined with 4-5 assay cycles (2 min. mix,
2 min. measuring), and all parameters were obtained after the respective drug application. Basal OCR and PPRwere measured prior
to oligomycin treatment. For the measurement of different mitochondrial respiration states, oligomycin A (Oligo, 5 mg/ml) was used to
inhibit the ATP synthase, followed by Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 mM) to induce maximal sub-
strate oxidation capacity, and a cocktail containing rotenone (Rot, 5 mM) and antimycin A (Ant, 2 mM) to inhibit ETC activity and deter-
mine non-mitochondrial oxygen uptake. Finally, 2-deoxyglucose (2-DG, 100mM) was added to block glycolysis. Extracellular acid-
ification rate (ECAR) was converted to proton production rate (PPR) based on machine algorithms and the buffer capacity of the
medium. The OCR/PPR ratio was calculated over the averaged basal values. Each value is calculated averaging 3-5 time points
from 3 technical replicates.
Proteome analysis
Isolated mitochondria (10 mg) were used per biological replicate. SDS was added to a final concentration of 2% for efficient solubi-
lization, prior to tryptic protein digest using a modified FASP protocol (Wisniewski et al., 2009). Proteomic measurements were per-
formed on aQ-Exactive HFmass spectrometer (ThermoScientific) online coupled to anUltimate 3000 nano-RSLC (Dionex). PeptidesCell Stem Cell 28, 524–534.e1–e7, March 4, 2021 e5
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OPEN ACCESS Short Articlewere separated on a C18 nanoEase MZ HSS T3 column (100Å, 1.8 mm, 75 mm x 250 mm; Waters) in a 95 min non-linear acetonitrile
gradient. Precursor (scan range 300 – 1500 m/z) and TOP10 fragment spectra of charges 2-7 were acquired in the orbitrap mass
detector of the mass spectrometer, at resolutions of 60,000 and 15,000 respectively with a maximum injection time of 50 ms and
a dynamic exclusion of 30 s for each one. The individual raw-files were loaded to the Proteome discoverer 2.2 software (Thermo
scientific) allowing for peptide identification and label-free quantification using the Minora node. Searches were performed using
Sequest HT as a search engine in the Swissprot mouse database with the following search settings: 10 ppm precursor tolerance,
0.02 Da fragment tolerance, two missed cleavages allowed, carbamidomethyl on cysteine as fixed modification, deamidation of
glutamine and asparagine allowed as variable modification, as well as oxidation of methionine and Met-loss combined with acety-
lation at the N terminus of the protein. Proteins were quantified by summing up the abundances of allocated unique and razor pep-
tides; resulting protein abundances are given in Table S1. Mitochondrial proteins were classified using the mitoCARTA 2.0 database
(Calvo et al., 2016). Data were analyzed in RStudio (version 3.5.3), using the package DEP (Zhang et al., 2018). First, we filtered for
proteins identified in all replicates of at least one condition; then, data were normalized using variance stabilizing transformation (vsn).
Differential enrichment analysis was performed based on linear model. Identified proteins were considered as enriched in neurons if
the log2(fold-change value) was > 1 and enriched in astrocytes if the log2(fold-change value) was <1 and pvalue < 0.05 (according
to DEP output). Differentially enriched proteins (DEP) data are provided in Table S1. T-Distributed Stochastic Neighbor Embedding
(t-SNE) was computed from data normalized in DEP package in RStudio, as well as the heatmap of all considered proteins and the
distance matrix including hierarchical clustering. Gene Ontology analysis was performed in RStudio using the package ‘‘TopGO,’’
using exact Fisher test. Proteins were considered differentially enriched if log2(fold-change) > |1| and pval < 0.05. Complete list of
GO term is provided in Table S2. For Gene Set Enrichment Analysis (GSEA) the package ‘‘fgsea’’ in Rstudio was employed (Korot-
kevich et al., 2019). Complete list of GSEA term is provided in Table S2E.
Western Blot Analysis
Primary cultures of astrocytes or neurons were collected and lysed in RIPA buffer. Protein concentration was evaluated with RC DC
Protein assay (Bio-Rad Laboratories); 60mg of lysate was loaded in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a polyvinylidene fluoride (PVDF) membrane. Depending on the size of the protein analyzed, different gel
concentration was used. The primary and secondary antibodies used for Western Blot analysis are listed in Key Resources Table.
Immunocytochemistry
Cells were fixed in 4%paraformaldehyde (PFA) in PBS1X for 10min. at room temperature, washed in PBS1X twice for 5minutes, and
stored up to a month at 4C before staining. For Prdx2 staining, cells were fixed in ice-cold Methanol 20% for 10 minutes, washed
twice in PBS1X for 10 minutes, and subsequently stored and treated as other samples. Specimen were incubated in primary anti-
bodies (for concentration see Key Resources Table) in PBS1X containing 3% Bovine Serum Albumin (BSA) and 0.5% Triton
X-100 for 2 hours at room temperature or overnight at 4C. After washing twice for 5 minutes with PBS, cells were incubated with
the appropriate species- or subclass-specific secondary antibodies, with or without DAPI to label nuclei (blue), diluted 1:10000,
for 1 hour in the dark at room temperature. Optionally, after incubating with primary antibodies and washing with PBS, biotin-labeled
secondary antibodies were used at a dilution of 1:200 for 1 hour, followed by streptavidin-coupled fluorophores (1:500) for another
hour. Coverslips were then mounted with Aqua Poly/Mount (Polysciences, Warrington, PA). Samples were imaged at the LSM710
laser-scanning confocal or Axio Observer Z1 epifluorescence microscope (Carl Zeiss). Digital images were acquired using the
ZEN software (Carl Zeiss) at 80X, 40X or 25x.
RNA extraction, retro-transcription and Real Time Quantitative PCR (qRT-PCR)
RNA was extracted using Arcturus PicoPure RNA Isolation Kit (Thermo Fisher Scientific) according to the manufacturer’s instruc-
tions, including removal of genomic DNA. 100ng RNA was reverse transcribed using the ThermoFisher cDNA first strand kit. Each
cDNA sample was diluted 1:5. qPCR reactions were performed on an Applied Biosystems QuantStudio 6 Flex Real-Time PCR Sys-
tem, or Roche LightCycler 480. Each 10 mL reaction consisted of 5 mL of PowerUp SYBR Green Master Mix (Thermo Fisher), 0.05 mL
of forward and reverse primer (100 mM) and 5 mL of DNA appropriately diluted. qRT-PCR primers can be found in Key Resource table.
The expression of each gene was analyzed in triplicate. Data were subjected to normalization by using Gapdh as housekeeping
genes and expressed as mRNA fold change compared to control. Quantification was performed on 3 independent biological sam-
ples, each time as technical triplicate. Off targets were selected from the UCSC genome browser, potentially targeting intergenic as
well as exon regions. Primers are listed in Methods S1.
STAgR cloning
For generation of STAgR cloning fragments, we followed previously published protocols (Breunig et al., 2018a, 2018b; Gibson, 2011).
In particular, we generated individual cloning fragments for Gibson assembly by PCRs on 10 ng of vector templates (STAgR_Neo,
STAGR_gRNAScaffold_hU6, STAGR_gRNAScaffold_hH1, STAGR_gRNAScaffold_h7SK and/or STAGR_gRNAScaffold_mU6). The
mix contained 10 ml of high fidelity (HF) buffer, 1 ml of 10 mM dNTPs, 0.25 ml of overhang-primers (see key resources), 0.5 ml of HF
polymerase, 1.5 ml of dimethyl sulfoxide (DMSO) and enough H2O to reach a final volume of 50 ml. Reactions were incubated on a
thermocycler as follows: 1 cycle of 98C for 1 min 30 s; 38 cycles of 98C for 10 s, 59C (for gRNA scaffold)/ 68C (for SAM loop)
for 10 s, 72C for 30 s (for inserts) / 1 min 30 s (for vectors); 1 cycle of 72C for 10 min. 44.5 ml of the PCR reaction were mixede6 Cell Stem Cell 28, 524–534.e1–e7, March 4, 2021
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bation with 90 ml of magnetic beads for 2 min at room temperature (RT). Beads were pelleted through a magnet and washed twice
with 70% ethanol without complete resuspension. The pellet was then dissolved in 20ml H2O and separated from the beads. DNA
concentration was measured using a spectrophotometer. Gibson Assembly has been performed following a homemade Gibson as-
sembly mix. The 5x isothermal reaction buffer is composed as follows: 1 M Tris (Tris(hydroxymethyl)aminomethane)-HCl (pH 7.5),
300 ml of 1 M MgCl, 60ml of 100 mM dGTP (deoxyguanosine triphosphate), 60 ml of 100 mM dATP (deoxyadenosine triphosphate),
60 ml of 100 mM dTTP (deoxythymidine triphosphate), 60 ml of 100 mM dCTP (deoxycytidine triphosphate), 300 ml of 1 M DTT (dithio-
threitol), 1.5 g of PEG-8000 (polyethylene glycol), 300 ml of 100 mM NAD (nicotinamide adenine dinucleotide) and enough H2O to
obtain 6 ml. For the assembly master mix, 320 ml of 5x isothermal reaction buffer was combined with 697 ml of H2O, 3 ml of
10 U/ml T5 exonuclease, 20 ml of 2 U/ml DNA polymerase and 160 ml of 40 U/ml Taq DNA ligase. 7.5 ml of assembly master mix
have been mixed with 2.5 ml of insert and vector. A vector to insert ratio of 1:3 was used. Samples were incubated at 50C for
60 min and subsequently transformed into E. Coli. Resulting plasmids have been sequenced by the Sanger sequencing method
with the following primers: StAgR_seq_fwd1 (GAGTTAGGGGCGGGACTATG), StAgR_seq_fwd2 (ACTGGATCCGGTACCAAGG)
and StAgR_seq_rev (TTACGGTTCCTGGCCTTTTG). Verified inserts have been cut with KpnI and subcloned into pCDNA-miniCMV-
GFP. Primers for gRNA are listed in Methods S1 table.
Live-Imaging Microscopy
Continuous live imaging was performed with a Cell Observer (Zeiss) at a constant temperature of 37C and at 5% CO2. Phase-
contrast images were acquired every 10 min and fluorescence pictures every 4 hours for 6 days using a 10x phase contrast objective
(Zeiss) and an AxioCam HRm camera with a self-written VBA module remote controlling Zeiss AxioVision 4.7 software (TAT, Prof.
Dr. Timm Schroeder). Movies were assembled and analyzed using ImageJ (NIH) software, as also described in Gascón et al.
(2016). In Figure 4B data are shown as pool of five independent biological replicates; in Figures 4C–4G all cells considered from
all biological replicates are shown, indicated by different colors; statistics was performed on the 5 biological replicates using linear
regression in Rstudio (see below).
QUANTIFICATION AND STATISTICAL ANALYSIS
When virus was used to induce neuronal conversion (Figure 1; Figure S2; Figure 3; Figure S3; Figure 4), astrocytes were fixed at the
days after transduction, as indicated in the figures. Quantification for neuronal cells was based on b-III-tubulin immunoreactivity and
morphological parameters, e.g., appearance of processes longer than 3x the cell soma as in Gascón et al. (2016). Astrocytes were
quantified based on morphological features and Gfap expression, though Gfap is downregulated following direct conversion. For
quantification in Figure 2 and Figure S2, we selected 10 transduced cells per each condition (DsRed, Ascl1-ires-DsRed at day 1
and day 3, and DsRed, Ascl1-ires-DsRed with neuronal morphology or astrocytic morphology at day 5 and 7). ImageJ (v1.52p)
was used to define a region of interest (ROI) outlining a selected cell in order to measure the signal intensity for a given protein.
To prevent a possible bias due to the different mitochondrial content in astrocytes and neurons, we also evaluated the intensity of
Tomm20, a pan-mitochondrial protein. For each ROI, after subtracting the background value, we divided the intensity of the protein
of interest by the corresponding Tomm20 expression, and log transformed the value. The colocalization analysis was conducted us-
ing the Coloc2 plugin for ImageJ.
For time-lapse experiment quantifications (Figure 4 and Figure S4), cells were tracked in every frame of the movie. GFP+/DsRed+
cells acquiring neuronal morphology, with processes longer than 3x the cell soma, were quantified among the total GFP+/DsRed+
cells, as previously published (Gascón et al., 2016). In total, 158 cells were tracked in controls and 177 in Ascl1+Prdx2-Sod1 over
n = 5 biological replicates.
Morphological analysis of reprogrammed neuronal cells (Figures 3F–3H) was performed with the ImageJ plugin SNT (simple Neu-
rite tracer) (Ferreira et al., 2014) and different parameters were measured. Sholl analysis, also in ImageJ, was performed on each of
the traced neurons: a step size of 10mmwasmaintained constant, with the first radius defined according to the soma of each cell. We
evaluated 3-4 neurons per condition, in 4 biological replicates. Data were analyzed with Microsoft Excel, GraphPad Prism 7.0 soft-
ware and linear regression using ‘‘lm’’ function (R Stats package) in RStudio. Evaluation of the residuals for fitted linear models was
performed with the package ‘‘DHARMa’’ (Hartig and Lohse, 2020) in RStudio.
Statistics on the reprogramming efficiency in Figure S2 and Figure 4 was performed as follows: reprogramming efficiency was log2
transformed, in order to reduce differences in variance across experiments and to fit the data to a normal distribution. Then, linear
regression model was used, together with ‘‘DHARMa’’ package to evaluate the residuals. Statistics on Figure 2 and Figure S3 was
perfomerd log2-transformed ratio. Statistics on Figure 4 was evaluated using paired t test. The number of biological replicates is indi-
cated in the corresponding Figure legends. Data are plotted asmean ± standard error of themean (SEM). Significance is based on the
p value indicated on the graphs as * p % 0.05, ** p % 0.01, ***p % 0.001.Cell Stem Cell 28, 524–534.e1–e7, March 4, 2021 e7
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SUPPLEMENTAL MATERIAL  
Figure S1, related to Figure 1. Astrocytes and neurons from cerebral cortex differ in mitochondrial function 
(A-B) Longitudinal traces of extracellular flux analysis measured by Seahorse XF analyzer, comparing the 
Oxygen Consumption Rate (A) and the Proton Production Rate (B) of astrocytes (blue) versus neurons (red) 
over time, after challenging the cells with different ETC inhibitors. Values are normalized per 1000 cells. Each 
time point is shown as mean ± SD. n=3 experimental batches for each group. 
(C) Barplot showing OCR/PPR ratio in cultures of primary astrocytes versus neurons, as measured by Seahorse
XF analyzer. * p ≤ 0.05. n=3 for each group.
(D) Immunoblot detection of mitochondrial proteins in different fractions (800g, nuclear; S.N., cytosolic;
9000g, mitochondria and other organelles) isolated from astrocytes or neurons. 
(E) Electron Microscopy images of mitochondria isolated from astrocyte and neuron cultures. Scale bar: 5µm.
Magnifications scale bar: 500nm. 
(F) Graphs showing the membrane potential of mitochondria isolated from astrocytes (upper panel) and
neurons (lower panel) measured by Rhodamine 123 assay, indicating their healthy functional state. 
(G) Graphs showing the swelling parameter of mitochondria isolated from astrocytes (upper panel) and
neurons (lower panel) by absorbance at 540nm indicating their healthy functional state. 
(H) Boxplot depicting abundances of all proteins before (upper panel) and after (lower panel) normalization.
(I) Unsupervised cluster analysis of the samples considering all quantified proteins.
(J) t-SNE of the samples, based on all proteins after normalization.
(K) Boxplot depicting abundances of mitochondrial proteins selected according to mitoCarta before (upper
panel) and after (lower panel) normalization. 
(L) Unsupervised cluster analysis of the samples considering only mitochondrial proteins.
(M) Barplot showing the number of mitochondrial proteins identified by mass spec in astrocytes (blue) and
neurons (red). Each dot represents a biological replicate. 
(N) Barplot depicting the percentage of mitochondrial protein abundance over total protein abundance in
astrocytes (blue) and neurons (red). Each dot represents a biological replicate. 
(O) Western blots of total lysates from cultured astrocytes or neurons confirming the selective cell enrichment
by high amounts of Adlh1l1 in astrocyte lysates, equal mitochondrial protein loading by Tomm20 and the higher 
amount of Sfxn5 and Cpox in astrocytes and Gls in neurons. 
(P,Q) Venn Diagrams of all astrocyte-enriched (I) and neuron-enriched (J) mitochondrial proteins detected by 
Fecher et al. and our analysis showing a high degree of overlap given that mitochondrial proteins were isolated at 
different stages (adult versus postnatal), from different regions (cerebellum versus cortex) and in different 
































































































































surviving reprogrammed cell Dead reprogrammed cell Dead un-reprogrammed cell
Figure S2, related to Figure 1 and 4. Etomoxir treatment improves direct neuronal reprogramming. 
(A) Schematic drawing of the experimental setup.
(B) Micrographs showing the Ascl1-transduced cells (DsRed+) that are βIII-tubulin+ neurons (in white), nuclei
labeled in DAPI (Blue), in the treatment conditions indicated. Scale bar: 50µm. 
(C) Histogram depicting the percent of βIII-tubulin+ cells amongst Ascl1-transduced DsRed+ cells at 8 DPI.
Data are shown as mean±SEM. Each dot represents a biological replicate (n=3 for experimental condition). *p ≤ 
0.05 
(D) Micrographs showing the efficiency of neuronal conversion in upon Neurog2 expression together with
treatment of different concentration of Etomoxir. Reprogrammed neurons (DsRed+) are βIII-tubulin+ (in white). 
Nuclei labeled in DAPI (Blue). Scale bar: 50µm. 
(E) Histogram depicting the percentage of βIII-tubulin+ cells amongst Neurog2-transduced DsRed+ cells at 8
DPI. Data are shown mean±SEM. Each dot represents a biological replicate (n=3 for experimental condition). *p 
≤ 0.05 




























































































Pearson R: 0.15 ± 0.01 Pearson R: 0.67 ± 0.01
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Figure S3, related to Figure 2. Mitochondrial protein changes during astrocyte-to-neuron reprogramming 
 (A, B) Micrographs showing immunostainings of the astrocyte-enriched mitochondrial protein Cpox in 
astrocytes transduced with DsRed (control) or Ascl1-ires-DsRed at 1 (A) or 7 (B) DPI as indicated. Mitochondria 
are identified by the expression of Tomm20. Scale bar: 20µm. 
(C) Example of scatter plot of the pixel intensity correlation between Tomm20 and Cpox in Ascl1-transduced
cells at 1 (left panel) and 7 (right panel) DPI. Pearson’s coefficient as average of 3 cells/biological replicate; n=3 
biological replicates. 
(D) Violin plot depicting the log2-ratio of the intensity of the expression of Cpox versus Tomm20 over time
(D1, D3, D5, D7) and in cortical astrocyte cultures at day 7. Each dot represents 1 analyzed cell. 10 cells analyzed 
per biological replicate, each condition. n=3 biological replicates; ***p ≤ 0.001. 
(E, F) Micrographs showing the expression of the neuron-specific mitochondrial protein Prdx2 in astrocytes 
transduced with DsRed (control) or Ascl1-ires-DsRed at 1 (E) and 7 (F) DPI. Mitochondria are identified by the 
expression of Tomm20. Scale bar: 20µm. 
(G) Example of scatter plot of the pixel intensity correlation between Tomm20 and Gls in Ascl1-transduced
cells at 1 (left panel) and 7 (right panel) DPI. Pearson’s coefficient as average of 3 cells/biological replicate; n=3 
biological replicates. 
(H) Violin plot depicting the log2-ratio of the intensity of the expression of Gls versus Tomm20 over time (D1,
D3, D5, D7) and in E14 cortex-derived cultures at 7 days in vitro. Each dot represents 1 analyzed cell. 10 cells 

















































































































































































































































Acot7 Arg2 Dnm3 Gls Mgst1 Mgst3 Pgam5 Prdx2 Prdx6 Slc25a22 Sod1
Genes gRNA-ctl gRNA-Prdx2-Sod1 gRNA-Arg2-Gls gRNA-AD
GAPDH 27 25,88333333 25,29666667 27,04666667
Prdx2 30,06666667 25,85333333
Sod1 26,91333333 24,23
Arg2 40,54333333 28,22333333 29,36666667
Gls 34,59666667 31,34333333
Dnm3 37,68 33,71666667
Genes gRNA-ctl gRNA-Acot7 gRNA-Slc25a22 gRNA-Pgam5 gRNA-Prdx6 gRNA-Mgst1 gRNA-Mgst3








Figure S4, related to Figure 3. Characterization of selected candidates 
(A) Unsupervised heatmap depicting the relative expression of the selected candidates.
(B) Graphs depicting the log2-normalized abundance of the astrocyte-enriched (blue dots) and neuron-enriched
(red dots) candidates, as analyzed in Figure 2. Each dot represents a biological replicate. 
(C) Real Time quantitative PCR (RT-qPCR) showing the fold change of putative off-targets following the
transfection of gene-specific gRNA. Data are shown as fold change over the gRNA-scramble control (mean ± 
SEM). None of this is significant over Paired t-test used. control. n=3 biological replicates for each group. 
(D) Single channel immunofluorescence images showing reprogrammed neurons (βIII-tubulin+-DsRed+-GFP+)
transfected by Ascl1-ires-DsRed (red) and different STAgR constructs (green). Scale bar: 100µm. 
2.2 Aim of the Study II 
The aim of the second study was to investigate the role of mitochondrial metabolism in the 
direct neuronal reprogramming of human cells and discover potential treatments to improve 
reprogramming as well as treat mitochondrial dysfunction.  
Mitochondrial deficiency limits the direct neuronal reprogramming of 
human cells 
Giovanna Sonsalla, Therese Riedemann, Mirjana Gusic, Ejona Rusha, Micha Drukker, Sonia 
Najas, Aleks Janjic, Wolfgang Enard, Pawel Smialowski, Holger Prokisch, Magdalena Götz, 
and Giacomo Masserdotti 
For this paper, being the first author, I performed most of the experiments except for the 
electrophysiology, and I analyzed the data with the exception of the RNAseq analysis which 
was conducted by Giacomo Masserdotti. I wrote and revised the first draft of the manuscript 
with Magdalena Götz and Giacomo Masserdotti.  
This project is finalized in a manuscript that will be submitted to Cell Stem Cell in June 2021 
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Direct neuronal reprogramming is a powerful tool for replacing neurons lost in disease or 
traumatic injury, and is ultimately being developed for use in human patients. However, major 
barriers identified in murine cell reprogramming remain unexplored in human glia to neuron 
conversion. Mitochondria play a major role in the conversion process, as well as in 
neurodevelopmental and neurological disease, and differ profoundly between glia and neurons. 
Here we show that even common components of the mitochondria, such as Complex I function, 
are limiting in the conversion to neurons, by using iPSC-derived glia from patients with a 
Complex I mutation (Leigh syndrome). We further identify treatments to overcome this hurdle, 
most surprisingly blockers of the unfolded protein response, which highlight mitochondria-ER 
communication as a key event in the reprogramming of both control and patient cells. Taken 
together, disease modeling using patient cells for glia to neuron reprogramming unraveled 
novel pathways to improve the metabolic hurdles in this process and achieve high efficiencies 






Restoring the loss of functional neurons resulting from brain injury or neurodegenerative 
disease is of paramount importance, as disease due to neuron loss cannot currently be treated 
causally. A particularly promising approach for brain repair involves the recruitment and direct 
neuronal reprogramming of endogenous cells already present in the brain (Barker et al., 2018; 
Vignoles et al., 2019). This therapeutic strategy has been pioneered in 2002 (Heins et al., 2002) 
and been successfully improved over many years enlisting glial cells in vitro (Berninger et al., 
2007; Heinrich et al., 2010; Masserdotti et al., 2015) and in vivo with mouse models (Heinrich 
et al., 2014; Torper et al., 2015; Mattugini et al., 2019). However, there are many hurdles to 
direct neuronal reprogramming that prevent a high reprogramming efficiency and full neuronal 
maturation, including neuronal repressors (e.g., RE-1 transcription repressor complex (REST); 
Masserdotti et al., 2015) and the chromatin context (Wapinski et al., 2013; Smith et al., 2016).  
 
In particular, mitochondria have been identified as a major barrier to the reprogramming of glia 
to neurons, due to the metabolic conversion from glycolysis to oxidative phosphorylation 
(oxphos) that occurs in parallel (Gascón et al., 2016; Camandola & Mattson, 2017). Indeed, 
neuronal reprogramming even after brain injury in vivo can be significantly improved by 
alleviating the stress associated with the shifted metabolism, such as by the application of 
antioxidants or Bcl2 (Gascón et al., 2016). Furthermore, we recently demonstrated that the 
mitochondrial proteome differs profoundly between glia and neurons and neuron-enriched 
proteins appear only late in reprogramming (Russo et al., 2021). Accordingly, the early 
activation of only 1 or 2 neuron-enriched mitochondrial proteins from the start of the 
reprogramming process could potently improve the neuronal conversion (Russo et al., 2021). 
However, it is unknown to which extent mitochondrial proteins present in all cells, such as 
Complexes I-IV (CI-IV) of the electron transport chain (ETC), would affect neuronal 
reprogramming. Blocking oxphos by oligomycin A treatment completely abolished the 
reprogramming of murine astrocytes into neurons (Gascón et al., 2016), but whether this is a 
general phenotype is unknown. Conversely, oxphos itself can have limiting effects on 
reprogramming, such as through the generation of reactive oxygen species (ROS), which are 
deleterious for direct neuronal reprogramming in murine glia (Gascón et al., 2016; Russo et al., 
2021). We were therefore interested to determine the effects of CI mutations in the conversion 
process of human glial cells to neurons. Indeed, very little is known about the role of 
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mitochondria in the reprogramming of human cells. Although some studies have investigated 
the reprogramming potential of glial cells of human origin (Zhang et al., 2015; Nolbrant et al., 
2020), nothing is known about the metabolic hurdles as this area is still vastly understudied 
and is hampered by lengthy protocols and low reprogramming efficiencies.  
 
Understanding the role of mitochondrial metabolism is not only important for neuronal 
reprogramming, but is also essential for directly treating neurodegenerative diseases, as 
mitochondrial dysfunction is one of their main hallmarks (Watts et al., 2018; Stanga et al., 
2020). Indeed, mitochondria are not only relevant in the aging context but also play a major 
role in early-onset diseases, such as Leigh syndrome (LS) (Rahman et al., 1996; Hong et al., 
2020). The direct neuronal reprogramming of human cells can thus be used as a valuable tool, 
not only for neuronal replacement strategies, but also in the context of disease modeling and 
novel treatment discovery. Therefore, cells from patients with a mutation in NDUFS4, a 
subunit of CI, were investigated and compared to cells from control donors. The cells were 
studied not only in resting conditions, but also under stress during direct neuronal 
reprogramming. Interestingly, treatments targeting underlying mechanisms of mitochondrial 
impairment did not only lead to improvements in patient cell reprogramming, but also in 
control cells, and led to the novel discovery of the unfolded protein response as a major barrier 




Comparable astrocyte differentiation of NDUFS4-patients and controls 
We aimed at investigating the role of metabolism in the direct neuronal reprogramming of 
human glial cells by studying patients with a mitochondrial deficiency. To this end, control 
donor and NDUFS4-mutant patient iPSCs were successfully differentiated into glial progenitor 
cells (GPCs) and astrocytes following a protocol adapted from Santos et al., 2017 (Fig. S1A). 
There were no detectable differences between the patient and control cells over the course of 
astrocyte differentiation based on immunocytochemistry analysis (Fig. S1B). To ensure our 
results were not biased by one specific mutation, we analyzed iPSCs from three separate 
patients, each containing unique mutations in NDUFS4 (Fig. S1C; #114107, #87971, #79787). 
Transcriptome analysis of the three patient and three control cell lines further demonstrated the 
loss of pluripotency markers and accumulation of markers for astrocytes over time (Fig. S1D). 
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There were few genes differentially expressed between patient and control cells, demonstrating 
that astrocyte differentiation is much less impaired than neuronal differentiation, as was shown 
by patient iPSCs from other LS patients (Inak et al., 2021) However, gene set enrichment 
(GSEA) analysis revealed functional transcriptome differences, such as the downregulation of 
genes related to inflammation (Fig. S1E), as well as mitochondrial biogenesis (Fig. S1F) in 
patient cells compared to controls.  
 
Interestingly, the functionality of the cells in basal conditions appeared similar, as determined 
through a glutamate uptake assay (Fig. S1G) and the measured oxygen consumption rate at 
resting basal condition (Fig. S1H). However, when the cells were challenged by different ETC 
inhibitors, control GPCs showed a significantly higher maximal respiration and spare 
respiratory capacity compared to patient GPCs (Fig. S1H). The mitochondrial metabolic deficit 
demonstrated in these results in NDUFS4-mutant GPCs is consistent with previously published 
data on NDUFS4-mutant fibroblasts (Catania et al., 2019), and cells from LS patients with 
other mutations in CI or CIV (Inak et al., 2021).  
 
Mitochondrial deficiency impairs direct neuronal reprogramming of GPCs 
Since a defect in mitochondrial metabolism could be detected in the patients at the GPC stage, 
we decided to focus on this cell stage for the neuronal reprogramming experiments conducted 
according to the paradigm illustrated in Figure 1A. Control and patient GPCs were transduced 
with a retrovirus encoding either the red fluorescent protein (DsRed) as a control condition, or 
different proneural transcription factors, including the well-established factors Neurogenin-2 
(Neurog2) and Achaete-scute homolog 1 (Ascl1) (Berninger et al., 2007; Heinrich et al., 2010; 
Gascón et al., 2016; Rivetti di Val Cervo et al., 2017; Russo et al., 2021). We also tested the 
phospho-mutant versions of Neurog2 and Ascl1 (hereby referred to as pMutNeurog2 and 
pMutAscl1), because of their enhanced neurogenic activity in vivo (Ali et al., 2011; 2014). 
Interestingly, GPCs differentiated from control donor-iPSCs showed a significantly higher 
reprogramming efficiency (Neurog2 median = 49.25, IQR = 13.05; pMutNeurog2 median = 
61.88, IQR = 15.89) than GPCs obtained from patient-derived iPSCs (Neurog2 median = 32.39, 
IQR = 12.75; pMutNeurog2 median = 36.96, IQR = 14.77) upon the expression of either 
Neurog2 or pMutNeurog2 (Fig. 1B, 1C). Although pMutNeurog2 further increased the 
reprogramming efficiency of control cells compared to wild type Neurog2, supporting the 
notion of its enhanced neurogenic capability, there was no parallel increase seen with the 
patient cells. In contrast, both Ascl1 and pMutAscl1 conditions led to a lot of cell death in both 
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genotypes, with very few infected cells surviving to day 20, although controls were still 
reprogrammed more efficiently than patients (control: Ascl1 median = 33.33, IQR = 29.65; 
pMutAscl1 median = 30, IQR = 31.52; patient: Ascl1 median = 7.14, IQR = 25; pMutAscl1 
median = 3.33, IQR = 13.51) (Fig. 1B, 1C). Such transcription factor preference is consistent 
with previous studies that showed that Neurog2 is more effective in astrocytic cells than Ascl1 
(Berninger et al., 2007).  
 
As Bcl2 has a positive effect in the neuronal reprogramming of murine astrocytes through its 
reduction of oxidative stress (Gascón et al., 2016), we tested its expression in combination with 
each of the above-mentioned four proneural factors (Fig. 1D, 1E). Green fluorescence protein 
(GFP) was included with DsRed as a double-transduction control. Bcl2 further enhanced the 
reprogramming efficiency of control cells, both in the Neurog2 (median = 50.37, IQR = 12.98) 
and pMutNeurog2 (median = 64.16, IQR = 21.12) conditions. Surprisingly, Bcl2 did not 
significantly affect the reprogramming efficiency of NDUFS4-mutant cells either in Neurog2 
(median = 34.15, IQR = 13.16) or pMutNeurog2 (median = 38.89, IQR = 11.17) conditions. 
Similar to the single factor conditions, Bcl2 combined with Ascl1 did not have a synergistic 
effect in the GPCs, regardless of donor type (control: Ascl1 median = 7.14, IQR = 13.28; 
pMutAscl1 median = 12.5, IQR = 13.35; patient: Ascl1 median = 17.44, IQR = 18.66; 
pMutAscl1 median = 13.33, IQR = 22.5) (Fig. 1D, 1E). This could indicate that apoptosis and 
ferroptosis, triggered by excessive ROS levels, and decreased by Bcl2 (Gascón et al., 2016) are 
not a limitation in this reprogramming paradigm – neither for patient nor control cells.  
 
Therefore, although differences between control and mitochondrial-deficient GPCs were not 
detected at resting conditions, once the cells were challenged by conversion towards a neuronal 
fate significant differences became apparent.  
 
 
Treatments alleviating different aspects of mitochondrial dysfunction rescue the 
reprogramming of NDUFS4-mutant GPCs 
Given the differences between murine and human glial cells, and the need to alleviate the 
deficits of the patient cells, we explored the effects of manipulating several pathways – the 




To do so, the neuronal reprogramming paradigm was conducted as before, except that the cells 
were treated with different compounds during the first media change at Day 2. Control and 
patient GPCs were either treated with Oligomycin A (OligoA), a blocker of the ATP synthase 
in the ETC, or with α-tocopherol, an analog of Vitamin E and a ROS scavenger. The cells were 
then fixed at day 20 and the proportion of neurons amongst the transduced GPCs was evaluated. 
Both control and patient GPCs had their reprogramming blocked by treatment with OligoA 
(Fig. 2A, 2B), as was the case for murine astrocytes (Gascón et al., 2016). Intriguingly, α-
tocopherol did not significantly improve the neuronal reprogramming, neither of control nor 
patient GPCs, demonstrating important differences between human and murine glial cells.  
 
Since neither Bcl2 nor α-tocopherol improved the patient GPCs reprogramming, reducing 
oxidative stress was not sufficient to rescue their conversion. Therefore, we decided to explore 
other aspects of metabolic stress and selected compounds that target different branches of 
mitochondrial dysfunction (Russel et al., 2020) (Fig. 2C-E). Mutations in CI can interfere with 
its ability to pass electrons down the ETC; therefore idebenone, a ubiquinone analog, was 
included to pass electrons in place of CI, albeit without restoring the proton pump function of 
CI (Haefeli et al., 2011). We also tested the mitophagy activator Urolithin A (UA) to address 
the possible accumulation of dysfunctional mitochondria that can be toxic for the cell (Ryu et 
al., 2016). Idebenone caused a mild improvement (control: median = 61.67, IQR = 7.06; 
patient: median = 49.71, IQR = 17.34). The mitophagy activator had the least effect on the 
neuronal reprogramming (control: median = 48.55, IQR = 6.58; patient: median = 46.66, IQR 
= 15.72), suggesting that mitochondrial turn-over is not a major roadblock. The NAD+ 
precursor nicotinamide riboside (NR) was chosen to address the NAD+/NADH redox balance, 
which is disrupted in NDUFS4-mutant patients (Lee et al., 2019). Remarkably, NR 
significantly improved the reprogramming efficiency of both mutant (median = 66.55, IQR = 
22.51), and control GPCs (median = 71.02, IQR = 6.17), thus supporting mitochondrial 
oxidative metabolism (Cantó et al., 2012) as a limiting factor in direct reprogramming.  
 
Due to the proximity and functional interaction that occurs between the mitochondria and the 
endoplasmic reticulum (ER) (Moltedo et al., 2019), we tested the possibility that the ER stress 
pathway known as the unfolded protein response (UPR) is involved during reprogramming. To 
this end, we inhibited two different branches of the UPR pathway, the IRE1 branch by 
treatment with STF-083010 (STF) and the PERK branch with AMG-PERK 44 (AMG) (Li et 
al., 2020).  
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The IRE1 branch triggers the generation of chaperones by activation of XBP-1, and the PERK 
branch inhibits translation, among other things, through the activation of eukaryotic translation 
initiation factor 2 alpha (eIF2α) (Wang & Kaufman, 2016). Interestingly, both UPR inhibitors 
had a significant improvement on the reprogramming efficiency of the cells compared to the 
Neurog2 alone condition (Fig. 2C-D).  Once again, the control GPCs (STF median = 76.32, 
IQR = 6.64; AMG median = 74.52, IQR = 6.46) had augmented neuronal reprogramming 
reaching almost 80% efficiency. Strikingly, blocking the UPR with either inhibitor also 
allowed the patient GPCs to achieve a very high proportion of neurons reaching almost 70 % 
(STF median = 67.85, IQR = 9.14; AMG median = 66.1, IQR = 15.7). These data indicate that 
the normally beneficial UPR response is a hurdle in neuronal reprogramming and patient cells 
can indeed convert to neurons efficiently upon blocking the UPR. 
 
A prominent role for ER stress and the redox status of the cell are thus implicated in metabolic 
function and reprogramming. We next wanted to determine if enhanced cell survival accounted 
for the differences observed in the treatment conditions.  
 
Reprogramming dynamics are influenced, and neuronal functionality is rescued upon UPR 
treatment of NDUFS4-mutant cells  
Previous work showed that cell death is a major limiting factor in direct neuronal 
reprogramming (Gascón et al., 2016; Russo et al., 2021) and an excessive UPR response elicits 
cell death (Hetz et al., 2012; 2020). We therefore aimed to monitor if and when this may be the 
case in human GPC reprogramming and to detect any differences between control and patient 
cells, and upon treatment. To elucidate the reprogramming dynamics in control and patient 
GPCs, we followed their conversion process over time by live imaging in 3 different time 
windows across the 20-day reprogramming protocol: days 4-8, 8-12 and 13-17 (Fig. S2A).  
We had hypothesized that the low reprogramming efficiency of patient cells could be due to 
cell death occurring at early stages of the reprogramming process, as the stress from their 
oxphos deficit prevented them from fully converting and instead triggered cell death pathways. 
Thus, we investigated the number of transduced cells at early time points of reprogramming 
and normalized the results to the control DsRed condition. Interestingly, there was no overall 
difference in cell death between the control and patient cells (Fig. S2B-D), although there was 
a difference in timing, as more patient cell death occurred in the second block (days 8-12) 
versus more control cell death in the third block (days 13-17). Neither the treatment with α-




We also investigated the appearance of neuronal cells in the reprogramming process, focusing 
on days 13-17 (Fig. S2E). A higher reprogramming efficiency was observed in the control 
GPCs compared to patient GPCs at this late time interval, despite their increased cell death, 
further strengthening the notion that late cell death is a byproduct of successful reprogramming 
(Gascón et al., 2016). Both α-tocopherol and STF enhanced the reprogramming efficiency and 
control cells were always more efficient than patient cells (Fig, S2E).  
 
To assess whether the UPR treatments not only improved the reprogramming efficiency, but 
also had a positive effect on the activity of reprogrammed cells, we performed 
electrophysiological analysis on neuronal cells derived from control or patient GPCs, either 
with or without UPR-inhibitor treatment. To achieve functionally mature neurons cells were 
plated on an astrocyte feeder layer as described before (Mertens et al., 2015) (Fig. 3A). Both 
control and patient GPCs were transduced with Neurog2+Bcl2 and cultured for ~ 60 days. A 
greater percentage of control derived neurons (65%) were able to fire an action potential 
compared to patient-derived neurons (45%) (Fig. 3C). Therefore, the mitochondrial deficiency 
of the patient cells not only hinders their reprogramming efficiency, but also reduces the 
functionality of the resulting reprogrammed neurons. Remarkably, double the amount of 
patient-derived neuronal cells showed action potentials following treatment with the UPR 
inhibitor AMG (88%) similar to control-derived neurons. The rescue of patient cells upon 
AMG treatment not only increased the proportion of recorded cells that fired an action 
potential, but also led to increased amplitude and decreased duration of the recorded APs (Fig. 
3D, 3E), suggestive of improved neuronal maturation.  
 
Furthermore, spontaneous AP firing was recorded from a patient cell treated with AMG, and 
this was not detected in any of the other control or patient cells.  Thus, the UPR inhibition not 
only led to a significant increase in control and patient GPC reprogramming ability, but also 
improved the percentage of reprogrammed neurons showing an action potential and their 
electrophysiological properties. It is therefore a novel major hurdle in direct neuronal 
reprogramming and even allows the deficits of the patient cells in neuronal conversion to be 






Fibroblasts with a mitochondrial deficiency can also be rescued by targeting the UPR 
To test if the above-described effects and results are cell type-specific, we investigated direct 
reprogramming of a different human starter cell type, namely fibroblasts. The fibroblasts were 
obtained from three control donors and three NDUFS4-mutant patients, two of which were 
used to generate iPSCs (#79787, #114107). The fibroblasts were reprogrammed with the same 
factors and protocol employed for the GPCs direct conversion (Figure 1A). Intriguingly, 
neither the control (Neurog2 median = 5.23, IQR = 1.34; pMutNeurog2 median = 15.91, IQR 
= 6.16) nor patient fibroblasts (Neurog2 median = 3.95, IQR = 3.66; pMutNeurog2 median = 
6.42, IQR = 12.54) showed a high reprogramming efficiency when transduced with Neurog2 
or pMutNeurog2, in stark contrast to the GPCs (Fig. 4A, 4B) and in line with previous 
observations (Liu et al., 2013). Likewise, Ascl1 alone had a relatively low reprogramming 
efficiency with the human fibroblasts, as was previously reported (Pang et al., 2011). 
Conversely, pMutAscl1 significantly increased the proportion of induced neurons from both 
the control (Ascl1 median = 12, IQR = 7.69; pMutAscl1 median = 36.97, IQR = 14.72) and 
patient cells (Ascl1 median = 8.33, IQR = 11.81; pMutAscl1 median = 35.14, IQR = 14.13). 
Remarkably, the co-expression of Bcl2 improved pMutAscl1-mediated neuronal conversion, 
but only in control fibroblasts (Fig. 4C, 4D).  Indeed, these results, consistent over 3 different 
cell lines, suggest that NDUFS4-mutant fibroblasts can be reprogrammed to a certain 
efficiency, which cannot be further improved by established neurogenic factors, thus implying 
the presence of additional limiting hurdles in the process.  
 
As the NDUFS4-mutant fibroblasts showed a similar reprogramming deficit as the GPCs, we 
tested if the same treatments improving GPC-to-neuron conversion were also successful for 
the patient-derived fibroblasts. Fibroblasts were transduced with Neurog2 and treated during 
the first media change on day 2, then fixed on day 20 for analysis. Despite the very low 
reprogramming efficiency induced by Neurog2, some treatments were still able to significantly 
increase the neuronal conversion in both control and patient cells (Fig. S3). Intriguingly, only 
the UPR inhibitor AMG had a significant improvement on both control (median = 13.17, IQR 
= 2.66) and patient (median = 9.77, IQR = 2) cells (though not completely rescuing the 
efficiency to the levels of the control), thus implicating PERK-mediated UPR stress as a hurdle 
to direct neuronal reprogramming in fibroblasts. Furthermore, STF also significantly improved 
patient cell (median = 5.62, IQR = 5) reprogramming, even rescuing the patient fibroblast 
reprogramming to within control cell reprogramming levels (median = 7.69, IQR = 10.95). 
Interestingly, NR and idebenone increased the neuronal conversion in control (NR median = 
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11.91, IQR.= 1.39; idebenone median = 12.3, IQR = 8.7), but not patient cells (NR median = 
4.74, IQR = 1.62; idebenone median = 3.57, IQR = 5.12), highlighting some key differences in 
their response, as between GPC and fibroblast neuronal reprogramming. 
 
Together, these data reinforce the observation that pharmacological treatments, aimed at 
regulating either metabolic mediators (NR) or cellular stress (AMG, STF), can indeed improve 





Here we unraveled three major findings using a glia-to-neuron reprogramming paradigm. Most 
importantly, we discovered a novel pathway, the unfolded protein response, as a major hurdle 
in this reprogramming process. We further show that blocking this pathway is sufficient to 
almost completely rescue the neuronal conversion deficits of LS patient-derived glial cells, and 
we demonstrate that differentiation into the astrocyte lineage is virtually unaffected by the LS 
mutation in the CI protein NDUFS4.  
 
We differentiated iPSCs carrying three different mutations in the NDUFS4 gene into GPCs in 
parallel with iPSCs from control donors and observed no major differences in astrocyte 
markers, glutamate up-take or a comprehensive RNA-seq analysis. Also, we did not observe 
maintenance of proliferation signatures as previously described for LS-patient cells with 
mutations in the CIV protein SURF1 (Inak et al., 2021). While the SURF1 mutation results in 
defective neural stem cells, gliogenesis, neurogenesis, and neuronal differentiation (Inak et al., 
2021), our three NDUFS4-mutant iPSC lines differentiated in a comparable manner to control 
cells towards the astrocyte lineage. This was the case despite deficits in mitochondrial function 
as detected by the seahorse analysis of GPCs or fibroblasts, namely lower maximal respiration 
and spare respiratory capacity. There are similarities not only in the pathology of the LS 
patients carrying mutations in different ETC complex genes (Gerards et al., 2016; Hong et al., 
2020), but also at the cellular and molecular level. Neurogenesis and neuronal differentiation 
were shown to be defective in all LS patient-derived iPSC differentiation paradigms tested so 
far (Lorenz et al., 2017; Galera-Monge et al., 2020; Inak et al., 2021) and this deficiency was 
also prominent in the glia-to-neuron fate conversion tested here. Patient GPCs could convert 
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into functional neurons, but with a reduced efficiency not exceeding ~40% without additional 
treatments. Moreover, the NDUFS4-mutant GPCs showed similar deficits at the transcriptome 
level as those observed in SURF1-mutant NPCs. For example, there was a reduced expression 
of genes involved in regulating inflammation in patient GPCs compared to controls (Fig. S1E), 
as well as downregulation of PPARGC1A (Fig S1F), which encodes for PGC-1α, a known 
modulator of mitochondrial biogenesis (Liang & Ward, 2006), as was observed in SURF1-
mutant NPCs (Inak et al., 2021). Conversely, we did not observe maintenance of proliferation 
or pluripotency genes when differentiating the NDUFS4 patient cells into GPCs, highlighting 
important differences and similarities in the cellular and molecular phenotype of LS patient-
derived iPSCs during differentiation into different lineages.  
 
One of the main aims of this and previous studies is to identify possible novel treatment options 
for LS patients, and also to improve human glia-to-neuron reprogramming for patients 
suffering from stroke or neurodegeneration. Mitochondrial conversion is a major hurdle in glia-
to-neuron reprogramming due to the slow turn-over of mitochondrial proteins (Russo et al., 
2021) and excessive ROS production (Gascón et al., 2016). We expected GPCs from LS 
patients to struggle even more with this mitochondrial adaptation, due to generally increased 
ROS levels (Verkaart et al., 2007; Valsecchi et al., 2013) and reduced PGC-1α expression, 
which indicates lower mitochondrial biogenesis. However, treatment with a ROS scavenger 
(α-tocopherol), re-establishing the transfer of electrons by the ubiquinone analog idebenone or 
increasing mitochondrial turn-over by Urolithin A, did not have a strong effect on 
reprogramming – neither for patient- nor control-derived cells. For control cells this shows a 
notable difference to the results obtained with murine astrocytes (Gascón et al., 2016), 
highlighting the species and cell-type specificity of the conversion process. These results are 
also consistent with the antioxidant treatment of SURF1-mutant cells, as little improvement 
upon treatment was shown in SURF1 NPCs or neurogenesis (Inak et al., 2021). Conversely, 
SURF1-mutant neurogenesis was improved by increasing mitochondrial mass using the PPAR 
agonist bezafibrate (Inak et al., 2021), while removing defective mitochondria and increasing 
turn-over failed to improve neuronal conversion of both control and LS patient cells in our 
study.  
 
CI converts NADH to NAD+, and most LS patient cells show reduced NAD+ levels and 
NAD+/NADH ratio (Thompson Legault et al., 2015; Iannetti et al., 2018; Inak et al., 2021). 
Accordingly, restoring this balance through NR treatment has been a therapeutic strategy in 
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mouse models (Khan et al., 2014), and has also proved to be effective in improving the 
reprogramming deficit, not only of patient cells, but, remarkably, it had a strong effect also in 
the control cells. One possible explanation is that when cells are undergoing forced neuronal 
conversion and switch from favoring a glycolytic metabolism to oxphos, the redox energy of 
the cell can become unbalanced. The correct level of NAD+ is crucial for cellular function, as 
it has been shown to be involved in mitochondrial biogenesis (Bai et al., 2011) and the 
regulation of proteins, including histone acetylation via Sirtuins (Karamanlidis et al., 2013; Lee 
et al., 2019; Chakrabarty and Chandel, 2021). Thus, adequate NAD+ levels may help gene 
activation processes during the course of reprogramming.  
 
The most surprising and novel finding was the identification of the UPR as a major roadblock 
in direct reprogramming, with its inhibition achieving a very high efficiency of conversion into 
neurons. The UPR is activated in the ER upon accumulation of misfolded proteins and in the 
presence of high ROS levels (Li et al., 2020; Cao et al., 2014; Hetz et al., 2020). The UPR 
coordinates the increased expression of chaperones, reduced translation rates and mounts an 
antioxidant response (Wang & Kaufman, 2016), all designed to improve the rate of adequately 
folded proteins. During prolonged activation, the UPR elicits cell death, typically via apoptosis 
(Rutkowski et al., 2006; Tabas & Ron, 2011). We had previously observed a high expression 
of genes associated with the UPR in the scRNA-seq of murine astrocytes converting to neurons 
(Najas et al., unpublished data) and therefore tested if UPR inhibition could enhance the direct 
neuronal reprogramming of human cells. Indeed, inhibitors targeting two separate branches of 
the UPR pathway (i.e., PERK and IRE1) profoundly increased the reprogramming efficiency 
and maturation of the induced neurons of both control and NDUFS4-patient derived cells. 
Strikingly, live imaging of the conversion process did not reveal a major difference in cell 
death, suggesting other UPR-mediated processes as hurdles in reprogramming. One intriguing 
possibility is that the reduced global translation rate due to UPR activation is deleterious to the 
conversion process during which many new proteins are required. Indeed, our recent work 
showed a difference of ~20% of the mitochondria proteins between astrocytes and neurons that 
needs to be adapted during the conversion process (Russo et al., 2021), in addition to the need 
of many new functional channels, receptors, cytoskeletal changes, and much more. A reduced 
translation rate could thus be a major limitation in this process and would also fit to the PERK-
eIF2a pathway inhibitor being most effective in our study. Interestingly, the UPR response can 
also be elicited in development by interfering with codon translation speed resulting in a 
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reduced generation of neurons (Laguesse et al., 2015) and is elicited by Zika virus infections 
blocking neurogenesis (Alfano et al., 2019).  
 
Moreover, the tight interconnection between the ER and mitochondria coordinates key cellular 
functions such as calcium homeostasis, inflammation signaling and autophagy, among others 
(Missiroli et al., 2018). For example, it has been shown that ER stress instigates mitochondrial 
Ca2+ influx to provide energy for protein folding (Rossi et al., 2019). However, the 
subsequently increased ROS generation can in turn further enhance ER stress and lead to the 
activation of apoptotic pathways (Martucciello et al., 2020). Therefore, blocking this feedback 
loop between the organelles can be a possible explanation for the positive effect of the UPR 
inhibitors on reprogramming efficiency. Similar to how mitochondrial dysfunction has been 
linked to neurodegenerative diseases, protein accumulation and the activated UPR pathway 
have also been tied to these disorders (Hetz et al., 2017). Most excitingly, blocking the UPR 
also allowed a very high efficiency of neuronal induction from patient GPCs, as they reached 
a proportion of more than 60% neurons, identifying the UPR as a novel pathway responsible 
for limiting neuron generation in this paradigm.  
 
In conclusion, this work revealed a new major hurdle in neuronal reprogramming, the unfolded 
protein response, allowing efficient conversion of human glial cells even from LS patients. 
This highlights not only the validity of using direct neuronal reprogramming to model 
mitochondrial disease, but also unravels therapeutic strategies aimed at replacing functional 
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Materials and Methods 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Human iPSCs and fibroblasts 
The control fibroblast cell line NDHFneo was obtained from Lonza (Cat. No. CC-2509). The 
other two control fibroblast cell lines (#47041, #61691) and the three NDUFS4-mutant patient 
fibroblast cell lines (#79787, #114107, #114106) were obtained from skin biopsies of patients with 
signed informed consent. The cell line #79787 belongs to a patient with the homozygous frameshift 
mutation c.462delA (p.Lys154fs) within the NDUFS4 gene. The cell lines #114107 and #114106 
belong to patients with a substitution mutation in the NDUFS4 gene, at c.119G>A (p.Trp40) and 
at c.316C>T (p.Arg106) respectively.  
The control iPSC cell line UKERi82a-R1-002 was obtained as part of the ForIPS research 
consortium. The ethics approval is No. 4120, FAU Erlangen-Nuernberg, Germany. Detailed 
genetic information can be found in Popp et al., 2018. The other two control iPSC cell lines (#1 
and HMGU12) and the three patient iPSC cell lines (#87971, #79787, #114107) were generated by 
the iPSC core unit (headed by Micha Drukker) at the Helmholtz Zentrum München.  
Primary cultures of mouse cortical astrocytes 
Astrocytes were isolated and cultured as previously described, with small changes (Heins et al., 
2002; Heinrich et al., 2011). The meninges was removed, and then the grey matter tissue from the 
cerebral cortex of C57BL/6J mice at postnatal day 5-7 (P5–P7) was dissected and mechanically 
dissociated. The dissociated cells were centrifuged at 1,400rpm for 5min, re-suspended and plated 
in a T25 flask in mouse astrocyte medium (DMEM/F12 (1:1) plus Glutamax, 10% fetal bovine 
serum (FBS), penicillin /streptomycin (P/S), 1x B27 serum-free-supplement, 10 ng/ml epidermal 
growth factor (EGF), and 10 ng/ml basic fibroblast growth factor (bFGF)). The cells reached ~80% 
confluency after 7 days and were then passaged using trypsin/EDTA and subsequently plated on 
poly-D-lysine coated glass coverslips in a 24-well dish. Fresh mouse astrocyte medium was used 
to plate the cells at a density of 45,000-55,000 cells per coverslip. The primary mouse astrocytes 
were maintained in an incubator at 37ºC and with 5% CO2. 
Human iPSC culture 
iPSCs were cultured on Geltrex™ LDEV-Free, Reduced Growth Factor Basement Membrane 
Matrix coated 6-well plates in mTESR1 medium containing 1× mTESR1 supplement. Media was 
changed every day. For passaging, the cells were incubated with Collagenase Type IV for 5–7 
minutes at 37°C. The collagenase was aspirated and fresh mTESR1 (with supplement) medium 
was added to each well. A cell scraper was used to collect the cells, and they were subsequently 
plated on a fresh 6-well plate at the desired dilution.  
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Generation of human GPCs and Astrocytes 
Glial progenitor cells (GPCs) and astrocytes were generated as previously described with 
modifications (Santos et al., 2017). Briefly, confluent iPSC cultures were dissociated with 
collagenase, collected with a cell scraper and then cultured in suspension to form embryoid bodies. 
The first 24hrs the cells were cultured in mTESR1 with 1× mTESR1 supplement and 10 μM Rock 
Inhibitor Y-27632. For the next two weeks the cells were cultured in Astrocyte medium (AM) 
supplemented with 20ng/ml Noggin and 10ng/mL PDGFAA, and an additional week with only 
PDGFAA. The embryoid bodies were then manually dissociated by pipetting and the resulting 
GPCs were plated on poly-L-ornithine (PO) and laminin-coated dishes in AM supplemented with 
10ng/ml bFGF and 10ng/ml EGF. Upon reaching ~80% confluency, the GPCs were passaged using 
Accutase. The GPCs were maintained in culture until ~day 45-50 of glial differentiation, and then 
astrocytes were differentiated from the GPCs in AM supplemented with 10ng/ml LIF. The media 
was changed every second day.  
Human fibroblast culture 
The human fibroblasts were cultured in T75 flasks with fibroblast media consisting of DMEM 
plus Glutamax, P/S (1:100), and FBS 10%. Upon reaching ~80% confluency the fibroblasts were 
passaged using Trypsin/EDTA. The media was changed every second day.   
 
METHODS DETAILS 
Direct neuronal reprogramming 
Two days post-transduction, GPC media or fibroblast media was replaced with fresh neuronal 
differentiation media consisting of DMEM/F12 and Neurobasal media (1:1), 1x P/S, 1x B27 
supplement, 1x N2 supplement and 1x MEM non-essential amino acids (NEAA) solution. The 
media was supplemented with growth factors and small molecules (adapted from the media used 
in Drouin-Ouellet et al., 2017) at the following concentrations:  LDN‐193189 (0.5 μM), LM‐22A4 
(2 μM), GDNF (2 ng/ml), CHIR99021 (2 μM), NT3 (10 ng/μl), SB‐431542 (10 μM), db‐cAMP 
(0.1 μg/ml), and Noggin (50 ng/ml), as well as valproic acid sodium salt (VPA; 1 mM). The media 
was partially changed every second day. From day seventeen post-transduction until the end of the 
experiment, the neuronal media was only supplemented with growth factors (GDNF, LM‐22A4, 
NT3, and db‐cAMP). At day twenty post-transduction the cells were fixed with 4% 
paraformaldehyde (PFA) for 10min, and then stored in 1xPBS at 4ºC for further analysis. During 
reprogramming the cultures were maintained in an incubator at 37ºC, 5% O2 and 5% CO2. 
Bulk RNA sequencing and analysis 
Cells at iPSC, GPC and astrocyte stages were collected and RNA was isolated on column using 
the PicPureTM RNAextraction kit (Applied Biosystems). RNA quality and concentration were 
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evaluated with an Agilent BioAnalyzer 2100 (Agilent). All included samples had a RIN>9. 10ng 
of RNA from each sample was used to generate the RNA-seq libraries using bulk-adapted 
mcSCRB-seq protocol (Bagnoli et al., 2018): cDNA was generated by oligo-dT primers containing 
well-specific (e.g. sample specific) barcodes and unique molecular identifiers (UMIs). 
Unincorporated barcode primers were digested using Exonuclease I (Thermo Fisher). cDNA was 
pre-amplified using KAPA HiFi HotStart polymerase (Roche) and pooled before Nextera libraries 
were constructed from 0.8 ng of pre-amplified cleaned up cDNA using Nextera XT Kit (Illumina). 
3’ ends were enriched with a custom P5 primer (P5NEXTPT5, IDT) and libraries were size selected 
using 2% E6 Gel Agarose EX Gels (Life Technologies), cut out in the range of 300–800 bp, and 
extracted using the Monarch DNA Gel Extraction Kit (New England Biolabs) according to 
manufacturer’s recommendations. Libraries were paired end sequenced on an Illumina HiSeq 1500 
instrument. Sixteen bases were sequenced within the first read to obtain cellular and molecular 
barcodes, and 50 bases were sequenced in the second read into the cDNA fragment. An additional 
eight bases were sequenced to obtain the i7 barcode. On average, we sequence around 20 million 
read/sample. Gene-based transcripts counts were obtained by running the zUMI pipeline (Parekh 
et al., 2018) (version 0.0.2) using Ensembl annotation release 81 (hg38_Oct2017/ensembl90). We 
analyzed 3 biological replicates per stage per cell line. One sample (#87971, iPSC stage) was 
analyzed twice. 
The analysis was performed using R (3.5.3) and RStudio (version 1.2.1335). Differential gene 
expression analysis was performed using DESEQ2 package (Love et al., “Moderated estimation of 
fold change and dispersion for RNA-seq data with DESeq2”, 2014): 3 main stages were considered 
(iPSC, GPC and Astrocytes) belonging to 2 different donors (Control and Patient). Gene Ontology 
enrichment on Biological Process (BP) analysis was performed using the package “TopGO”: 
differentially expressed genes (Log2FC>1, pvalue<0.05 or Log2FC<-1, pvalue<0.05) were 
provided as input, while the list of the genes with a pvalue were used as background. Top 20 GO 
terms, ranked based on Exact Fisher score (<0.01), were selected; GO terms were then ranked for 
the enrichment, obtained by diving the number of detected genes versus the number of expected 
genes, and top 5 were plotted. Gene Set Enrichment Analysis (Subramanian et al., 2005) was 
performed using the package “fgsea” in Rstudio (Sergushichev A (2016). “An algorithm for fast 
pre-ranked gene set enrichment analysis using cumulative statistic calculation”). 
Cell cycle score was generated by summing the normalized gene expression, obtained from 
DESeq2, of the genes listed in Tirosh (Tirosh et al, Science 2016) for G1/S and G2/M. Genes 
plotted in Figure S1D were selected based on pluripotent stem cell markers (Giulitti et al, Nature 
Cell Biology, 2019, figure 3A) and known astrocytic markers (e.g. Sox9) and markers identified in 
Barbar (Barbar et al., Neuron, 2020, Figures 2D and 2E). 
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Plasmids and viral production 
The plasmids containing Ascl1 or Neurog2 cDNA were previously described (Heinrich et al., 
2010). Briefly, the coding sequence of the reprogramming factors was cloned downstream of a 
CAG promoter and followed by an intra-ribosome-entry-site (IRES) together with DsRed coding 
gene. The plasmid containing Bcl2 was previously described (Gascón et al., 2016). The phospho-
incompetent forms of Neurog2 and Ascl1 were a kind gift of Prof. Anna Philpott. cDNA of these 
phospho-mutants was cloned in the same plasmid used for the wild type forms of Neurog2 and 
Ascl1. Viral vectors were produced as described (Heinrich et al., 2011).   
Transduction 
The GPCs were plated on PO/laminin-coated glass coverslips, and the fibroblasts were plated 
on 0.1% gelatin-coated glass coverslips, in 24-well plates at a density of 40,000 cells per well. The 
day after plating the cells were transduced with 1µl of virus per well. Once the cells were 
transduced, they were placed in an incubator at 37ºC, 5% O2 and 5% CO2. Two days post-
transduction the cells had their media changed to neuronal differentiation media, as is described 
above.  
Pharmacological treatment 
The pharmacological treatment of the GPCs and fibroblasts undergoing reprogramming was 
conducted during the first media change, at two days post-transduction. The cells were treated once 
with each compound at the following concentrations: α-tocopherol (10 μM), Oligomycin A (1 
μg/ml), Urolithin A (2 μg/ml), Nicotinamide riboside (10 μM), Idebenone (1 μg/ml), AMG PERK-
44 (10 μM), and STF-083010 (10 μM).  
Glutamate Uptake Assay 
The iPSCs, GPCs and astrocytes were plated on 6-well plates, and upon reaching confluency 
the cells were treated with glutamate to reach a final concentration of 10μM, 100μM or they were 
left untreated. The cells were incubated for 30min, and then the supernatant was removed from the 
cells across the different conditions. The glutamate concentration of each supernatant was 
subsequently analyzed using the Glutamate Assay Kit (ab83389) from Abcam. The Glutamate 
Assay Kit instructions were followed as described in the Abcam protocol booklet.  
Seahorse experiments  
Human fibroblasts, iPSC-derived GPCs and iPSC-derived astrocytes were plated on XF96 V3-
PS 96-well cell culture microplates from Seahorse Bioscience and analyzed the day after plating. 
The cells were seeded at a density of 20,000 cells per well, and the four corner wells contained only 
media for background correction. Before the Seahorse analysis, cells were washed once with un-
buffered media, and then incubated with 180μl of the bicarbonate-free DMEM in an air incubator 
without CO2 at 37°C for 30 min. The XF96 plate was then placed in the XF96 Extracellular Flux 
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Analyzer (Seahorse Bioscience) and the oxygen consumption rates (OCR) were measured. The 
OCR was first measured with no additions, and then again after adding various compounds to 
obtain measurements of different respiration states. First, Oligomycin A (1 μM) was added to 
inhibit ATP synthase, followed by carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
(FCCP, 0.4 μM) to determine the maximal oxidation capacity, and finally a combination of 
rotenone (2 μM) and Antimycin A (2.5 μM) to block ETC activity. The OCR was measured at three 
time points for each measurement condition, and ~16-24 technical replicate wells were plated for 
each cell line. After the Seahorse Assay finished, the normalization for the number of cells in each 
well was conducted using the CyQuant Assay.  
Three biological replicates were conducted for the Seahorse data in Figure S1. The parameters 
depicted in Figure S1 are from OCR measurements in different conditions: Basal respiration is 
calculated from the OCR measurements before the first compound injection; ATP-linked 
respiration is calculated from the OCR before oligomycin injection minus OCR after oligomycin 
injection; Maximal respiration is calculated from the OCR after FCCP injection; Spare respiratory 
capacity is calculated from maximal respiration minus basal respiration.  
Immunocytochemistry  
Cells were fixed with 4% PFA for 10 min. at room temperature, and then stored in 1xPBS at 
4°C before staining. The cells were incubated in blocking solution (1xPBS plus 3% Bovine Serum 
Albumin (BSA) and 0.5% Triton X-100) for 30min, and were subsequently incubated with primary 
antibodies diluted in blocking solution for 2 hours at room temperature or overnight at 4°C. After 
washing 3x for 5 minutes each with 1xPBS, the cells were incubated with the correct species-
specific secondary antibodies at a dilution of 1:1000 for 1hr in the dark at room temperature. DAPI 
was also added during this step to label the nuclei, diluted at 1:10,000 in blocking solution. The 
cells were washed 3x for 5 minutes each with 1xPBS, and then the coverslips were mounted with 
Aqua Poly/Mount. The cells were imaged at the Axio Observer Z1 epifluorescence microscope 
(Carl Zeiss) or the LSM710 laser-scanning confocal. Digital images were acquired using the ZEN 
software (Carl Zeiss) at 20X, 25X or 40X. 
The following primary and secondary antibodies were used: 
Species Primary Antibodies Dilution Company Catalog number 
Rabbit  FGFR3 1:200 Santa Cruz sc-123 
Mouse IgG1 S100β 1:200 Sigma S2532 
Rat IgG2a RFP 1:200 Helmholtz Facility 5F8 
Chicken GFP 1:300 Aves Labs GFP-1020 
Mouse IgG1 MAP2 1:200 Sigma M4403 
Guinea Pig β-III-tubulin 1:300 Synaptic Systems 302304 
Reactivity  Secondary Antibodies Dilution Company  Catalog number 
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Chicken  Alexa Fluor 488 1:1000 Thermo Fisher  A11039 
Rat  Alexa Fluor 546 1:1000 Thermo Fisher A11081 
Guinea Pig Alexa Fluor 647 1:1000 Thermo Fisher A21450 
Mouse IgG1 Alexa Fluor 488 1:1000 Thermo Fisher A21121 
Rabbit Cy3 1:1000 Jackson Laboratory 711-165-152 
 
Co-culture for electrophysiology 
Human GPCs were plated on 6-well plates at ~210,000 cells per well. The following day the 
cells were transduced with 5 μl of virus per well. Two days post-transduction the GPCs were 
washed twice with 1xPBS and plated on top of the mouse astrocytes (that had been plated the day 
before in 24-well plates). The co-culture cells were maintained in mouse astrocyte conditioned 
media (media taken from T75 flasks of mouse astrocyte cultures after 3-4 days and supplemented 
with the neuronal reprogramming media factors plus 10 μM Rock Inhibitor Y-27632. The media 
was partially changed every second day.  
Whole-cell patch-clamp recordings 
Whole-cell patch-clamp measurements were performed as previously described (Schieweck et 
al., accepted, Riedemann et al., 2018). Briefly, coverslips with cultured iNeurons were transferred 
to an organ bath mounted on the stage of an upright microscope (BX-RFA-1-5, Olympus, Japan). 
A single coverslip was continuously perfused with artificial cerebro-spinal fluid (ASCF) containing 
(in mM): NaCl (125), KCl (3), NaH2PO4 (1.25), NaHCO3 (25), CaCl2 (2), MgCl2 (2) and D-Glucose 
(25 mM). The ACSF was saturated with 95% O2 / 5% CO2 to maintain a pH of 7.4. The osmolarity 
of the ACSF ranged between 305 to 318 mOsmol. The perfusion rate with ACSF was set to 3 mL 
/ min and recordings were performed at 28°C. Cultured cells were visualized with a Dodt contrast 
tube (DGC, Scientifica, UK) that was attached to the microscope. Successfully transduced neurons 
were identified by DsRed expression with the help of a fluorescence lamp (pE-300, CooLED, UK) 
and epifluorescence optics for red fluorescence (filter: ZT635dcrb, Chroma Technology, USA). 
Images were taken and displayed using a software-operated microscope camera (Evolve 512 Delta, 
Teledyne Photometrics, USA). The electrodes for whole cell patch-clamp recordings were 
fabricated from borosilicate glass capillaries (OD: 1.5 mm, ID: 0.86 mm, Hugo Sachs Elektronik-
Harvard Apparatus, March-Hugstetten, Germany) and filled with a solution composed of (in 
mM):  K-gluconate (135), KCl (4), NaCl (2), EGTA (0.2), HEPES (10), Mg-ATP (4), Na-GTP 
(0.5), and phosphocreatine (10). The osmolarity ranged between 288-295 mOsmol, the pH was 
adjusted to 7.3. The electrodes (resistance: 3 – 5 M ) were connected to the headstage of a npi 
ELC-03XS amplifier (npi, Tamm, Germany). The recorded signals were amplified (x20), filtered 
at 20 kHz, digitized at a sampling rate of 50 kHz and stored on a computer for off-line analysis. 
Data acquisition was performed by means of a CED 1401 Power 3 system in conjunction with the 
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Signal6 data acquisition software (Cambridge electronic design, Cambridge, England). The input 
resistance was determined by injecting at least 10 small hyperpolarizing current steps (500 ms, 1-
10 pA) into the cells and by determining the averaged voltage deflection in response to the current 
injection. The input resistance was then calculated according to Ohm’s law (R= V/I). The properties 
of single action potentials (AP) were obtained from recordings in which action potentials were 
elicited by means of just suprathreshold current steps or current ramps (duration: 50 ms). The 
following AP parameters were analyzed: AP amplitude, AP duration, AP threshold, AP rising 
slope. The amplitude was determined as the difference between the resting membrane potential and 
the AP peak voltage. Duration, rising slope and spike threshold were determined according to 
methods given by Bean (2007): Single spikes were differentiated, and the spike duration 
corresponded to the temporal difference between the maximum and the minimum of the 
differentiated spike. The rising slope was equal to the maximum of the first spike derivative. For 
the spike threshold analysis, the differentiated spike was plotted as a function of the membrane 
voltage. In this phase plane, the threshold corresponded to the point where the rising slope of the 
membrane voltage displayed a sudden increase. To test whether an iNeuron was able to fire 
repetitive action potentials, at least 20 current steps with increasing amplitudes (duration: 1 s) were 
injected into the cells. Depending on a cell’s input resistance, these current steps ranged between 
1-10 pA. Data analysis was performed using IGOR Pro 6 together with the Neuromatic IGOR 
plugin (Rothman and Silver, 2018). 
Live-Imaging Microscopy  
Continuous live imaging was performed with a Cell Observer (Zeiss) microscope and the cells 
were maintained in a chamber with 37°C temperature and with 5% CO2. The imaging was 
conducted over 5 days, with phase-contrast images being acquired every 10 min 
and fluorescence pictures every 4 hours using a 10x phase contrast objective (Zeiss) and an 
AxioCam HRm camera with a self-written VBA module remote controlling Zeiss AxioVision 4.7 
software (TAT, Prof. Dr. Timm Schroeder). The images were analyzed using ImageJ (NIH) 
software (as described in Gascón et al., 2016).  
 
QUANTIFICATION AND STATISTICS 
The efficiency of neuronal reprogramming for both GPCs and fibroblasts across conditions was 
analyzed at day 20 post-transduction. The quantification of neuronal-like cells was conducted as 
previously described (Gascón et al., 2016): in essence, morphological parameters such as the length 
of processes and β-III-tubulin immunoreactivity were assessed.  
The continuous live imaging experiments were analyzed at 4 time points across the 5 days (0hrs, 
48hrs, 80hrs and 100hrs). The number of DsRed+ cells was calculated for each time point to 
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determine the amount of transduced-cell death occurring over the experiment. The reprogramming 
efficiency was analyzed as detailed above.  
Data were analyzed with Microsoft Excel, GraphPad Prism 7.0 software and linear regression 
using “lm” function (R Stats package) in RStudio. Evaluation of the residuals for fitted linear 
models was performed with the package “DHARMa” (Florian Hartig (2020). DHARMa: Residual 
Diagnostics for Hierarchical (Multi-Level / Mixed) Regression Models. R package version 0.3.2.0. 
https://CRAN.R-project.org/package=DHARMa) in RStudio. 
The number of biological replicates is detailed in the Figure Legends, and the data are plotted 
as either median ± interquartile range (IQR) or mean ± SEM. The significance illustrated in the 
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Figure 1: NDUFS4-mutant glial cells exhibit impaired neuronal reprogramming.  
(A) Schematic of the experimental protocol used for direct neuronal reprogramming.  
(B) Micrographs showing immunostaining of control and patient GPCs transduced with one 
transcription factor at day 20 of neuronal reprogramming. Scale bars, 50μm.  
(C) Boxplot of reprogramming efficiency of control and patient GPCs across the single 
transcription factor conditions. Efficiency is defined as the ratio of βIII-tubulin+/DsRed+ to DsRed+ 
cells. Data are shown as median ± IQR. *p ≤ 0.05, **p ≤ 0.01. n = 5 per experimental condition.  
(D) Micrographs of control and patient GPCs transduced with two transcription factors at day 20 
of neuronal reprogramming. Scale bars, 50μm. 
(E) Boxplot of reprogramming efficiency of control and patient GPCs across double transduction 
conditions. Data are shown as median ± IQR. ***p ≤ 0.001. n = 5 per experimental condition. 
 
Figure 2: Neuronal reprogramming deficit of patient GPCs can be rescued and control 
GPCs reprogramming further improved with pharmacological treatments 
(A) Micrographs of control and patient GPCs transduced with Neurog2 alone or in combination 
with OligoA and α-tocopherol treatment. Scale bars, 50 μm.  
(B) Boxplot of reprogramming efficiency of control and patient GPCs across the different treatment 
conditions. Data are shown as median ± IQR. **p ≤ 0.01. n = 3 per experimental condition. 
(C) Micrographs of control and patient GPCs transduced with Neurog2 alone or in combination 
with Nicotinamide Riboside (NR), Urolithin A (UA), Idebenone, STF-083010 (STF) or AMG-
PERK 44 (AMG) treatment. Scale bars, 50 μm. 
(D) Boxplot of reprogramming efficiency of control and patient GPCs treated with AMG, STF or 
untreated. Significant differences between control and patient GPC reprogramming are indicated, 
as well as the significance of treated control and patient conditions relative to their respective 
untreated condition. Data are shown as median ± IQR. *p ≤ 0.05, ***p ≤ 0.001. n = 3 per 
experimental condition (HMGU12, #79787, #114107), n = 2 per experimental condition (#1, 
#87971). 
(E) Boxplot of reprogramming efficiency of control and patient GPCs treated with Idebenone, NR, 
Urolithin A, or untreated. Significant differences between control and patient GPC reprogramming 
are indicated, as well as the significance of treated control and patient conditions relative to their 
respective untreated condition. Data are shown as median ± IQR. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 




Figure 3: Patient reprogrammed neurons display impaired functionality that can be rescued 
upon UPR inhibitor treatment.   
(A) Schematic of the mouse astrocyte co-culture paradigm used to obtain recordings from 
reprogrammed neurons.  
(B) Representative traces of recordings from the three conditions.  
(C) Histogram showing the percentage of recorded reprogrammed neurons across different 
conditions that fired or did not fire an action potential. Control (n = 17, 65% AP, 34% no AP), 
Patient (n = 11, 45% AP, 55% no AP), Patient plus AMG (n = 8, 88% AP, 12% no AP).  
(D) Boxplot of action potential amplitude recorded from the three conditions. Data are shown as 
median ± IQR. 
(E) Boxplot of action potential duration recorded from the three conditions. Data are shown as 
median ± IQR. 
 
Figure 4: Reprogramming deficiency verified with NDUFS4-mutant fibroblasts  
(A) Micrographs of control and patient fibroblasts transduced with one transcription factor at day 
20 of neuronal reprogramming. Scale bars, 50 μm. 
(B) Boxplot of reprogramming efficiency of control and patient fibroblasts across the different 
transcription factor conditions. Data are shown as median ± IQR. **p ≤ 0.01. n = 3 per experimental 
condition. 
(C) Micrographs of control and patient fibroblasts transduced with two transcription factors at day 
20 of neuronal reprogramming. Scale bars, 50 μm. 
(D) Boxplot of reprogramming efficiency of control and patient fibroblasts across double 
transduction conditions. Data are shown as median ± IQR. ***p ≤ 0.001. n = 3 per experimental 
condition. 
 
Supplementary Figure 1: NDUFS4-mutant iPSCs can be differentiated into glial cells 
comparable to control donor iPSCs.  
(A) Schematic of the differentiation protocol used to obtain iPSC-derived glial cells.  
(B) Micrographs of control and patient cells at two different stages of glial differentiation. Scale 
bars, 50 μm. 
(C) Schematic of the NDUFS4 gene demonstrating the location of each mutation for the respective 
patient cell lines. (iPSCs: #114107, #87971, #79787). (Fibroblasts: #114107, #114106, #79787).  
(D) Heatmap analysis of different pluripotent and astrocyte markers across control and patient cells 




(E) Barplot showing the log2(fold change) of genes involved in the chemokine mediated signaling 
pathway, identified by gene set enrichment analysis (GSEA) analysis  
(F) Barplot showing the log2(fold change) of the main genes involved in fatty acid metabolic 
process, identified by GSEA analysis. 
(G) Histogram of the glutamate concentration present in the media after glutamate treatment, used 
as an indicator of residual glutamate that was not taken up by the cells. Data are shown as 
mean from 3 technical replicates. n = 1 per experimental condition. 
(H) Histogram of four different parameters obtained from measurement by the Seahorse XF 
analyzer, comparing between control and patient cells at the GPC stage. Data are shown as mean 
± SEM. *p ≤ 0.05, n = 3 per experimental condition.  
(I) Histogram of four different parameters obtained from measurement by the Seahorse XF 
analyzer, comparing between control and patient cells at the astrocyte stage. Data are shown as 
mean ± SEM. n = 3 per experimental condition. 
 
Supplementary Figure 2: Time course analysis of reprogramming reveals different patterns 
of cell death in control and patient GPCs 
(A) Schematic of the neuronal reprogramming paradigm, with three different time blocks indicated 
for the time course analysis.  
(B) Time course analysis of the percentage of transduced cells at the indicated time points (Days 
4-8). Results normalized to the DsRed condition. Data are shown as mean ± SEM, n =2. 
(C) Time course analysis of the percentage of transduced cells at the indicated time points (Days 
8-12). Results normalized to the DsRed condition. Data are shown as mean ± SEM, n = 2.  
(D) Time course analysis of the percentage of transduced cells at the indicated time points (Days 
13-17). Results normalized to the DsRed condition. Data are shown as mean, n = 1.  
(E) Time course analysis of the percentage of cells acquiring neuronal morphology over transduced 
cells at the indicated time points (Days 13-17). Data are shown as mean, n = 1.  
 
Supplementary Figure 3: Patient fibroblasts reprogramming efficiency can also be partially 
rescued by blocking the UPR pathway.  
(A) Micrographs of control and patient fibroblasts transduced with Neurog2 alone or in 
combination with Nicotinamide Riboside (NR), Urolithin A (UA), Idebenone, STF-083010 (STF) 
or AMG-PERK 44 (AMG) treatment. Scale bars, 50 μm. 
(B) Boxplot of reprogramming efficiency of control and patient fibroblasts across the different 
treatment conditions. Significant differences between control and patient fibroblast reprogramming 
are indicated, as well as the significance of treated control and patient conditions relative to their 
90
 
respective untreated condition. Data are shown as median ± IQR. *p ≤ 0.05, ***p ≤ 0.001. n = 3 per 
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My PhD projects focused on the role of metabolism in direct neuronal reprogramming. In 
Russo et al. (2021) the mitochondrial proteomes of murine astrocytes and neurons were 
investigated, further revealing the metabolic differences between the cell types. This 
information was utilized to express neuron-enriched mitochondrial proteins during the process 
of neuronal reprogramming. Intriguingly, priming the astrocyte mitochondria for their neuronal 
fate led to a significant increase in reprogramming efficiency. Therefore, the role of the 
mitochondria as an essential driver during murine cell reprogramming was established. 
However, the role of mitochondria in human cell reprogramming is much less well understood. 
As such, in Sonsalla et al. human cells were obtained from control donors and patients with a 
mitochondrial deficiency. The cells were differentiated into astrocytes and then their neuronal 
reprogramming ability was investigated. Clear differences were observed in the 
reprogramming of control versus patient cells, thus highlighting the importance of functioning 
oxphos metabolism for neuronal conversion. The UPR pathway was identified as a novel player 
in the reprogramming process, as its inhibition led to improvements in both the patient and 
control cells. Different aspects of mitochondrial function in reprogramming were therefore 
revealed in my PhD studies, with implications for therapeutic applications.  
 
3.1 Project 1: Murine astrocyte direct neuronal reprogramming is enhanced by the 
manipulation of mitochondrial proteins 
 
The role of mitochondria in reprogramming is important to understand, as mitochondria are 
not only involved in the regulation of metabolic pathways, but they also play a prominent role 
in regulating transcription and the synthesis of macromolecules. During endogenous cell fate 
conversion, it is known that mitochondria change to match the requirements of the new cell 
identity. For example, transcriptional studies have shown a downregulation of genes related to 
aerobic glycolysis and upregulation of genes related to oxphos in neural progenitor cells during 
neuronal differentiation (Agostini et al., 2016; Zheng et al., 2016). Furthermore, a 
mitochondrial protein knockout inhibiting the use of oxphos by neural stem cells in vivo 
resulted in reduced neurogenesis and defects in cortical development (Khacho et al., 2017). We 
wanted to investigate if the metabolic plasticity of mitochondria in reprogramming is consistent 




In Russo et al. (2021), the mitochondrial differences between astrocytes and neurons were 
investigated and established. Murine cortical astrocytes and E14-derived cortical neurons were 
used as in vitro models. Seahorse analysis demonstrated functional metabolic differences, such 
as the ability of astrocytes to utilize both oxphos and glycolysis for energy generation, whereas 
neurons rely more on oxphos. During neuronal reprogramming, a switch in mitochondrial 
metabolism was detected through morphological analysis, as murine astrocytes had elongated 
mitochondria, while smaller mitochondria were present in Ascl1-induced neurons; consistent 
with previous reports of neurons (Misgeld & Schwarz, 2017) and astrocytes (Motori et al., 
2013). We then investigated the metabolic profile of astrocytes and neurons at the molecular 
level by conducting proteomic analysis on isolated mitochondria from the two cell types. The 
higher metabolic plasticity of astrocytes was reflected by their gene ontology (GO) terms, as 
well as by their enrichment of the fatty acid oxidation pathway. In contrast, mitochondria from 
neurons had enrichment for RNA metabolism. Considering that mitochondrial morphology 
was shown to change over the course of reprogramming, we also wanted to examine how cell-
specific mitochondrial protein expression was altered during forced cell fate change. 
Interestingly, the astrocyte-enriched proteins Sfxn5 and Cpox were downregulated in cells that 
successfully reprogrammed into induced neurons, whereas transduced cells that remained 
astrocytic retained a higher expression of these proteins. The shift in protein expression 
occurred late in the conversion process, and this was also reflected in the delayed acquisition 
of the neuron-enriched mitochondrial proteins Prdx2 and Gls. Since the change in 
mitochondrial proteins was only detected in induced neurons, we wanted to explore if we could 
enhance neuronal reprogramming by harnessing the expression of proteins related to neuronal 
metabolism. To this end, we crossed the astrocyte-specific ALDH1L1:Cre mouse line with a 
transgenic mouse line where transcriptional activators were fused to catalytically inactive Cas9 
(dCas9). The resulting primary mouse astrocyte cultures were then transfected with the 
neurogenic factor Ascl1, as well as guide RNAs (gRNA) that targeted specific neuron-enriched 
proteins. Notably, the initiation of neuron mitochondrial gene expression during neuronal 
reprogramming did indeed increase the reprogramming efficiency. In particular, the gene Sod1 
alone or in combination with Prdx2 led to a strong increase in efficiency, possibly due to their 
antioxidant activity. Interestingly, genes with antioxidant function but enriched in astrocytes 
did not have the same effect on reprogramming. The induction of Sod1 and Prdx2 also led to 
an improvement in the morphology of the reprogrammed neurons and was found to speed up 
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the conversion process and reduce cell death. Therefore, we clearly illustrated the functional 
relevance of the shift in mitochondrial proteins during forced cell fate conversion.  
 
The specialization of the mitochondria across different cell types is important to understand 
not only in regard to its role in cellular bioenergetics, but also due to its involvement in 
signaling events, generation of metabolic precursors, and epigenetic modifications (Matilainen 
et al., 2017; Spinelli & Haigis, 2018). Indeed, disease pathologies influencing the mitochondria 
of specific cell types further support the need for greater understanding in this field 
(Suomalainen & Battersby, 2018). Although it can be useful to compare mitochondria in 
pathological/treated and healthy conditions at the whole tissue level (Chou et al., 2011; Nilsen 
et al., 2007), the impact of individual cell types on the respective conditions is lost. The 
mitochondrial proteome across organs has been investigated (Mootha et al., 2003; Pagliarini et 
al., 2008), as has the molecular diversity of mitochondria in brain cells (Fecher et al., 2019; 
Graham et al., 2017; Völgyi et al., 2015), however, the relevance of these findings for forced 
neuronal cell fate conversion has not previously been established.  
 
Metabolic plasticity in neuronal reprogramming  
 
In our study, we further elucidated the metabolic differences underlying astrocytes and neurons 
and applied our findings to neuronal reprogramming. The GO term analysis of mitochondrial 
astrocytes showed enrichment for fatty acid β-oxidation and lipid metabolism, which is 
supported at the transcriptional level by previous results in murine astrocytes (van Deijk et al., 
2017) and through in situ lipid tracing (Hofmann et al., 2017). Interestingly, lipid metabolism 
also regulates the activity of neural stem cells (NSCs) (Knobloch et al., 2017) and is involved 
in hematopoietic stem cell maintenance (Ito et al., 2012). There is a reduced reliance on lipid 
metabolism for energy generation as NSCs differentiate into neurons during endogenous 
neurogenesis (Llorens-Bobadilla et al., 2015), and we show that these results are mirrored 
during the direct reprogramming of astrocytes into induced neurons. For example, when fatty 
acid β-oxidation was blocked in murine astrocytes during neuronal reprogramming using 
etomoxir, there was an increase in the reprogramming efficiency (Russo et al., 2021).   
 
The benefit of harnessing cellular metabolism during reprogramming has previously been 
established not in the neuronal context, but for the generation of pluripotent stem cells (Wu et 
al., 2016). When somatic cells undergo forced cell fate conversion into a pluripotent fate, they 
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switch to favoring glycolysis for energy generation as shown by upregulation of glycolytic 
genes and concomitant downregulation of genes related to the ETC (Folmes et al., 2011). 
Indeed, assisting the metabolic switch by blocking oxphos with ETC inhibitor treatment (Son 
et al., 2013) or stimulating glycolysis through PS48 treatment (Zhu et al., 2010) increased the 
pluripotent reprogramming efficiency. Thus, understanding the role of metabolism in cell fate 
transition is not only beneficial for directly replacing neuronal loss upon injury or disease, but 
also for tissue repair by inducing differentiated cells back into a pluripotent state.   
 
Morphological changes occur in parallel to mitochondrial metabolism alterations  
 
The metabolic transition during cell fate change does not only occur at the functional level but 
is also reflected in mitochondrial structural changes. The reduction of proteins implicated in 
mitochondrial fusion dynamics (mitofusin 1 and 2) led to the more fragmented mitochondria 
favored by stem cells and thus increased pluripotent reprogramming efficiency (Son et al., 
2015). Stem cells have smaller and rounder mitochondria with poorly developed cristae 
(Prigione et al., 2010), and upon pluripotent reprogramming fibroblasts have been shown to 
lose their mature mitochondrial morphology and adopt that reminiscent of stem cells (Prigione 
et al., 2011).    
 
We used electron microscopy to examine the isolated mitochondria from astrocytes and 
neurons. Our results are consistent with previous reports of neuronal mitochondria having 
smaller and less branched morphology in order to provide energy to the axons (Misgeld & 
Schwarz, 2017). The extended network of mitochondria in astrocytes was further confirmed in 
vivo (Motori et al., 2013). The importance of cell-type-specific mitochondrial morphology has 
also been established in vivo in relation to endogenous neurogenesis, as inhibition of the fission 
factor Drp1 caused developmental abnormalities and death (Ishihara et al., 2009), and also 
impeded adult neurogenesis (Steib et al., 2014). Indeed, the structural changes accompanying 
the bioenergetic transition are not limited to morphology adjustments, but can also require 
mitochondrial turnover such as mitophagy, a specific form of autophagy. Sequestosome 1 
(SQSTM1/p62), which is linked to mitophagy (Park et al., 2014), is required for successful 
neuronal differentiation (Calvo-Garrido et al., 2019). Specifically, the metabolic shift from 
glycolysis to oxphos was blocked upon p62 KO in neuroepithelial stem cells through, among 
other things, upregulation of the glycolytic gene lactate dehydrogenase A (LDHA) (Calvo-
Garrido et al., 2019).  Interestingly, in Sonsalla et al., the neuronal reprogramming efficiency 
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of human cells was not improved when they were treated with the mitophagy activator 
Urolithin A. Therefore, although mitophagy can assist the shift of metabolic machinery, 
enhanced activation is not necessarily beneficial for neuronal fate acquisition.  
 
Expression of neuron-enriched proteins significantly improves neuronal reprogramming 
efficiency 
 
We found that the unique metabolic program of astrocytes and neurons is further defined by 
their mitochondrial proteome, with one-fifth of proteins found to be significantly different 
between the two cell types. Intriguingly, the failure of a cell to both downregulate astrocyte-
enriched and acquire neuron-enriched mitochondrial proteins was mirrored by its unsuccessful 
reprogramming. Therefore, we influenced this metabolic conversion and see if there was a 
concomitant increase in reprogramming efficiency. To this end, 8 neuron-enriched 
mitochondrial proteins were chosen to have their expression induced through the use of gene-
specific gRNAs. In order to test the collaborative effects of inducing multiple enriched genes 
at once, we used the multiplexed CRISPR technique known as string assembly gRNA cloning 
(STAgR) (Breunig et al., 2018). As was previously mentioned, the genes Sod1 and Prdx2, 
which protect against oxidative stress, were included. Interestingly, Prdx2 alone did not have 
a beneficial effect on the cellular conversion, in contrast to Sod1, indicating that regardless of 
their functional relevance, not all enriched proteins are sufficient by themselves to enhance the 
reprogramming process. Sod1 has been shown to protect cells against superoxide radical 
damage and has been implicated in neurodegenerative disease (Brasil et al., 2019; Gill et al., 
2019; Pharaoh et al., 2019). A synergistic effect was demonstrated with the combination of 
Sod1 and Prdx2, in line with the known neuroprotective role of Prdx2 in injury paradigms 
(Boulos et al., 2007). The elevated oxidative stress in converting astrocytes can lead to cell 
death (Gascón et al., 2016), and thus preempting the heightened ROS by early induction of 
antioxidant proteins could reduce this effect.    
 
Induction of enriched genes unrelated to antioxidative roles, such as Pgam5 and Slc25a22, still 
led to a significant increase in reprogramming efficiency. Mitochondrial homeostasis is 
monitored by the mitochondrial phosphatase Pgam5 through its role in mitochondrial dynamics 
and cell death pathways (Cheng et al., 2021; Lu et al., 2016; Ma et al., 2020; Wang et al., 2012). 
Therefore, the function of Pgam5 in regulating mitochondrial biogenesis and fission could 
account for its advantageous effect in neuronal reprogramming. On the other hand, the 
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glutamate transporter Slc25a22 is imperative to prevent the build-up of intracellular glutamate 
(Goubert et al., 2017), which can result, among other things, in impaired mitochondrial 
metabolism. Indeed, the importance of these proteins for cellular function is reflected by their 
prominent positions in injury and disease; for both Pgam5 (Cheng et al., 2021; Lu et al., 2014) 
and Slc25a22 (Molinari et al., 2009; Molinari et al., 2005; Palmieri et al., 2020). Strikingly, 
when proteins were induced that were associated with antioxidant function but enriched in 
astrocytes rather than neurons, there was no favorable effect detected. Thus, although proteins 
can have similar functions, there are clearly other factors that make them especially suited for 
specific cellular environments, and so the enrichment of different antioxidative proteins is not 
superfluous.   
 
The speed of metabolic conversion seems to be an important factor in successful 
reprogramming. Although changes in transcription have been detected already at 48h after 
neuronal induction, metabolic genes, such as those related to lipid metabolism, were not yet 
altered (Masserdotti et al., 2015). Therefore, there appears to be a delay in the transition of the 
metabolic machinery. Interestingly, when the mitochondria structure was influenced to 
promote glycolysis through depletion of mitofusin-1 and -2, the enhanced pluripotent 
reprogramming was matched by an early upregulation during the reprogramming process of 
genes related to glycolysis (Son et al., 2015). Our findings further support these conclusions, 
as the induction of the neuron-enriched mitochondrial proteins Sod1 and Prdx2 over time 
course analysis not only increased the number of reprogrammed cells surviving, but also 
increased their conversion speed.   
 
The activation of genes by CRISPR/Cas9-based transcriptional activators is an exciting avenue 
for cellular reprogramming, as the DNA of the cell is directly manipulated by targeting 
endogenous genes, in contrast to the traditional viral vector-based method of introducing 
exogenous transgenes (Chakraborty et al., 2014). The CRISPR system allows for the 
simultaneous manipulation of multiple target genes (McCarty et al., 2020), and it has been 
utilized successfully both in vitro (Black et al., 2016; Rubio et al., 2016) and in vivo  (Zhou et 
al., 2018; 2020). Genome-wide screens using CRISPR technology can also provide valuable 
information regarding the impact of specific transcription factors on the cell-fate determination 
(Black et al., 2020; Liu et al., 2018) and can be used to further identify pertinent proteins for 
reprogramming. Indeed, we were able to use CRISPR to harness neuron-enriched 
mitochondrial proteins, and further highlight the importance of mitochondrial metabolism in 
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reprogramming. Considering the wide-spread functions of mitochondrial proteins and 
metabolites, both in regulating cellular bioenergetics and epigenetics, much can be learned 
from studying their role in cell fate determination.  
 
Our work has established a solid foundation that we can build on by continuing to investigate 
the metabolic hurdles underlying reprogramming and ultimately increase conversion 
efficiencies. To make these results relevant for therapeutic applications, it will be necessary to 
verify the results not only in our in vitro paradigm but also in the in vivo context. Although the 
changes in some mitochondria proteins were analyzed during reprogramming through 
immunocytochemistry, full proteome analysis of the mitochondria at different stages of 
reprogramming would provide a great deal of valuable information, especially regarding the 
reprogramming-resistant cells.  In comparison to murine cells, very little is known about the 
role of mitochondria in human cell direct reprogramming, and therefore this was the focus of 
my second PhD project.  
 
3.2 Project 2: Direct neuronal reprogramming of human cells is hindered by oxphos 
deficit  
 
While we established the prominent role of metabolism as a hurdle and a driver in direct 
neuronal reprogramming (Gascón et al., 2016; Russo et al., 2021), these findings were mainly 
limited to murine cells. In order to apply neuronal reprogramming as a therapeutic strategy in 
human patients, the conversion of human cells needs to be optimized. Thus, we decided to 
study the metabolic switch that has been demonstrated in murine cell reprogramming as well 
as during endogenous neurogenesis. Understanding the role of mitochondria in human cells is 
also important because mitochondrial dysfunction has been implicated in aging, as well as in 
various diseases (Stanga et al., 2020; Watts et al., 2018). To this end, we obtained human cells 
from control donors and from patients with a mitochondrial mutation in CI of the ETC.  
 
In Sonsalla et al., human iPSCs from control donors and NDUFS4-mutant patients were 
differentiated into glial progenitor cells (GPCs) and astrocytes. Patient cells were able to 
differentiate in a manner comparable to controls, although differences could be detected when 
the ETC was challenged, such as during oxygen consumption analysis. Transcriptomic analysis 
demonstrated that both patient and control cells upregulated astrocyte marker expression in a 
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similar manner, however, unique pathways were upregulated in their respective GO term 
analysis. In order to assess the impact of the oxphos defect on the cell’s ability to adopt a 
neuronal identity, we took GPCs from control and patient cells and transduced them with 
different combinations of proneural transcription factors. Interestingly, the patient GPCs 
converted at a significantly lower efficiency compared to the control GPCs. Not only was their 
efficiency affected, but also the functionality of the patient cells was altered, as evidenced by 
the fewer action potentials elicited from the patient compared to control induced neurons. We 
wanted to understand what aspects of mitochondrial function were most critical for a successful 
cell fate conversion, and thus various treatments were tested, including α-tocopherol (ROS 
scavenger), NR (NAD+/NADH balance), idebenone (ubiquinone analog), UA (mitophagy 
activator), and STF/AMG (inhibitors of the UPR pathway). Intriguingly, NR and the UPR 
inhibitors (STF and AMG) significantly improved the reprogramming efficiency of not only 
the patient cells, but also the control cells. The treatment with AMG also rescued the 
functionality of the patient cells, as demonstrated by their improved action potential activity. 
We confirmed that the influence of the oxphos deficit on neuronal reprogramming was not 
limited to glial cell conversion but was also relevant for other somatic cells. Patient and control 
fibroblasts underwent reprogramming, and once again confirmed the reprogramming 
impairment of patient cells that could be alleviated upon UPR inhibitor treatment. Therefore, 
the importance of a functioning oxphos metabolic machinery was established for direct 
neuronal reprogramming, and possible treatments for enhancing the neuronal conversion were 
identified.  
 
Differential gene expression and features of CI dysfunction 
 
Although both control and patient cells obtained astrocyte-specific genes in a similar manner 
during glial differentiation, differential gene expression was still detected between the two 
donor types. For example, the gene PPARGC1A, which encodes for the protein PGC-1α, was 
upregulated in control cells compared to NDUFS4-mutant patients. PGC-1α is known to 
stimulate oxphos and mitochondrial biogenesis, as well as to maintain mitochondrial 
homeostasis through the modulation of ROS production (Handschin & Spiegelman, 2006; Lin 
et al., 2005; Wu et al., 1999). Due to the essential role of PGC-1α in mitochondrial function, it 
has unsurprisingly been associated with various neurodegenerative diseases (Rudenok et al., 
2020; Soyal et al., 2012, 2019). The reduced expression of PPARGC1A in patient cells thus 
possibly reflects the mitochondrial dysfunction present as a result of their NDUFS4 mutation. 
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Consistent with our results, downregulation of PPARGC1A was also observed in NPCs from 
LS patients with a mutation in SURF1 (Inak et al., 2021). Interestingly, the inflammatory 
response was also upregulated in control cells compared to patient cells. The ability of control 
cells to more effectively utilize oxphos for energy generation compared to patient cells could 
mean that a parallel increase in ROS levels occurs, and ROS is known to be involved in 
inflammation-signaling pathways (Forrester et al., 2018; Zhou et al., 2011). Indeed, ROS can 
lead to the activation of the NLRP3 inflammasome, which in turn leads to the secretion of 
inflammatory cytokines such as IL-1β (Zhou et al., 2011), which was shown to be differentially 
upregulated in the control cells. Therefore, although patient cells were able to compensate for 
their metabolic defects and successfully differentiate into astrocytes, distinct transcriptome 
signatures were still revealed between control and patient cells.  
 
A deficit in the oxidative respiration of patient GPCs was revealed when the ETC was pressured 
during Seahorse analysis. The metabolic plasticity of glial cells compared to neurons, 
especially their ability to more readily compensate with glycolysis for energy production, 
probably accounts for the otherwise comparable functionality between control and patient glial 
cells. However, when the cells were forced to favor the oxphos metabolic pathway during direct 
neuronal reprogramming, significant differences were revealed in the abilities of the control 
and patient cells. The impact of mitochondrial dysfunction on neuronal fate acquisition was 
recently investigated using patient cells containing a mutation in SURF1, which is involved in 
the assembly of CIV of the ETC (Inak et al., 2021). The SURF1-mutant cells displayed 
defective neuronal maturation, including reduced oxphos bioenergetics. Furthermore, multi-
omics analysis revealed that the patient cells were detained in a glycolytic and proliferative 
state, which hindered their ability to obtain a neuronal identity. Stimulating mitochondrial 
biogenesis through bezafibrate treatment enhanced the neuronal differentiation of SURF1-
mutant cells (Inak et al., 2021). Therefore, a functional oxphos metabolism is instrumental for 
endogenous neuronal conversion, consistent with the results from Sonsalla et al. regarding 
neuronal fate acquisition during direct reprogramming. We investigated diverse features of 
mitochondrial metabolism to better understand their relative contribution to mitochondrial 
dysfunction, as well as their role in the metabolic switch.   
 
CI has three main roles in mitochondrial metabolism; the transfer of electrons along the ETC, 
the oxidation of NADH to NAD+, and maintaining the mitochondrial membrane potential 
through its proton pumping activity (Hirst, 2013). Therefore, CI deficiency can lead to various 
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aberrations in mitochondrial function. For example, failure to properly pass electrons along the 
ETC can lead to the increased release of free electrons, which are then able to react with oxygen 
and amplify the ROS generation. Additionally, if the oxidation of NADH by CI is disrupted it 
can lead to disequilibrium of the NADH/NAD+ ratio, the repercussions of which include the 
buildup of lactate. Finally, a reduction in ATP synthesis can result from the compromised 
proton pumping ability of CI and the subsequently diminished membrane potential (Hirst, 
2013). In order to address the reprogramming deficiency observed in the patient cells, as well 
as to possibly enhance control cell reprogramming, we treated multiple aspects of 
mitochondrial metabolism, including the ones described above.  
 
The role of ROS in mitochondrial dysfunction and the metabolic switch 
 
First, we decided to target oxidative stress, since not only was enhanced ROS generation known 
to be a potential side effect of CI defects, but alleviating ROS levels had previously proven 
beneficial in the neuronal reprogramming of murine astrocytes (Gascón et al., 2016). We 
treated oxidative stress using α-tocopherol (α-toc), which is an analog of Vitamin E and a ROS 
scavenger. Unexpectedly, α-toc treatment did not lead to a significant improvement in the 
reprogramming efficiency of either the control or patient cells. This was against our 
predictions, since mitochondrial oxphos metabolism, in addition to generating a large amount 
of metabolic energy, also concomitantly generates a great deal of ROS. Even in healthy cells, 
the electron transfer that occurs at CI and CIII is leaky, and thus instead of being passed down 
the ETC, some electrons react directly with oxygen and form superoxide (Marchi et al., 2012). 
Mitochondrial superoxide dismutase (SOD) can then dismutate superoxide into hydrogen 
peroxide, or superoxide can also react with nitric oxide and generate reactive nitrogen species 
(RNS) (Marchi et al., 2012). The damage resulting from this ROS production is wide-ranging, 
involving mtDNA and mitochondrial protein impairment as well as lipid peroxidation (Marchi 
et al., 2012).  However, it is important to note that ROS also has favorable functions, for 
example as a mediator of mitochondrial dynamics (Cid-Castro et al., 2018), and as an essential 
signaling molecule (Vicente-Gutiérrez et al., 2021). Indeed, elevated ROS is actually a normal 
and functional component of endogenous neuronal differentiation (Hou et al., 2013; Khacho et 
al., 2017; Rharass et al., 2014) and it also occurs transiently during the pluripotent 
reprogramming of somatic cells into iPSCs (Ying et al., 2016). Interestingly, during mouse 
adult hippocampal neurogenesis, the fluctuation of ROS levels were shown to be inversed, as 
the quiescent neural precursor cells (NPCs) had higher ROS levels that actually decreased as 
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the cells shifted toward neuronal lineage differentiation (Adusumilli et al., 2021). Therefore, 
although imbalanced ROS levels can be detrimental to the cell, ROS dynamics have also been 
shown to be an integral component of cell fate conversion. These factors could thus account 
for the lack of reprogramming improvement we observed with ROS scavenger treatment.   
 
Nonetheless, the lack of benefit from the α-toc treatment was an especially surprising result for 
the NDUFS4-mutant patient cells, since increased ROS levels have previously been reported 
in patient cells (Breuer et al., 2013; Distelmaier et al., 2009a), and antioxidants have even been 
investigated as a therapeutic treatment (De Haas et al., 2017; Distelmaier et al., 2009b). One 
possible explanation for the absence of detected improvement is that the cells used for our 
reprogramming experiments were incubated at oxygen levels comparable to those present in 
the physiological brain, i.e., ~5% O2  (Carreau et al., 2011). Low oxygen conditions have 
previously been shown to be beneficial for neuronal reprogramming (Davila et al., 2013) and 
they allowed us to make our reprogramming experiments more similar to the in vivo 
environment. In hypoxic conditions the transcription of glycolytic genes, such as LDHA, is 
activated by hypoxia-inducible factor 1α (HIF-1α), and this stimulation of glycolysis enhances 
iPSC reprogramming (Yoshida et al., 2009). Although it seems counterintuitive that triggering 
glycolysis would assist neuronal reprogramming, forcibly slowing down the oxphos metabolic 
switch might allow the cell to upregulate other neuron-enriched mitochondrial proteins in the 
meantime and better handle the new metabolic pressures. Curtailing oxidative metabolism 
early in the reprogramming process would also reduce the concomitant spike of ROS that 
normally occurs, and in that case treating with ROS scavengers would be unnecessary. 
Interestingly, hypoxia has been shown to have protective functions in mitochondrial disease 
(Ferrari et al., 2017; Jain et al., 2016). Another explanation is that although the α-toc treatment 
might have helped, its beneficial effect was undetected because it was insufficient to overcome 
the other reprogramming hurdles the cell faced. In corroboration of our results, antioxidant 
treatment was also unsuccessful at improving the defective neuronal morphogenesis of SURF1 
NPCs (Inak et al., 2021). Thus, we decided to instead target other features of mitochondrial 
metabolism that have also been highlighted in mitochondrial disease (Russell et al., 2020).  
 
Investigating electron transfer, mitophagy and NAD+ in relation to mitochondrial metabolism  
 
The disruption of electron transfer along the ETC not only leads to increased ROS, but also 
hampers ATP production. To address this issue, we used the synthetic quinone, idebenone, 
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which has an antioxidant function, but is also able to pass electrons down the ETC and partially 
rescue ATP generation (Haefeli et al., 2011). However, idebenone did not lead to a strong 
improvement in our control or patient cells during reprogramming. Consistent with our results, 
there was only a mild improvement when idebenone was given to patients with the 
mitochondrial disorder known as Leber’s hereditary optic neuropathy (Klopstock et al., 2011), 
and when idebenone was tested in clinical trials for MS it did not significantly hinder the 
disease progression (Kosa et al., 2020). Another possible target for treating mitochondrial 
dysfunction is the process of mitophagy, a specific form of autophagy that was first described 
in 1998 (Scott & Klionsky, 1998). Mitophagy is essential for cell maintenance and 
functionality, and disruption of this pathway has been linked to multiple neurodegenerative 
diseases (Martinez-Vicente, 2017; Rodolfo et al., 2018; Youle & Narendra, 2011). However, 
increasing mitophagy during reprogramming by treatment with the mitophagy activator 
Urolithin A (UA) did not have a significant effect on the neuronal conversion of control or 
patient cells. Although UA treatment has led to improvements in mouse models of aging (Ryu 
et al., 2016), as well as in elderly individuals (Andreux et al., 2019), boosting mitophagy is not 
advantageous to cell fate change in our paradigm. Therefore, partially rescuing the electron 
transfer along the ETC or stimulating mitophagy were not sufficient to overcome 
reprogramming hurdles or alleviate the oxphos deficit.     
 
Intriguingly, treatment with the NAD+ precursor, nicotinamide riboside (NR), during 
reprogramming led to a significant improvement in the reprogramming efficiency of both 
control and patient cells. The altered ratio of NAD+ to NADH is a known side-effect of 
mitochondrial dysfunction (Gomes et al., 2013; Lautrup et al., 2019), and reduced NAD+ was 
detected in iPSC-derived neurons from patients with a mitochondrial deficiency (Inak et al., 
2021). In accordance with our results, treatment with NR has led to increased mitochondrial 
biogenesis and boosted oxidative capacity in mouse skeletal muscle (Cantó et al., 2012; Khan 
et al., 2014). Furthermore, a NAD+ redox imbalance was demonstrated in a mouse model of 
LS, but the symptoms could be improved upon administration of the exogenous NAD+ 
precursor nicotinamide mononucleotide (NMN) (Lee et al., 2019). Indeed, NAD+ is not only 
involved in cellular bioenergetics but is also a crucial substrate for many enzymes, such as poly 
ADP‐ribose polymerases (PARPs), cyclic ADP‐ribose (cADPR) synthases, and sirtuin 
deacetylases (Katsyuba & Auwerx, 2017; Yang & Sauve, 2016). Thus, NAD+ may also assist 




Interaction between the ER and mitochondria: UPR pathway 
 
The most striking improvement to direct neuronal reprogramming in both the patient and 
control cells was observed with the inhibition of the unfolded protein response (UPR), which 
is an endoplasmic reticulum (ER) stress response pathway. The identification of the UPR 
pathway as a major obstacle to reprogramming was an engrossing and unexpected result, which 
highlights an important role for the ER in reprogramming that we had not previously 
considered.  
 
Similar to mitochondrial dysfunction, ER stress and the UPR have been implicated in diabetes 
and cancer, as well as in various neurodegenerative diseases (Remondelli & Renna, 2017; 
Xiang et al., 2017; Zhao & Ackerman, 2006). Interestingly, the mitochondria and the ER have 
many integrated signaling pathways and even have designated regions of close physical 
association, known as mitochondria-associated membranes (MAMs). These areas allow for the 
efficient coordination of calcium homeostasis, inflammation signaling, and autophagy, among 
others (Missiroli et al., 2018). Indeed, a constant low-level calcium transfer from the ER to the 
mitochondria through the inositol trisphosphate receptor (InsP3R) calcium release channel is 
essential to sustain oxphos levels (Cárdenas et al., 2010). On the other hand, an overload of 
calcium can lead to cell death through the parallel increase in ROS along with oxphos 
stimulation and opening of the permeability transition pore (PTP) in the mitochondria, which 
leads to swelling and apoptosis (Hajnóczky et al., 2006). Indeed, the interactions between the 
ER and mitochondria do not occur only as part of normal cellular function but are also 
influenced during times of dysfunction. In order to restore homeostasis during times of ER 
stress, one cellular response is to activate the UPR (Senft & Ronai, 2015; Xiang et al., 2017). 
As illustrated in Figure 3, there are three different branches of the UPR: double-stranded RNA-
activated protein kinase (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), 
and activating transcription factor 6 (ATF6) (Li et al., 2020). The three transmembrane proteins 
listed above each carry out specific functions. Protein translation is inhibited by PERK through 
the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) (Senft & Ronai, 
2015). In addition, ATF4 is upregulated, which leads to the increased expression of chaperones 
to assist in protein folding, as well as proteins related to the antioxidant response. IRE1 
stimulates the production of chaperones by activating the transcription factor XBP-1, and it 
also fosters mRNA degradation. Finally, ATF6 translocates to the Golgi, where it is cleaved, 
and subsequently activates transcription factors in the nucleus, such as C/EBP homologous 
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protein (CHOP). The UPR can ultimately result in the activation of cell death pathways if the 




Figure 3: The three transmembrane sensors of the UPR pathway. The downstream functions of protein 
kinase (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription 
factor 6 (ATF6) are illustrated (Li et al., 2020; this is an open access article distributed under the terms 
of the Creative Commons Attribution License) 
 
 
Strikingly, we observed a significantly increased neuronal reprogramming efficiency in both 
control and NDUFS4-mutant cells upon inhibition of either the IRE1 (STF-083010 inhibitor) 
or PERK (AMG PERK 44 inhibitor) branch of the UPR. This was very intriguing, as the UPR 
is initially activated in a protective manner to re-equilibrate cellular homeostasis, such as 
through stimulating the transcription of chaperones to assist with the management of misfolded 
proteins and through the reduction of global protein translation (Wang & Kaufman, 2016). The 
UPR can also directly benefit the mitochondria, as PERK-mediated activation of ATF4 leads 
to the upregulation of parkin, which can prevent mitochondrial damage (Bouman et al., 2011). 
However, once the UPR has been chronically active it becomes detrimental to the cell and 
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ultimately leads to cell death (Wang & Kaufman, 2016). Therefore, one possibility is that 
during times of prolonged cellular stress, such as during forced cell fate conversion, the UPR 
can activate cell death pathways and thus be a hurdle to reprogramming. The close association 
between the mitochondria and the ER implies that the ER is influenced by the mitochondrial 
switch in metabolic profile, and in addition mitochondria stress itself has been shown to 
activate the UPR pathway (Bouman et al., 2011). Interestingly, ER stress has also been linked 
directly to the regulation of NDUFS4 localization. The ER membrane protein B cell receptor–
associated protein 31 (BAP31) forms a complex with translocase of the outer mitochondrial 
membrane 40 (Tom40) (Namba, 2019). This BAP31-Tom40 complex is involved in the 
translocation of NDUFS4 from the cytosol into the mitochondria. It was shown that ER stress 
caused this BAP31-Tom40 complex to dissociate, thus reducing the amount of NDUFS4 that 
could join CI. This reduction resulted in disrupted mitochondria homeostasis and reduced 
oxygen consumption (Namba, 2019). Therefore, although ER stress can be neuroprotective, it 
can also have many adverse effects on cellular function.   
 
Intriguingly, inhibition of two separate branches of the UPR led to improved reprogramming. 
The beneficial effect we observed by targeting the IRE1 branch of the UPR could be due to its 
upregulation of pro-apoptotic and pro-inflammatory proteins during extended periods of ER 
stress (Chen & Brandizzi, 2013; Lerner et al., 2012). Furthermore, IRE1 has been shown to 
mediate a reduction in glycolysis and mitochondrial respiration during UPR activation (van der 
Harg et al., 2017), and this decreased metabolism could hinder cell fate conversion. The PERK 
branch, on the other hand, reduces the protein load on the cell by attenuating translation 
(Harding et al., 2000). This reduction of translation could be detrimental to the cells undergoing 
reprogramming, as the change in cell identity would require the generation of new proteins. 
Indeed, activation of the PERK-mediated UPR during murine cortical neurogenesis led to a 
disruption in the generation of neurons (Laguesse et al., 2015). A notable and novel role for 
the UPR pathway as a significant obstacle in direct neuronal reprogramming is thus established.  
 
In this study, new aspects of mitochondrial function related to direct neuronal reprogramming 
in human cells were revealed, markedly the relevance of redox equilibrium and the UPR 
pathway. Interestingly, the ROS scavenger treatment found to be beneficial during murine cell 
reprogramming (Gascón et al., 2016) did not have a significant effect on the human cells. In 
order to better understand the role of ROS in human cell reprogramming, and in relation to 
cells with a mitochondrial deficiency, oxidative stress should be monitored in cells at different 
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stages of the reprogramming process, for instance through CellRox treatment. It would also be 
interesting to assess specific features of ROS damage, such as lipid peroxidation. 
Transcriptomic analysis has previously been done on murine cells undergoing reprogramming 
to elucidate the transcriptional changes occurring at the early stages of the reprogramming 
process (Masserdotti et al., 2015). To complement our understanding of reprogramming and 
increase its relevance for therapeutic applications, it would be important to conduct scRNA-
seq analysis on human cells early in the reprogramming paradigm. Comparing control and 
patient cells would reveal valuable information regarding the metabolic switch and also provide 
insights into mitochondrial disease. Furthermore, the induction of the UPR pathway has 
previously been observed by us in murine astrocytes undergoing reprogramming (Najas et al., 
unpublished data), however we still need to confirm the presence of UPR activation during the 
neuronal reprogramming of human cells. It would be interesting to include the UPR inhibitor 
treatment in the scRNA-seq experiment, as that would further elucidate the underlying 
influence of our novel finding on neuronal reprogramming. 
 
3.3 Concluding remarks  
 
In conclusion, my PhD studies highlighted the importance of the mitochondria as a driver not 
only in the neuronal reprogramming of murine cells, but also in regard to human cell 
reprogramming paradigms. Forced cell fate conversion causes the cells to change their 
metabolic phenotype at a greater speed than required during endogenous neurogenesis, thus 
leading to increased stress and cell death. Supporting the cells through the switch, such as by 
upregulating specific neuron-enriched proteins, can be a useful strategy for increasing 
reprogramming efficiencies and improving the quality of the resulting induced neurons. 
Alleviating mitochondrial stress is also relevant for directly treating the mitochondrial 
dysfunction observed in neurodegenerative disease. Investigating cells from human control 
donors and NDUFS4-mutant patients emphasized the importance of the redox balance 
homeostasis in mitochondrial function and revealed the UPR as a new pathway relevant for 
direct neuronal reprogramming. The underlying mechanisms responsible for this role of the 
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